{"meta":{"query_hash":"4bfe58bd6a87","filters":{"venue":"Journal of Medical Economics"},"cohort_total":199,"direct_labels_cover":0,"predictions_cover":199,"exported":199,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4bfe58bd6a87","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Medical+Economics"},"results":[{"id":"W1746649267","doi":"10.3111/13696998.2015.1096274","title":"Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Rivaroxaban; Warfarin; Deep vein; Low molecular weight heparin; Vitamin K antagonist; Thrombosis; Retrospective cohort study; Cohort; Emergency medicine; Internal medicine; Surgery; Atrial fibrillation","score_opus":0.009687734678044244,"score_gpt":0.23199207026472532,"score_spread":0.22230433558668108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1746649267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719375,0.00009884788,0.00009309545,0.0015503044,0.00014573036,0.00027228417,0.0000047879234,0.0000072877438,0.00063389004],"genre_scores_gemma":[0.99857605,0.00043866978,0.00050544774,0.0003010946,0.00012690503,0.0000029167682,0.000010487889,0.000026357528,0.000012093295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853,0.00003093423,0.0005468659,0.00016616129,0.00052045507,0.00020559065],"domain_scores_gemma":[0.9982309,0.00005864152,0.00053916144,0.00016592344,0.00033155546,0.00067385135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048159983,0.0001698156,0.0007794394,0.00013588107,0.000027580225,0.000025611367,0.00015924285,0.00012350673,0.000064043605],"category_scores_gemma":[0.00017218919,0.00011044671,0.000063665364,0.00008361961,0.00018456025,0.00020534464,0.00007214898,0.00025232663,0.0000025633572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028832033,0.0019095067,0.9870648,0.000051671595,0.00064679055,0.000034848286,0.000467559,0.000046335193,4.525208e-7,0.00024626037,0.0019847024,0.0072587617],"study_design_scores_gemma":[0.010010147,0.007068987,0.98042357,0.0005297075,0.0004415729,0.000012027716,0.00037489625,0.00033826707,0.00004806416,0.0000318671,0.00057271356,0.00014817367],"about_ca_topic_score_codex":0.00013216231,"about_ca_topic_score_gemma":0.00011183955,"teacher_disagreement_score":0.009721826,"about_ca_system_score_codex":0.00018284492,"about_ca_system_score_gemma":0.00019208132,"threshold_uncertainty_score":0.4503886},"labels":[],"label_agreement":null},{"id":"W1930311159","doi":"10.3111/13696998.2015.1063501","title":"Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Memantine; Medicine; Rivastigmine; Dementia; Galantamine; Deprescribing; Donepezil; Quality of life (healthcare); Clinical trial; Health care; Cohort; Cost–utility analysis; Cost-effectiveness analysis; Disease; Cost effectiveness; Intensive care medicine; Internal medicine; Polypharmacy; Nursing","score_opus":0.10165036613212446,"score_gpt":0.3853281472543629,"score_spread":0.2836777811222384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1930311159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623246,0.0004454697,0.00051635137,0.010699413,0.00024799278,0.0017603387,0.00007031646,0.000002178905,0.000025494477],"genre_scores_gemma":[0.99721265,0.00026123412,0.000340694,0.0018377381,0.00024292796,0.00005523755,0.000013741943,0.000015604512,0.000020160302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717945,0.00022754013,0.0013899085,0.00021281476,0.0007216463,0.00026861456],"domain_scores_gemma":[0.9973126,0.00043966423,0.0005263299,0.00045774903,0.0007757498,0.0004879035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023683526,0.00019576776,0.00089190766,0.00037986046,0.00004541774,0.000023937499,0.00046643653,0.00008824739,0.000112804526],"category_scores_gemma":[0.0007046776,0.00009863817,0.00040288438,0.0007180565,0.000114121714,0.00007482555,0.00006953153,0.00019415899,0.0000016966878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09382865,0.020806367,0.62178296,0.00027554564,0.023617838,0.00011291011,0.021156028,0.040242504,0.0029915408,0.00009529785,0.012197037,0.16289334],"study_design_scores_gemma":[0.047683552,0.011510087,0.7743076,0.0007806866,0.01036835,0.000097570955,0.005995068,0.08589164,0.044493318,0.00015679146,0.018183991,0.0005313549],"about_ca_topic_score_codex":0.00016475352,"about_ca_topic_score_gemma":0.0004745657,"teacher_disagreement_score":0.16236198,"about_ca_system_score_codex":0.0001029015,"about_ca_system_score_gemma":0.00064648053,"threshold_uncertainty_score":0.40223476},"labels":[],"label_agreement":null},{"id":"W1946341976","doi":"10.3111/13696998.2015.1074583","title":"Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Atrial fibrillation; Cohort; Population; Internal medicine; Cohort study; Pediatrics; Pharmacy; Medical diagnosis; Anticoagulant; Emergency medicine","score_opus":0.03697641372363858,"score_gpt":0.30439554598215685,"score_spread":0.26741913225851827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946341976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974316,0.00013492217,0.00040170972,0.0013712442,0.00026583296,0.00024337723,0.0000015063297,0.000003967958,0.00014583836],"genre_scores_gemma":[0.9979717,0.0009509802,0.0002634534,0.000070556955,0.00068872405,8.115113e-8,0.000023087096,0.000012102691,0.00001928048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867195,0.000039712755,0.00069779897,0.00008373571,0.00040944546,0.00009733077],"domain_scores_gemma":[0.99890125,0.000065693865,0.0005579277,0.000089672714,0.0002073236,0.0001781518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007117323,0.00009052229,0.00044101363,0.00020244592,0.000010173963,0.0000119196375,0.00007249291,0.000109449094,0.000033118053],"category_scores_gemma":[0.00033490063,0.00006351476,0.000121757745,0.00013161656,0.000039268554,0.00016898282,0.000016289565,0.00008931349,0.0000024890203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015969832,0.000016683882,0.9835633,0.0000111327445,0.00011429549,0.00001038965,0.00014141494,0.0016164208,0.000005257918,0.00010971552,0.00016990438,0.012644484],"study_design_scores_gemma":[0.031873703,0.0026537098,0.94290185,0.00029801854,0.00013351557,0.000023925548,0.00019934488,0.01795902,0.00018337526,0.00010078745,0.0035252739,0.00014750387],"about_ca_topic_score_codex":0.00004044216,"about_ca_topic_score_gemma":0.0000082425,"teacher_disagreement_score":0.040661495,"about_ca_system_score_codex":0.0001461056,"about_ca_system_score_gemma":0.00022057441,"threshold_uncertainty_score":0.2590057},"labels":[],"label_agreement":null},{"id":"W1952035361","doi":"10.3111/13696998.2015.1116991","title":"Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD","year":2015,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; COPD; Asthma; Intensive care medicine; Bronchodilator Agents; Bronchodilator; Internal medicine","score_opus":0.09494829862117907,"score_gpt":0.39897040001971373,"score_spread":0.3040221013985347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1952035361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001797133,0.9966512,0.00002194549,0.0002597133,0.00014040305,0.0009781373,0.00003382505,0.0000026974951,0.00011498109],"genre_scores_gemma":[0.00025564714,0.9988112,0.00008691987,0.00058710185,0.00016489199,0.000021993415,0.000009884925,0.00003874383,0.000023638793],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99489534,0.0003680225,0.0038823052,0.00025774754,0.00037202323,0.00022456319],"domain_scores_gemma":[0.9965315,0.00033201536,0.0018709403,0.0003204753,0.00010402469,0.00084108365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030257844,0.00034968162,0.007387091,0.0007078072,0.000009719064,0.000018367482,0.00036852362,0.0004096895,0.00010139608],"category_scores_gemma":[0.00084664085,0.00023765906,0.0006095011,0.00014917045,0.00008240754,0.00015414067,0.00010041851,0.00066603534,0.000014084206],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006694,0.00014213294,0.00001621458,0.95913464,0.0003369471,0.00023458741,0.000050033505,0.00043165393,1.7319806e-8,0.00006644455,0.0006355715,0.038884807],"study_design_scores_gemma":[0.0015461091,0.0002499213,0.0000042455486,0.965026,0.0014476578,0.0009753437,0.0000933232,0.0027695263,1.0514352e-7,0.00010106506,0.027546242,0.00024044882],"about_ca_topic_score_codex":0.00001570428,"about_ca_topic_score_gemma":0.000036844864,"teacher_disagreement_score":0.03864436,"about_ca_system_score_codex":0.0006060735,"about_ca_system_score_gemma":0.0043711727,"threshold_uncertainty_score":0.9691455},"labels":[],"label_agreement":null},{"id":"W1967232800","doi":"10.3111/13696998.2010.535577","title":"Changing costs and the impact on RSV prophylaxis","year":2010,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster Children's Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Intensive care medicine; Pre-exposure prophylaxis; Virology; Human immunodeficiency virus (HIV)","score_opus":0.023397017125700272,"score_gpt":0.3641934151618424,"score_spread":0.34079639803614215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967232800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99021333,0.00008890875,0.000035357854,0.007319668,0.00034257333,0.00014113497,9.435164e-7,0.000003838972,0.0018542423],"genre_scores_gemma":[0.9976175,0.00030329116,0.000046517256,0.00093532837,0.0010120455,0.0000023345103,2.1826388e-7,0.000010519166,0.000072257404],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906486,0.00006051174,0.00033537217,0.00007544445,0.00028980544,0.00017399098],"domain_scores_gemma":[0.9988811,0.00034393297,0.00015183684,0.00015610183,0.00008719228,0.00037981552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031436083,0.00007779607,0.00027994567,0.0002298134,0.00007341834,0.000046686397,0.00014591275,0.00013716794,0.00048573693],"category_scores_gemma":[0.0018527228,0.000037332065,0.00012996145,0.00008923681,0.000315157,0.00007979096,0.000049605995,0.0013848504,0.00002403867],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056270827,0.00068403437,0.029306568,0.00008865525,0.0007523471,0.0004345568,0.00081416074,0.000098267476,0.0019150219,0.014303803,0.0058166794,0.94015884],"study_design_scores_gemma":[0.15006138,0.050369143,0.3558917,0.0023953933,0.00066066225,0.05316975,0.0037660399,0.117914096,0.026155533,0.012747185,0.22500715,0.001861954],"about_ca_topic_score_codex":0.000017163906,"about_ca_topic_score_gemma":0.000008414471,"teacher_disagreement_score":0.93829685,"about_ca_system_score_codex":0.00010395033,"about_ca_system_score_gemma":0.00038455514,"threshold_uncertainty_score":0.60165626},"labels":[],"label_agreement":null},{"id":"W1968579243","doi":"10.3111/13696998.2014.909436","title":"Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"Janssen Scientific Affairs","keywords":"Medicine; Infliximab; Inflammatory bowel disease; Disease; Health care; Internal medicine; Intensive care medicine","score_opus":0.008427640331969043,"score_gpt":0.251802811231127,"score_spread":0.24337517089915797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968579243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699676,0.00030451105,0.00043373494,0.0013439064,0.00043897767,0.00037489785,0.00005549168,0.000004949673,0.000046768113],"genre_scores_gemma":[0.9939873,0.0016169313,0.00020810972,0.0026214458,0.0012678576,0.000060559432,0.000060364535,0.000059768758,0.000117620664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983382,0.00009258916,0.0006768442,0.00025311083,0.00032872142,0.0003105094],"domain_scores_gemma":[0.9976568,0.000045785622,0.0007353429,0.00031638882,0.00034056327,0.000905127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005751189,0.00023280537,0.00033276962,0.00005875013,0.00008043431,0.000041504565,0.00043761585,0.00021723329,0.00006254315],"category_scores_gemma":[0.0003542772,0.00016583661,0.00019843862,0.000020400063,0.00011081079,0.000018782954,0.00007428289,0.00021449052,0.000005430697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03324979,0.001481921,0.84534717,0.0008461255,0.0008104964,0.00017763599,0.00018952122,0.00066635985,0.00007330149,0.00045824374,0.031974673,0.08472479],"study_design_scores_gemma":[0.024528768,0.004165588,0.78876275,0.0008903631,0.000089626184,0.000030831667,0.00018587972,0.002291731,0.0004600543,0.00014871305,0.17769918,0.0007465217],"about_ca_topic_score_codex":0.000002222594,"about_ca_topic_score_gemma":0.00009131864,"teacher_disagreement_score":0.1457245,"about_ca_system_score_codex":0.00011703559,"about_ca_system_score_gemma":0.00096535956,"threshold_uncertainty_score":0.676262},"labels":[],"label_agreement":null},{"id":"W1971766459","doi":"10.3111/13696998.2014.925462","title":"Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians)","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Spasticity; Botulinum toxin; Stroke (engine); Cross-sectional study; Patient satisfaction; Physical therapy; Surgery","score_opus":0.013724026640931654,"score_gpt":0.2616882392279374,"score_spread":0.24796421258700574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971766459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959384,0.000043044303,0.00030635225,0.002946528,0.00038230105,0.00011790212,0.000064787826,0.000007851896,0.00019278754],"genre_scores_gemma":[0.99738634,0.00071000867,0.00025799128,0.0012047332,0.0003476164,0.0000011736724,0.000028328308,0.000013500134,0.00005028731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984453,0.00016652,0.00067849376,0.00022987188,0.00029532122,0.00018449254],"domain_scores_gemma":[0.9986698,0.00051789987,0.0003514687,0.0000976389,0.00008803407,0.00027518405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077195687,0.00014953749,0.0004243347,0.00010250333,0.00004150066,0.000030503035,0.00007154951,0.00023152982,0.0000778988],"category_scores_gemma":[0.0005646694,0.00010048108,0.00009652039,0.000047430953,0.00015988495,0.00011030302,0.00002180577,0.00053854927,0.000008204325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023189578,0.00037591497,0.928837,0.0000050938766,0.00015151358,0.00004109626,0.000090125664,0.000797829,0.00007657758,0.000024049614,0.000022467097,0.06725937],"study_design_scores_gemma":[0.018044392,0.0026836924,0.9734557,0.0000486584,0.000049454487,0.00006126771,0.000026141917,0.0049301647,0.000068934205,0.00018942624,0.000347971,0.000094190065],"about_ca_topic_score_codex":0.0005328024,"about_ca_topic_score_gemma":0.0012221826,"teacher_disagreement_score":0.06716518,"about_ca_system_score_codex":0.00012724147,"about_ca_system_score_gemma":0.00014275966,"threshold_uncertainty_score":0.40974993},"labels":[],"label_agreement":null},{"id":"W1972283859","doi":"10.3111/13696998.2012.697085","title":"Cost-effectiveness of partially-hydrolyzed formula for prevention of atopic dermatitis in Australia","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; PharmIdeas (Canada)","funders":"","keywords":"Medicine; Atopic dermatitis; Dermatology","score_opus":0.0847164040903863,"score_gpt":0.391799723611668,"score_spread":0.30708331952128165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972283859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99716556,0.00024390992,0.0014853586,0.0005683738,0.00019652242,0.00027320004,0.0000038497656,0.0000010303232,0.0000622077],"genre_scores_gemma":[0.9989598,0.0003924336,0.00037863603,0.000030960284,0.00018475989,0.00000908481,0.0000046961245,0.0000064084725,0.000033215056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988178,0.00008573599,0.0006500973,0.000050542345,0.00021406713,0.00018178276],"domain_scores_gemma":[0.99904287,0.0002753821,0.00029717296,0.00007675837,0.000091885355,0.00021591892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021016153,0.00006133234,0.0004323631,0.00013955787,0.000009732097,0.0000026593877,0.00011245439,0.00014425073,0.00019128725],"category_scores_gemma":[0.0004907919,0.000050798557,0.00018346799,0.00005906021,0.00007038798,0.00014811986,0.000021846752,0.00021471301,0.0000014735916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008924513,0.010616453,0.47206354,0.014632731,0.0032230427,0.00010835319,0.002928018,0.002643728,0.010339456,0.03415877,0.0028871617,0.43747425],"study_design_scores_gemma":[0.029099725,0.0044157477,0.8232925,0.0038610492,0.000093926086,0.0003881186,0.0003364176,0.007772536,0.10121985,0.0062535214,0.023000063,0.00026656102],"about_ca_topic_score_codex":0.00002079273,"about_ca_topic_score_gemma":0.000053531334,"teacher_disagreement_score":0.43720767,"about_ca_system_score_codex":0.00007244018,"about_ca_system_score_gemma":0.00020478133,"threshold_uncertainty_score":0.20944613},"labels":[],"label_agreement":null},{"id":"W1979583846","doi":"10.3111/13696998.2014.950669","title":"Healthcare costs for Crohn’s disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"","keywords":"Medicine; Infliximab; Propensity score matching; Internal medicine; Pharmacy; Rheumatoid arthritis; Crohn's disease; Surgery; Disease; Family medicine","score_opus":0.00986530010196417,"score_gpt":0.2562391222970435,"score_spread":0.2463738221950793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979583846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989959,0.000105964136,0.000079904574,0.0001878498,0.00012806011,0.00045910422,0.000031261523,0.0000011946163,0.0000107658725],"genre_scores_gemma":[0.99957496,0.000072388975,0.000087075314,0.0001302975,0.00008185678,0.000012858886,0.00001646284,0.0000110459105,0.000013059805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990405,0.00011514752,0.0004624967,0.00011648,0.00014373536,0.0001216725],"domain_scores_gemma":[0.99852383,0.000055654207,0.00067802856,0.00021452461,0.0002506772,0.0002772889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019074336,0.00011313411,0.00031038772,0.000022924682,0.000035383753,0.0000056182653,0.00022674928,0.000095380674,0.0000037318127],"category_scores_gemma":[0.00037487762,0.000066351095,0.00014372046,0.000021336815,0.00012946276,0.0000057125035,0.00004285409,0.00007064397,2.816163e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048407977,0.00074823294,0.9813552,0.0003927895,0.00021664928,0.000009142018,0.0000821551,0.000054199558,0.00032417398,0.00012138778,0.0003605045,0.011494791],"study_design_scores_gemma":[0.00851069,0.00441166,0.96895164,0.00038984086,0.0001939148,0.0000038576004,0.000022148355,0.0018242209,0.014246865,0.000043516724,0.0012596425,0.00014200469],"about_ca_topic_score_codex":0.000021181573,"about_ca_topic_score_gemma":0.000101156875,"teacher_disagreement_score":0.01392269,"about_ca_system_score_codex":0.00008832962,"about_ca_system_score_gemma":0.000621787,"threshold_uncertainty_score":0.27057192},"labels":[],"label_agreement":null},{"id":"W1981297777","doi":"10.3111/13696990903442155","title":"The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; St. Joseph’s Healthcare Hamilton; McMaster Children's Hospital; St. Michael's Hospital; Sunnybrook Health Science Centre","funders":"Abbott Laboratories","keywords":"Palivizumab; Medicine; Pediatrics; Gestational age; Cost effectiveness; Cost-effectiveness analysis; Emergency medicine; Respiratory system; Pregnancy; Internal medicine","score_opus":0.03774025749135262,"score_gpt":0.36185564054048613,"score_spread":0.3241153830491335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981297777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934427,0.00022713032,0.000006536627,0.0052089,0.00014202061,0.000306215,0.0000019165245,9.401541e-7,0.0006636156],"genre_scores_gemma":[0.99854887,0.0004149976,0.000005011836,0.000874723,0.00013536344,0.0000051697475,4.5283028e-7,0.0000061627293,0.000009231151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820983,0.00042112666,0.00066007103,0.00008506245,0.00036260206,0.00026129847],"domain_scores_gemma":[0.99836814,0.00084495026,0.00017438059,0.00021500206,0.00011079017,0.0002867408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061737457,0.00008307456,0.0003257114,0.00034889212,0.000043032258,0.000042741234,0.00041434573,0.00013296798,0.00004983666],"category_scores_gemma":[0.0021540914,0.00004708173,0.00008411907,0.00021950906,0.00015394186,0.0001230884,0.000021026653,0.0009411301,0.0000075487114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007914634,0.0002997332,0.7789691,0.00009239192,0.00007053899,0.0005506363,0.00088997395,0.00018244814,0.000063304025,0.0011145584,0.0001163024,0.21685956],"study_design_scores_gemma":[0.0025861326,0.00069575815,0.99149233,0.0005776462,0.000012580771,0.00042684661,0.00024298561,0.00089916453,0.00006765786,0.0007695729,0.0021751781,0.000054158423],"about_ca_topic_score_codex":0.008267484,"about_ca_topic_score_gemma":0.1416891,"teacher_disagreement_score":0.2168054,"about_ca_system_score_codex":0.00082671555,"about_ca_system_score_gemma":0.0021203686,"threshold_uncertainty_score":0.99833655},"labels":[],"label_agreement":null},{"id":"W1985042637","doi":"10.3111/13696998.2011.630850","title":"The STARRT trial: a cost comparison of optimal vs sub-optimal initiation of dialysis in Canada","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Humber River Regional Hospital","funders":"","keywords":"Medicine; Renal replacement therapy; End stage renal disease; Dialysis; Hemodialysis; Emergency medicine; Catheter; Central venous catheter; Confounding; Peritoneal dialysis; Kidney disease; Propensity score matching; Surgery; Internal medicine; Intensive care medicine","score_opus":0.03940392721939861,"score_gpt":0.28253163898858413,"score_spread":0.24312771176918552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985042637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694645,0.0002514825,0.00021592934,0.0014068596,0.0003613863,0.00018978649,0.000007326576,9.1524265e-7,0.00061985076],"genre_scores_gemma":[0.99845505,0.0009605317,0.00023565238,0.0001714648,0.00015469662,0.000003365764,0.000004759634,0.0000076046654,0.0000068854297],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977498,0.000088858425,0.0014481094,0.00008284624,0.00048170477,0.00014869541],"domain_scores_gemma":[0.9982552,0.00023447603,0.0009912368,0.00014874616,0.00011998357,0.0002503374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016437942,0.00008740974,0.0006996192,0.00013806262,0.000020737954,0.0000073429546,0.00023246695,0.00006293582,0.00021235186],"category_scores_gemma":[0.00047942452,0.00005674769,0.00021161833,0.00010601031,0.000095020165,0.0000569832,0.000050974875,0.00023736105,8.289167e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24334654,0.010619096,0.31988063,0.0010396758,0.009574138,0.0007927646,0.009488727,0.030113166,0.00018339056,0.0065844604,0.04006988,0.32830754],"study_design_scores_gemma":[0.21449724,0.009488436,0.4663074,0.0020126996,0.006299058,0.00008518722,0.023802781,0.22024718,0.009481379,0.0004699398,0.046314564,0.0009941274],"about_ca_topic_score_codex":0.033377297,"about_ca_topic_score_gemma":0.14748256,"teacher_disagreement_score":0.32731342,"about_ca_system_score_codex":0.0002876405,"about_ca_system_score_gemma":0.0019900552,"threshold_uncertainty_score":0.97305954},"labels":[],"label_agreement":null},{"id":"W1992802587","doi":"10.3111/13696998.2014.897626","title":"Economic evaluation of BST-CarGel as an adjunct to microfracture vs microfracture alone in knee cartilage surgery","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Knee replacement; Surgery; Orthopedic surgery; Referral; Cartilage damage; Osteoarthritis; Articular cartilage","score_opus":0.016774454607737667,"score_gpt":0.29043597981595043,"score_spread":0.27366152520821274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992802587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930082,0.0006087011,0.00005289369,0.004453066,0.0011589018,0.000331253,0.000011528926,0.000006036433,0.00036942802],"genre_scores_gemma":[0.9956734,0.0003199183,0.00045391533,0.0024213225,0.0010113402,0.0000070726405,0.000035116478,0.000034105866,0.000043801814],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766994,0.00018571169,0.0011451207,0.00024705302,0.00046107924,0.0002910893],"domain_scores_gemma":[0.99801016,0.00026405006,0.0006004053,0.00029973418,0.00017368751,0.0006519383],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0043584458,0.00021693301,0.0010181847,0.00041425778,0.000026561147,0.000021781512,0.00018119918,0.0003799726,0.0009165232],"category_scores_gemma":[0.0008044255,0.00018626866,0.00027542602,0.000066706096,0.0000511661,0.00022988884,0.000037672,0.00044219158,0.00006031163],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008132176,0.0025057867,0.07904146,0.00033949545,0.00051990204,0.00047220686,0.0035379534,0.0013429249,0.03728697,0.0011849419,0.017531332,0.84810483],"study_design_scores_gemma":[0.10903844,0.031452294,0.120959826,0.0063016796,0.0041153105,0.0074232817,0.0037768935,0.010625022,0.5201267,0.01635378,0.16708873,0.0027380518],"about_ca_topic_score_codex":0.00008940555,"about_ca_topic_score_gemma":0.0006098832,"teacher_disagreement_score":0.8453668,"about_ca_system_score_codex":0.0004212969,"about_ca_system_score_gemma":0.001326124,"threshold_uncertainty_score":0.9999968},"labels":[],"label_agreement":null},{"id":"W1997932743","doi":"10.3111/13696998.2011.622323","title":"Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada); McMaster University","funders":"","keywords":"Medicine; Haemophilus influenzae; Conjugate vaccine; Cohort; Pneumococcal conjugate vaccine; Epidemiology; Disease burden; Pandemic; Pneumonia; Herd immunity; Streptococcus pneumoniae; Intensive care medicine; Disease; Environmental health; Vaccination; Infectious disease (medical specialty); Immunology; Population; Coronavirus disease 2019 (COVID-19); Immunization; Internal medicine; Antibiotics","score_opus":0.02227451260633569,"score_gpt":0.26485415048471544,"score_spread":0.24257963787837974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997932743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961657,0.0008582631,0.000051711155,0.0025409143,0.0001435592,0.00008546707,0.000004369529,7.798675e-7,0.000149226],"genre_scores_gemma":[0.98888135,0.0103794215,0.00006412376,0.0005873174,0.000075970376,9.1152043e-7,2.3594812e-7,0.0000059807,0.0000046617442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911165,0.000034632674,0.0005842064,0.00006706836,0.00007507302,0.00012736733],"domain_scores_gemma":[0.9990639,0.000106171734,0.00031817524,0.000082376835,0.000017356255,0.00041201877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085127435,0.000072524665,0.00048626275,0.000087827066,0.00002689564,0.0000046729947,0.00007112206,0.000054696317,0.00009161826],"category_scores_gemma":[0.00004917166,0.00004347714,0.00007602953,0.000021424477,0.00012543036,0.000046969762,0.000023967912,0.00029670948,2.5671534e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026080902,0.00017297345,0.926201,0.00026000376,0.00055533816,0.0001436283,0.004105356,0.0059130425,0.000013871363,0.00083701254,0.0017409113,0.057448808],"study_design_scores_gemma":[0.038603146,0.0026269678,0.4987152,0.0023694935,0.00037065044,0.007739516,0.0035052185,0.43940848,0.00006331593,0.0040073073,0.0020552208,0.0005354746],"about_ca_topic_score_codex":0.4436914,"about_ca_topic_score_gemma":0.28379542,"teacher_disagreement_score":0.43349543,"about_ca_system_score_codex":0.00047562766,"about_ca_system_score_gemma":0.00592742,"threshold_uncertainty_score":0.99970806},"labels":[],"label_agreement":null},{"id":"W1998523970","doi":"10.3111/13696998.2011.627405","title":"The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"Servier; Sanofi; McMaster University; AstraZeneca","keywords":"Medicine; Telmisartan; Ramipril; Internal medicine; Cardiology; Intensive care medicine","score_opus":0.10158244239599679,"score_gpt":0.3054804258251084,"score_spread":0.20389798342911164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998523970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948975,0.00005788706,0.00026933913,0.0035288373,0.00029660773,0.0008896559,0.000019702178,0.0000012909311,0.000039177117],"genre_scores_gemma":[0.9977681,0.00089468143,0.00029653864,0.0007005814,0.000077181896,0.000037346595,0.0000020544985,0.000009349205,0.00021414825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983838,0.00012428028,0.0009398339,0.000094366995,0.00032771289,0.00012996126],"domain_scores_gemma":[0.9976212,0.0005738828,0.001020041,0.00047317668,0.00018120358,0.0001305175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014945352,0.000080137914,0.0003096981,0.000033138043,0.00009811864,0.0000047713024,0.0005684024,0.00006726737,0.0002727583],"category_scores_gemma":[0.0018452959,0.000034049306,0.000156504,0.00009156105,0.00017130711,0.00006195818,0.00007858775,0.0002912694,0.000004683136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007181569,0.0012038295,0.97098833,0.000016994327,0.00029047613,5.639038e-7,0.00082549494,0.000020202857,0.0000022427785,0.00038440447,0.005962731,0.019586595],"study_design_scores_gemma":[0.003894498,0.0005836217,0.96764064,0.000100911726,0.0001442466,0.000007279216,0.0005404601,0.00024710642,0.000044156845,0.000594224,0.026162881,0.000039990566],"about_ca_topic_score_codex":0.00014618116,"about_ca_topic_score_gemma":0.00050285057,"teacher_disagreement_score":0.02020015,"about_ca_system_score_codex":0.000113299815,"about_ca_system_score_gemma":0.00041776497,"threshold_uncertainty_score":0.29865122},"labels":[],"label_agreement":null},{"id":"W2000275242","doi":"10.3111/13696998.2013.823869","title":"Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Novo Nordisk","keywords":"Medicine; Risperidone; Paliperidone; Paliperidone Palmitate; Quality of life (healthcare); Adverse effect; Olanzapine; Schizophrenia (object-oriented programming); Emergency medicine; Pediatrics; Psychiatry; Internal medicine","score_opus":0.04877902442352141,"score_gpt":0.3665994793210382,"score_spread":0.3178204548975168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000275242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944798,0.00047761403,0.0029849426,0.0013745736,0.00013218925,0.0005094379,0.000008364348,0.00000296741,0.000030106248],"genre_scores_gemma":[0.9953692,0.0006819913,0.0035646963,0.000040302693,0.00028253932,0.00002535565,0.000011604037,0.000014949237,0.000009352063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983239,0.00008568419,0.0008300701,0.00016592418,0.0003066548,0.00028772734],"domain_scores_gemma":[0.9975656,0.0012566993,0.00040334903,0.00016581768,0.00017779433,0.00043071376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012936058,0.00013299074,0.00090690755,0.0005618923,0.000031452,0.000033617922,0.00019539623,0.00016581517,0.00045033908],"category_scores_gemma":[0.0011309383,0.0000997714,0.00039091468,0.00032557282,0.0000902845,0.00015563447,0.000041161264,0.00040232914,0.0000067598125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027657682,0.0010447414,0.5656444,0.0003506203,0.0047467435,0.00014790337,0.000122211,0.002064082,0.00016089492,0.0005594331,0.000121478464,0.3973798],"study_design_scores_gemma":[0.018046008,0.0012697148,0.89686006,0.0004885597,0.00082810497,0.00010715219,0.00008990349,0.08097528,0.0006674037,0.00047080926,0.000089383284,0.00010763644],"about_ca_topic_score_codex":0.000054326283,"about_ca_topic_score_gemma":0.00035338872,"teacher_disagreement_score":0.39727217,"about_ca_system_score_codex":0.0004218867,"about_ca_system_score_gemma":0.00090447714,"threshold_uncertainty_score":0.4930897},"labels":[],"label_agreement":null},{"id":"W2004818337","doi":"10.3111/13696998.2012.703631","title":"A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies","year":2012,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Database; Retrospective cohort study; Cancer; MEDLINE; Family medicine; Internal medicine","score_opus":0.06342109857381367,"score_gpt":0.4330840846767386,"score_spread":0.3696629861029249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004818337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019207133,0.99101627,0.00000895326,0.00028177595,0.000884216,0.0030651628,0.0024535425,0.000003912584,0.00036542903],"genre_scores_gemma":[0.00013428865,0.9976841,0.00022333169,0.00038720173,0.000605017,0.0002650707,0.0004507312,0.000055717872,0.00019451212],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99612725,0.00015516378,0.0023643712,0.0005021616,0.0005266263,0.00032440742],"domain_scores_gemma":[0.99439937,0.00075230614,0.0032592127,0.0005954357,0.0006408587,0.00035279334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020163385,0.0004770026,0.0055353036,0.00027401076,0.00006546996,0.000021653663,0.00043499348,0.00026888776,0.0001822162],"category_scores_gemma":[0.0016080983,0.00031232397,0.00032029964,0.0003479911,0.00045340188,0.00028612575,0.00026562592,0.0010215619,0.0000010754449],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013307856,0.0039098524,0.07107618,0.45904598,0.023137761,0.00024611625,0.0017166528,0.000003497769,6.547534e-8,0.00014448247,0.03742046,0.3899911],"study_design_scores_gemma":[0.09886987,0.00046058276,0.0046826974,0.49329382,0.022442965,0.00007353402,0.00008843268,0.00006332948,0.0000012352136,0.000010936122,0.37950674,0.0005058671],"about_ca_topic_score_codex":0.0010354111,"about_ca_topic_score_gemma":0.0008015942,"teacher_disagreement_score":0.38948524,"about_ca_system_score_codex":0.0027221278,"about_ca_system_score_gemma":0.0067316093,"threshold_uncertainty_score":0.9999329},"labels":[],"label_agreement":null},{"id":"W2007452812","doi":"10.3111/13696998.2014.911184","title":"The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute; University of Alberta","funders":"Canadian Institutes of Health Research; Johnson and Johnson; Medicines Company; Servier; Sanofi; GlaxoSmithKline; Eli Lilly and Company","keywords":"Medicine; Emergency medicine; Stroke (engine); Myocardial infarction; Clinical trial; Randomized controlled trial; Acute coronary syndrome; Intervention (counseling); Indirect costs; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.054381040330305934,"score_gpt":0.36810470796049427,"score_spread":0.31372366763018833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007452812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724901,0.000070133996,0.00008087357,0.025983473,0.00024057984,0.0004475587,0.000010515611,0.000003774773,0.0006730465],"genre_scores_gemma":[0.9974006,0.0013220483,0.000047229172,0.0009586192,0.00019422309,0.00001676034,0.000004417424,0.000014907551,0.000041206164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981487,0.00027191153,0.00080093124,0.00012347712,0.00043785016,0.00021713256],"domain_scores_gemma":[0.9971274,0.0015248359,0.0003773639,0.00039710262,0.00023387109,0.00033943914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028978593,0.00010115775,0.00037932847,0.00010849843,0.00010852806,0.000037960137,0.00062874245,0.00011742189,0.0000897765],"category_scores_gemma":[0.00078860606,0.000057608268,0.0001184307,0.00014179003,0.00031610485,0.00014133305,0.00010071476,0.0008244535,0.000013652168],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045506697,0.0077931564,0.16964853,0.000091273876,0.021809978,0.001410412,0.006661854,0.005264461,0.00072568853,0.018290892,0.05499603,0.667801],"study_design_scores_gemma":[0.021493383,0.024590598,0.914184,0.000094823925,0.00079420704,0.0025230623,0.011153759,0.008713436,0.000089771725,0.0014673535,0.014626039,0.00026956564],"about_ca_topic_score_codex":0.00014420837,"about_ca_topic_score_gemma":0.00027652388,"teacher_disagreement_score":0.74453545,"about_ca_system_score_codex":0.00018790326,"about_ca_system_score_gemma":0.00095576775,"threshold_uncertainty_score":0.3581886},"labels":[],"label_agreement":null},{"id":"W2011880652","doi":"10.3111/13696998.2015.1044457","title":"A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Sudbury","funders":"","keywords":"Simeprevir; Medicine; Telaprevir; Ribavirin; Boceprevir; Internal medicine; Hepatitis C; Adverse effect; Sofosbuvir; Hepatitis C virus; Cost-effectiveness analysis; Cost effectiveness; Virology; Virus","score_opus":0.10284127353406106,"score_gpt":0.38346871081932143,"score_spread":0.2806274372852604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011880652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809369,0.00026900033,0.00046274927,0.017248837,0.00007106031,0.00038161554,0.00008128002,0.0000016333736,0.00054695975],"genre_scores_gemma":[0.9966382,0.0020748386,0.00015494357,0.0010355287,0.0000717454,0.0000056528625,0.0000058203873,0.00000859809,0.0000046897426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732506,0.00045064595,0.00087242806,0.00013159584,0.0010822015,0.00013807756],"domain_scores_gemma":[0.9975688,0.00044988302,0.00077205594,0.00032814627,0.0007351821,0.00014597624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004454285,0.00009614858,0.0005648609,0.00016583217,0.000032751897,0.000009890851,0.0004655296,0.00007067358,0.00024972146],"category_scores_gemma":[0.0004853798,0.000048802936,0.00016903576,0.0006412581,0.00023296889,0.00006771024,0.00010720965,0.0004981251,0.00000201453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000807721,0.00053251744,0.9796006,0.00009126992,0.0030137608,0.000009873796,0.00715634,0.0020646637,0.00000672033,0.0008757344,0.00094411697,0.0048966804],"study_design_scores_gemma":[0.0022248193,0.00044469483,0.9800432,0.00030961394,0.0004058825,0.000011587752,0.002190907,0.012307711,0.00006851018,0.00045740986,0.0014856762,0.000050003724],"about_ca_topic_score_codex":0.03243891,"about_ca_topic_score_gemma":0.08621807,"teacher_disagreement_score":0.053779155,"about_ca_system_score_codex":0.00057131395,"about_ca_system_score_gemma":0.0014897004,"threshold_uncertainty_score":0.97400415},"labels":[],"label_agreement":null},{"id":"W2016112560","doi":"10.3111/13696998.2014.1003644","title":"Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Anaplastic lymphoma kinase; Internal medicine; Medical diagnosis; Oncology; ALK inhibitor; Brain metastasis; Ceritinib; Cancer; Metastasis; Radiology","score_opus":0.018142104251795008,"score_gpt":0.33406712434552266,"score_spread":0.31592502009372764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016112560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992826,0.000574865,0.000051250307,0.005574908,0.00040221345,0.00029658285,0.0000655646,0.0000038709904,0.000204767],"genre_scores_gemma":[0.99592716,0.0021772562,0.00039321525,0.0007776463,0.00055187504,0.000013832445,0.000027649296,0.000023467077,0.00010789609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866563,0.000052530177,0.00074426446,0.00019148158,0.00015523718,0.00019085048],"domain_scores_gemma":[0.9985475,0.0001670647,0.00038226112,0.0001351686,0.00006280092,0.00070519804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052987464,0.00016139717,0.000616795,0.0001191054,0.00002066064,0.00002558808,0.00009926304,0.000115262046,0.000106885025],"category_scores_gemma":[0.00004730593,0.000107663654,0.00009783995,0.000025185513,0.000062756066,0.00011484141,0.000030440755,0.00021275508,0.0000037490847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003998786,0.00045553807,0.96685743,0.000027863503,0.0005515439,0.00007463369,0.00043466245,0.00031929964,7.785035e-8,0.000013390001,0.001305964,0.029559726],"study_design_scores_gemma":[0.072583996,0.006961822,0.8871367,0.0006170149,0.0017173572,0.00012229853,0.0007531381,0.004795046,0.000026837115,0.000036424597,0.02492338,0.00032598944],"about_ca_topic_score_codex":0.0012124159,"about_ca_topic_score_gemma":0.0011373623,"teacher_disagreement_score":0.07972073,"about_ca_system_score_codex":0.0008806575,"about_ca_system_score_gemma":0.0018904188,"threshold_uncertainty_score":0.43903962},"labels":[],"label_agreement":null},{"id":"W2016463457","doi":"10.3111/13696998.2013.838571","title":"Validation of an economic model of paliperidone palmitate for chronic schizophrenia","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Paliperidone Palmitate; Medicine; Schizophrenia (object-oriented programming); Paliperidone; Psychiatry; Internal medicine; Antipsychotic","score_opus":0.03119009469812346,"score_gpt":0.3072504701223904,"score_spread":0.2760603754242669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016463457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950077,0.00024182555,0.0008040344,0.003377678,0.00015534289,0.0003266036,0.00003306187,0.000003748404,0.00005001286],"genre_scores_gemma":[0.984842,0.0011001112,0.013484377,0.000052018997,0.00043592922,0.000015969044,0.000020309593,0.000020039623,0.000029248504],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99845856,0.000030673516,0.0009351187,0.00012924812,0.00024495946,0.00020144274],"domain_scores_gemma":[0.99837,0.00015080345,0.00056907616,0.00021562765,0.00018419212,0.00051033084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007736452,0.000116642535,0.00058359775,0.00017825433,0.000021795053,0.000014031153,0.0002193315,0.00013361892,0.00045809936],"category_scores_gemma":[0.00020287116,0.00009071654,0.0002443322,0.000027660031,0.00012364208,0.00025001128,0.000032586824,0.000197354,0.000013013072],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05906865,0.0040773796,0.004276351,0.0018178296,0.0046244,0.000060072445,0.000823348,0.059002873,0.023589727,0.022587407,0.0051854076,0.81488657],"study_design_scores_gemma":[0.034796588,0.0065884376,0.0049015796,0.00037453833,0.00034008065,0.00028871396,0.00016558268,0.85961455,0.07074784,0.021717569,0.00023417486,0.00023033704],"about_ca_topic_score_codex":0.00004176772,"about_ca_topic_score_gemma":0.000032544693,"teacher_disagreement_score":0.8146562,"about_ca_system_score_codex":0.00026409325,"about_ca_system_score_gemma":0.0020226594,"threshold_uncertainty_score":0.5015867},"labels":[],"label_agreement":null},{"id":"W2020081435","doi":"10.3111/13696998.2010.509244","title":"Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder","year":2010,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thornhill Medical (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Astellas Foundation for Research on Metabolic Disorders","keywords":"Solifenacin; Oxybutynin; Overactive bladder; Medicine; Tolterodine; Urology; Urinary incontinence; Cost–utility analysis; Quality-adjusted life year; Cost effectiveness","score_opus":0.014841219189673594,"score_gpt":0.30791645415538066,"score_spread":0.2930752349657071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020081435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968053,0.000014964275,0.00004981371,0.0021342114,0.00017658742,0.0004311307,0.00007698411,0.0000018164478,0.00030919403],"genre_scores_gemma":[0.9992342,0.000053310232,0.0001348514,0.00040170216,0.00010055043,0.000007609864,0.00003766195,0.000016179021,0.00001390937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982228,0.00010948511,0.00062141765,0.00017393022,0.00052302075,0.00034929675],"domain_scores_gemma":[0.9972238,0.00040909782,0.00024017516,0.00020284933,0.00037071592,0.0015533636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014382238,0.00013821245,0.00082197314,0.0012130867,0.000028904618,0.000016030952,0.0002166831,0.00016171946,0.0007835583],"category_scores_gemma":[0.00059290463,0.000105921405,0.00014726543,0.00051207724,0.00009570147,0.00013214882,0.000039299346,0.0009440585,0.000008439226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00425516,0.00070184027,0.9851495,0.000038737857,0.0016796895,0.00019563675,0.0004900534,0.001290349,0.00005772882,0.000044501026,0.00030122136,0.005795567],"study_design_scores_gemma":[0.006084541,0.00095417636,0.98759735,0.00009200029,0.0003777834,0.00002418003,0.0001747454,0.0029070918,0.0002905332,0.000021975418,0.0013576148,0.00011798838],"about_ca_topic_score_codex":0.014116974,"about_ca_topic_score_gemma":0.06203736,"teacher_disagreement_score":0.047920387,"about_ca_system_score_codex":0.00039717334,"about_ca_system_score_gemma":0.0024021633,"threshold_uncertainty_score":0.9924481},"labels":[],"label_agreement":null},{"id":"W2025655213","doi":"10.3111/13696998.2014.897628","title":"Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Medicine; Oxycodone; Medicaid; Medical prescription; Pharmacy; Opioid; Propensity score matching; Substance abuse; Medicare Part D; Opioid abuse; Emergency medicine; Observational study; Prescription drug; Psychiatry; Family medicine; Internal medicine; Health care; Pharmacology","score_opus":0.00829051050439042,"score_gpt":0.258836376412609,"score_spread":0.2505458659082186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025655213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740463,0.00019764777,0.00031318914,0.024792617,0.0001522764,0.00029147835,0.000002621026,0.000024252633,0.00017962338],"genre_scores_gemma":[0.9947066,0.0008143304,0.0004412639,0.0037099123,0.00024667958,0.000020336827,0.000012623786,0.000037144997,0.000011122565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975266,0.00014375377,0.0007516055,0.000241172,0.00095721363,0.0003796591],"domain_scores_gemma":[0.99810743,0.00029682607,0.00048219258,0.0003698565,0.00011908084,0.00062461523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019102369,0.00022834167,0.00068015594,0.00028004296,0.00005430713,0.000031959946,0.00059709814,0.0003800337,0.00022487644],"category_scores_gemma":[0.0010447298,0.00012230563,0.000087369146,0.00020948873,0.0003560976,0.0001229966,0.000036768128,0.0012230834,0.000010476221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054171057,0.01727638,0.5761692,0.00021527703,0.0020892723,0.007341451,0.0085585965,0.00040762132,0.000020991729,0.0055247066,0.002642431,0.37433696],"study_design_scores_gemma":[0.09864658,0.04509941,0.70235705,0.007700933,0.0019425969,0.021755442,0.011121075,0.053672384,0.0002831452,0.004545003,0.051329732,0.0015466165],"about_ca_topic_score_codex":0.000046166475,"about_ca_topic_score_gemma":0.00078845053,"teacher_disagreement_score":0.37279034,"about_ca_system_score_codex":0.00032413492,"about_ca_system_score_gemma":0.0011209915,"threshold_uncertainty_score":0.5313757},"labels":[],"label_agreement":null},{"id":"W2029977303","doi":"10.3111/13696990903438617","title":"Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Osteoarthritis; Placebo; Quality of life (healthcare); Chondroitin sulphate; Physical therapy; Internal medicine; Alternative medicine","score_opus":0.009613533774219517,"score_gpt":0.28202257187560875,"score_spread":0.2724090381013892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029977303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755263,0.00021154755,0.00001628501,0.0014486585,0.00013719042,0.00025132424,0.00004996966,0.000005636387,0.0003267421],"genre_scores_gemma":[0.99882823,0.00031739697,0.00024747255,0.0004213309,0.00012315149,0.0000012972215,0.000035377445,0.000011920463,0.000013806961],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980458,0.00006022548,0.0010705017,0.00019850144,0.00032855166,0.0002964212],"domain_scores_gemma":[0.9983792,0.000049759732,0.00070988404,0.00023298994,0.00007301228,0.00055517955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071911537,0.00018840151,0.0011534947,0.0005022186,0.000022201208,0.000014427466,0.00013567056,0.00014222188,0.00046232008],"category_scores_gemma":[0.00006451948,0.00013993657,0.0004445785,0.00015371795,0.000059536826,0.00014865569,0.000014181752,0.0003466114,0.000006621913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004346049,0.0014969985,0.27627766,0.00001829128,0.0005855952,0.00008200361,0.00020155823,0.00027682396,0.0000019486438,0.00019141252,0.00010903329,0.7164126],"study_design_scores_gemma":[0.025966996,0.051459398,0.92082965,0.00040027263,0.0002820459,0.0000505585,0.00007068153,0.0003195191,0.00007951982,0.00028137257,0.00010876485,0.00015121646],"about_ca_topic_score_codex":0.00011170052,"about_ca_topic_score_gemma":0.00029807954,"teacher_disagreement_score":0.7162614,"about_ca_system_score_codex":0.00057965406,"about_ca_system_score_gemma":0.0012398288,"threshold_uncertainty_score":0.57064474},"labels":[],"label_agreement":null},{"id":"W2030020820","doi":"10.3111/13696990802320908","title":"Seretide: a pharmacoeconomic analysis","year":2008,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University Health Network","funders":"U.S. National Library of Medicine","keywords":"Medicine; Pharmacoeconomics; Intensive care medicine","score_opus":0.05159584318216997,"score_gpt":0.3966179577317265,"score_spread":0.3450221145495565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030020820","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012914861,0.99532914,0.000037461235,0.00095033075,0.00067420944,0.00042394068,0.000089763904,0.000013867514,0.0011897802],"genre_scores_gemma":[0.00004446364,0.9962796,0.00017623277,0.0003475959,0.0024780123,0.000013064413,0.00008304736,0.00009184104,0.00048613636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952666,0.00023344134,0.0026692357,0.0004792951,0.00081074843,0.00054066506],"domain_scores_gemma":[0.9949361,0.0005245549,0.0017973662,0.0005682658,0.00020843255,0.0019652473],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012477256,0.00052515743,0.005294345,0.0015972995,0.00006911898,0.00004321052,0.0009959191,0.0007241155,0.007597268],"category_scores_gemma":[0.00047432794,0.00041909123,0.0042393585,0.00057517114,0.00036946338,0.0001738013,0.00025130913,0.002446368,0.00028780758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007941007,0.00026701126,0.00016090715,0.006241369,0.011249985,0.0021808038,0.000020348658,0.000015071449,1.91077e-8,0.0000673463,0.007837624,0.9718801],"study_design_scores_gemma":[0.0015376006,0.00009037193,0.00015075075,0.0031120833,0.010606225,0.008259181,0.000022686048,0.00091192586,2.476318e-7,0.000030352507,0.9749775,0.00030106882],"about_ca_topic_score_codex":0.000016643375,"about_ca_topic_score_gemma":0.0000067556516,"teacher_disagreement_score":0.971579,"about_ca_system_score_codex":0.0021130466,"about_ca_system_score_gemma":0.009918416,"threshold_uncertainty_score":0.99985504},"labels":[],"label_agreement":null},{"id":"W2035214881","doi":"10.3111/13696998.2014.979938","title":"Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Roche (Canada)","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Neoadjuvant therapy; Inflammatory breast cancer; Cancer","score_opus":0.024272920471406934,"score_gpt":0.34425611307015447,"score_spread":0.3199831925987475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035214881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938768,0.0006126849,0.001214225,0.003320165,0.00021187722,0.00059934653,0.00013300429,0.0000022849456,0.000029595662],"genre_scores_gemma":[0.9947027,0.0044027837,0.00015020491,0.00045053795,0.00019933796,0.000052071842,0.0000037575207,0.00002735978,0.000011252718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978677,0.00016711326,0.00086526433,0.00022861957,0.00054045237,0.00033082048],"domain_scores_gemma":[0.9973892,0.0011500838,0.00039959676,0.000171605,0.000356778,0.00053271325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018830914,0.00017305868,0.0011229481,0.00032590426,0.000032116,0.000016670068,0.00024332729,0.0001428619,0.0002742638],"category_scores_gemma":[0.00038647937,0.0001268817,0.00016908863,0.00024822922,0.00016046688,0.00011056827,0.0000364499,0.00048301189,2.3460112e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010872399,0.00019272762,0.19124466,0.00023860276,0.0017463185,0.0001173548,0.00045283025,0.004465755,0.00013843967,0.00008002468,0.00010830066,0.79034257],"study_design_scores_gemma":[0.014095132,0.0021825947,0.92369646,0.0012404437,0.00038630178,0.0003141745,0.00059858704,0.053156465,0.00076902745,0.00005262251,0.003274414,0.0002337756],"about_ca_topic_score_codex":0.138711,"about_ca_topic_score_gemma":0.5153628,"teacher_disagreement_score":0.7901088,"about_ca_system_score_codex":0.0021892237,"about_ca_system_score_gemma":0.009132836,"threshold_uncertainty_score":0.99648446},"labels":[],"label_agreement":null},{"id":"W2041738951","doi":"10.3111/13696998.2011.649326","title":"Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Dialysis; Erythropoietin; Kidney disease; Dosing; Emergency medicine; Statistical significance; Intensive care medicine; Internal medicine","score_opus":0.08573305352781532,"score_gpt":0.34126154978902756,"score_spread":0.2555284962612122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041738951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971699,0.0005221126,0.000072572344,0.0016315388,0.00018334578,0.00016502652,0.0000025585582,0.000002676571,0.0002502833],"genre_scores_gemma":[0.996245,0.0014460449,0.0020642816,0.00017621541,0.000048208753,0.0000012355679,0.0000040910913,0.000009243328,0.0000056381505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874955,0.000027761074,0.00079399796,0.000108059605,0.00020271994,0.00011788078],"domain_scores_gemma":[0.99907196,0.000079353435,0.00049311685,0.00006666494,0.00006501082,0.0002239067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041141326,0.000097447504,0.00043408002,0.00010536853,0.000024117671,0.000006327897,0.000050149338,0.000117917196,0.00010294229],"category_scores_gemma":[0.00028912374,0.00007850927,0.00004556115,0.00003947855,0.00015500278,0.00007384764,0.000054518074,0.00022308687,6.701143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017228842,0.0010701047,0.91341317,0.00015074578,0.00007118194,0.00003549774,0.008786175,0.000018055334,0.0000060468333,0.00016704813,0.00042534203,0.075684376],"study_design_scores_gemma":[0.020213008,0.0110665085,0.89012504,0.003193331,0.00035273566,0.00035224407,0.019242587,0.048611857,0.0025959937,0.00045383017,0.003387818,0.00040508277],"about_ca_topic_score_codex":0.000039269853,"about_ca_topic_score_gemma":0.000014420679,"teacher_disagreement_score":0.07527929,"about_ca_system_score_codex":0.00009297002,"about_ca_system_score_gemma":0.00009111509,"threshold_uncertainty_score":0.3201515},"labels":[],"label_agreement":null},{"id":"W2045243711","doi":"10.3111/13696998.2015.1036760","title":"Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"Reckitt Benckiser Pharmaceuticals","keywords":"Medicine; Medicaid; (+)-Naloxone; Buprenorphine; Opioid; Anesthesia; Medical emergency; Health care; Internal medicine","score_opus":0.04988832863885652,"score_gpt":0.3365930792004357,"score_spread":0.2867047505615792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045243711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98726714,0.001019994,0.00023914379,0.011006504,0.00014537906,0.00024159583,0.000040109295,0.000001549722,0.00003861189],"genre_scores_gemma":[0.99687934,0.0020088863,0.00035117296,0.00053498556,0.00014859177,0.000002768678,0.000054850156,0.000011066743,0.000008354766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986649,0.00007660125,0.000706217,0.000074660675,0.00035005785,0.00012752131],"domain_scores_gemma":[0.9985665,0.0003910069,0.0004962507,0.0001591562,0.00020143393,0.00018563228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017829781,0.00009803784,0.00040418273,0.00016296246,0.000015979478,0.0000073187866,0.00022094362,0.00010092433,0.00004753105],"category_scores_gemma":[0.001475158,0.000048553382,0.00012942262,0.00016617724,0.00016130786,0.00006547713,0.000037608483,0.00022593787,2.0664966e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00842874,0.0072268853,0.8085979,0.0014098064,0.0036714633,0.00014610302,0.051280178,0.02020136,0.0001783542,0.0023231732,0.065384336,0.031151675],"study_design_scores_gemma":[0.07229151,0.014307018,0.5513554,0.002441732,0.0020007035,0.0018385903,0.033833917,0.28268203,0.0017555846,0.013919353,0.023019372,0.0005547733],"about_ca_topic_score_codex":0.00038450444,"about_ca_topic_score_gemma":0.000058202833,"teacher_disagreement_score":0.26248068,"about_ca_system_score_codex":0.000092985945,"about_ca_system_score_gemma":0.0011444287,"threshold_uncertainty_score":0.20301674},"labels":[],"label_agreement":null},{"id":"W2048064344","doi":"10.3111/200609083099","title":"Prediction of acute and chronic complications by a new computer simulation model for type 1 and type 2 diabetes: the Diabetes Mel l it us Model (DMM)","year":2006,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Microalbuminuria; Diabetes mellitus; Type 2 diabetes; Myocardial infarction; Type 1 diabetes; Stroke (engine); Retinopathy; Type 2 Diabetes Mellitus; Diabetic retinopathy; Heart failure; Internal medicine; Disease; Surgery; Cardiology","score_opus":0.052407701612765235,"score_gpt":0.31573156604983793,"score_spread":0.2633238644370727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048064344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94738454,0.001048441,0.0387492,0.012221682,0.0001206058,0.00032813183,0.00003165499,0.000006468811,0.000109290384],"genre_scores_gemma":[0.99469423,0.0011212961,0.002331078,0.00083911483,0.00046088535,0.0000034690438,0.000050355542,0.000017066552,0.00048251834],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99912655,0.0000140618795,0.0004088899,0.00010693898,0.000187253,0.00015632976],"domain_scores_gemma":[0.9991827,0.00018838576,0.00020135228,0.00010941508,0.00016894475,0.0001491782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052506255,0.0000815119,0.00025783243,0.00007880556,0.00005451636,0.000028399912,0.000115841445,0.0000946982,0.000012840901],"category_scores_gemma":[0.00006125215,0.000056103407,0.000050175415,0.00006510283,0.000121451594,0.00011414609,0.00005724116,0.00017296354,7.140185e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031404622,0.00048729675,0.026218956,0.00055904005,0.0014263765,9.903806e-7,0.0002607383,0.7023021,0.0016404814,0.0021054028,0.1936383,0.0710463],"study_design_scores_gemma":[0.0015465951,0.00042844625,0.0022954077,0.0000867046,0.00022022458,9.63954e-7,0.0000049643295,0.99022835,0.00004486946,0.00182426,0.0032755719,0.00004365453],"about_ca_topic_score_codex":0.000001884068,"about_ca_topic_score_gemma":0.0000035165474,"teacher_disagreement_score":0.28792626,"about_ca_system_score_codex":0.000057457783,"about_ca_system_score_gemma":0.00024833204,"threshold_uncertainty_score":0.22878304},"labels":[],"label_agreement":null},{"id":"W2049204477","doi":"10.3111/13696998.2014.925905","title":"Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Takeda Pharmaceuticals International; U.S. Department of Labor","keywords":"Medicine; Diabetes mellitus; Emergency medicine; Total cost; Type 2 diabetes; Multivariate analysis; Type 2 Diabetes Mellitus; Logistic regression; Retrospective cohort study; Cost driver; Internal medicine; Endocrinology","score_opus":0.014911014080041403,"score_gpt":0.25825043689007543,"score_spread":0.24333942281003404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049204477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998487,0.00020620515,0.00018776546,0.0007916803,0.000051921103,0.00009514635,0.000025516027,0.0000035503606,0.00015122723],"genre_scores_gemma":[0.9970423,0.0022946093,0.00027842593,0.00011392211,0.000044318585,6.868501e-7,0.00020247979,0.0000065240165,0.000016730242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904335,0.00004050476,0.00039853604,0.000161775,0.00021332837,0.0001425092],"domain_scores_gemma":[0.9991318,0.00007467216,0.00030562797,0.00022567739,0.000074170115,0.00018805079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072548544,0.00009865372,0.0005865407,0.00018477756,0.000013264607,0.0000124155,0.00015425487,0.00007888893,0.00007317408],"category_scores_gemma":[0.0001941415,0.00007041866,0.000056071767,0.00025024987,0.00011609516,0.00013825117,0.00007025485,0.0001552846,0.0000014000117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043329617,0.0002978624,0.96256185,0.00003222873,0.0024711753,0.000029792609,0.000048098645,0.00005227135,0.000006493497,0.00040774568,0.0007663683,0.032892838],"study_design_scores_gemma":[0.009857981,0.0027208258,0.93553525,0.00031112367,0.004379527,0.000012351783,0.00020787196,0.042410992,0.00014147449,0.0002415729,0.004021855,0.00015914458],"about_ca_topic_score_codex":0.00003955494,"about_ca_topic_score_gemma":0.00012626605,"teacher_disagreement_score":0.04235872,"about_ca_system_score_codex":0.00026455102,"about_ca_system_score_gemma":0.00007064506,"threshold_uncertainty_score":0.28715897},"labels":[],"label_agreement":null},{"id":"W2050417509","doi":"10.3111/13696998.2013.841705","title":"Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Schizophrenia (object-oriented programming); Medicaid; Pediatrics; Internal medicine; Psychiatry; Health care","score_opus":0.01667223273340371,"score_gpt":0.2778757055518343,"score_spread":0.26120347281843054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050417509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949839,0.00014163906,0.000018445955,0.0043849736,0.00018784539,0.0002371021,0.000007655055,0.000003264792,0.00003518255],"genre_scores_gemma":[0.9967227,0.0022460548,0.0007085004,0.0001287302,0.00015083581,0.0000031871512,0.000008387166,0.000014119262,0.000017515667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983721,0.00007360186,0.00078744,0.00012679349,0.00041069058,0.00022939402],"domain_scores_gemma":[0.99851096,0.00027976616,0.00034559655,0.0001250118,0.0001714803,0.00056715985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068685075,0.000112359674,0.00050931197,0.00020105003,0.000019599054,0.000021871414,0.0001444331,0.00019864892,0.00032905486],"category_scores_gemma":[0.0015527543,0.00008616448,0.000094617724,0.00007441224,0.00006636712,0.00012908506,0.00006041943,0.00058777066,0.000009779585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006369109,0.0006888235,0.89500934,0.000043911674,0.00022006145,0.00008404906,0.00012772897,0.0000065726354,0.0000130614435,0.00012778124,0.0005444377,0.096765116],"study_design_scores_gemma":[0.016334834,0.00068703486,0.98005587,0.00054418907,0.000039341627,0.00007073248,0.00008133392,0.00145432,0.000027429474,0.00053673517,0.000100909325,0.000067242545],"about_ca_topic_score_codex":0.000052647083,"about_ca_topic_score_gemma":0.00012495248,"teacher_disagreement_score":0.09669787,"about_ca_system_score_codex":0.00017928437,"about_ca_system_score_gemma":0.0003206262,"threshold_uncertainty_score":0.360292},"labels":[],"label_agreement":null},{"id":"W2050660689","doi":"10.3111/13696998.2014.903256","title":"Is transcatheter aortic valve implantation (TAVI) a cost-effective treatment in patients who are ineligible for surgical aortic valve replacement? A systematic review of economic evaluations","year":2014,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Reimbursement; Economic evaluation; Purchasing power parity; MEDLINE; Health technology; Meta-analysis; Aortic valve replacement; Health care; Checklist; Cost effectiveness; Actuarial science; Finance; Stenosis; Internal medicine; Economics; Exchange rate","score_opus":0.034962450793082404,"score_gpt":0.4217727569544759,"score_spread":0.3868103061613935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050660689","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010573946,0.9742833,0.000041360523,0.000166325,0.0004445918,0.013843435,0.0006020356,0.0000058198425,0.000039191083],"genre_scores_gemma":[0.002360966,0.9947001,0.000024607976,0.00023699972,0.00022249854,0.001972648,0.00039223174,0.00006470484,0.00002525644],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9945797,0.000450359,0.0037459275,0.00041426564,0.0004818307,0.00032791635],"domain_scores_gemma":[0.9940779,0.0011366652,0.0035693243,0.00046605986,0.00025820665,0.0004918034],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0018972473,0.000523204,0.0066303895,0.00042161808,0.00003727097,0.000025331767,0.00021421321,0.0003468842,0.00014976626],"category_scores_gemma":[0.0005703863,0.00036321869,0.010241291,0.000109394896,0.00005681684,0.00010188912,0.000027653838,0.00028393074,0.000028021961],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041304328,0.001538257,0.0034296564,0.82080036,0.015676852,0.0000051326806,0.00014803729,0.000007393672,2.4989137e-9,0.00002968247,0.00030307498,0.1576485],"study_design_scores_gemma":[0.0180761,0.0031006678,0.001597189,0.87422764,0.08647548,0.0002255603,0.000043877997,0.0004094361,6.370798e-7,0.00007934269,0.01532874,0.00043530465],"about_ca_topic_score_codex":0.000020176196,"about_ca_topic_score_gemma":0.000005636251,"teacher_disagreement_score":0.1572132,"about_ca_system_score_codex":0.0023130851,"about_ca_system_score_gemma":0.0013931593,"threshold_uncertainty_score":0.999882},"labels":[],"label_agreement":null},{"id":"W2055583871","doi":"10.3111/13696998.2010.534670","title":"Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors","year":2010,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Sunitinib; Medicine; GiST; Imatinib; Imatinib mesylate; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Cancer; Stromal cell","score_opus":0.09181737849537273,"score_gpt":0.39409466349560496,"score_spread":0.3022772850002322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055583871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12443232,0.8730791,0.00013402013,0.0002547133,0.0003122291,0.0016321493,0.000078084035,0.000008507098,0.00006887354],"genre_scores_gemma":[0.005090185,0.99014837,0.0040997933,0.000023738534,0.0004595899,0.000041714917,0.000049668004,0.00007529043,0.000011676293],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9959427,0.0004781528,0.002049082,0.00029620892,0.0007394443,0.00049442844],"domain_scores_gemma":[0.9954966,0.0015460644,0.00139751,0.00030894618,0.00025155506,0.0009993702],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0037594433,0.0004653949,0.0036478455,0.0006722862,0.000023069808,0.000027093267,0.00045048527,0.00015167402,0.00023392028],"category_scores_gemma":[0.0026545727,0.000313301,0.00090193516,0.00022438675,0.00033748322,0.00009429531,0.00009698551,0.0025561254,0.0000139824715],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018796963,0.0026242966,0.0027980935,0.013959808,0.00041190445,0.01117649,0.000013378949,0.000006301779,0.000026374315,0.00017182028,0.00006180736,0.96687],"study_design_scores_gemma":[0.03989405,0.042464804,0.007612188,0.47835314,0.0023819627,0.25850433,0.00016470079,0.00031185296,0.00039060187,0.00041985986,0.1684437,0.0010588291],"about_ca_topic_score_codex":0.00003676932,"about_ca_topic_score_gemma":0.000017980517,"teacher_disagreement_score":0.9658112,"about_ca_system_score_codex":0.00051865645,"about_ca_system_score_gemma":0.004398047,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W2056855548","doi":"10.3111/13696998.2014.897627","title":"Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Asenapine; Medicine; Olanzapine; Ziprasidone; Schizophrenia (object-oriented programming); Antipsychotic; Quetiapine; Pharmacoeconomics; Psychiatry; Lurasidone; Intensive care medicine","score_opus":0.035539038075372634,"score_gpt":0.31342471114943127,"score_spread":0.27788567307405865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056855548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634117,0.00051993545,0.000021914535,0.0026400785,0.00011107958,0.00027275752,0.0000070925767,4.9740555e-7,0.000085464395],"genre_scores_gemma":[0.9976295,0.0019468048,0.0002303361,0.00006700517,0.00010582875,0.000008979949,0.000003596822,0.000006086706,0.0000018273043],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851453,0.00023379938,0.00061935675,0.00008291533,0.0003857695,0.00016364742],"domain_scores_gemma":[0.9983396,0.0010056896,0.00022938575,0.00016494883,0.000055033954,0.00020535995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015433674,0.00009243033,0.00059478317,0.0001548663,0.000008067984,0.0000030917404,0.00016968738,0.000057587647,0.00006863653],"category_scores_gemma":[0.00040643234,0.000052451738,0.00010164328,0.00010557466,0.000068554415,0.000030345098,0.000011668931,0.00020388984,8.2907604e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046678174,0.0052745645,0.36109266,0.0004471721,0.0007714985,0.0015320737,0.00055585057,0.0010298894,0.0001560968,0.004709815,0.0002402356,0.57751197],"study_design_scores_gemma":[0.048502237,0.0052283574,0.93186206,0.0008614559,0.00010192627,0.00051988324,0.000462907,0.004608243,0.0045092017,0.0012186352,0.0020165646,0.00010854115],"about_ca_topic_score_codex":0.1246263,"about_ca_topic_score_gemma":0.5304244,"teacher_disagreement_score":0.5774034,"about_ca_system_score_codex":0.0007995703,"about_ca_system_score_gemma":0.003557356,"threshold_uncertainty_score":0.8812029},"labels":[],"label_agreement":null},{"id":"W2059760712","doi":"10.3111/13696998.2015.1033423","title":"Costing bias in economic evaluations","year":2015,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"","keywords":"Activity-based costing; Health care; Risk analysis (engineering); Health economics; Process (computing); Key (lock); Psychological intervention; Target costing; Medicine; Operations management; Actuarial science; Computer science; Business; Economics; Nursing; Accounting; Computer security","score_opus":0.47134491339926743,"score_gpt":0.5149067998982277,"score_spread":0.04356188649896031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059760712","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01362036,0.008506838,0.00051798107,0.041882757,0.9275298,0.0006909419,0.0012060165,0.00003190999,0.006013412],"genre_scores_gemma":[0.0023495692,0.008818499,0.0021072438,0.0040980745,0.9811004,0.00006246391,0.00030364539,0.00023854418,0.00092159177],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97961986,0.0009023134,0.017121183,0.00082581636,0.000732886,0.00079791347],"domain_scores_gemma":[0.96919745,0.010713347,0.017554468,0.0008459328,0.00044377035,0.0012450034],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.12957981,0.0005629602,0.004127107,0.0016647461,0.00011351416,0.0002680547,0.001947075,0.0023127,0.001914846],"category_scores_gemma":[0.10246012,0.00070368045,0.0005732524,0.00017976416,0.00020295157,0.0009847704,0.000250282,0.0028892793,0.0025991665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004002401,0.00011729135,0.0009814282,0.00020779255,0.00018594929,0.000017267843,0.0005666804,0.0020465988,1.8565684e-8,0.006434422,0.9887415,0.00066101295],"study_design_scores_gemma":[0.003314327,0.00019870655,0.00014051472,0.00072259415,0.00003572095,0.000040746825,0.0005232113,0.0122474795,2.8745953e-7,0.02262355,0.9595554,0.00059750024],"about_ca_topic_score_codex":0.0011391215,"about_ca_topic_score_gemma":0.0017539302,"teacher_disagreement_score":0.053570587,"about_ca_system_score_codex":0.007662731,"about_ca_system_score_gemma":0.011722479,"threshold_uncertainty_score":0.99954146},"labels":[],"label_agreement":null},{"id":"W2060564338","doi":"10.3111/13696998.2012.757552","title":"Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prostate cancer; PCA3; Sample (material); Biopsy; Prostate biopsy; Gynecology; Cancer; Internal medicine","score_opus":0.04159686773515178,"score_gpt":0.3686790785733814,"score_spread":0.32708221083822964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060564338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99101615,0.0030577134,0.0008041424,0.003837713,0.0003931813,0.0006947933,0.00018723193,0.0000015209524,0.000007559993],"genre_scores_gemma":[0.9754876,0.020567115,0.0030555595,0.00022845615,0.00036431063,0.00026684845,0.000007640185,0.000017625029,0.0000048597776],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99867475,0.00002316108,0.0007710943,0.00010208594,0.00021492428,0.00021398245],"domain_scores_gemma":[0.9976594,0.0011516812,0.0006917298,0.00012977069,0.00016679405,0.0002006283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014968629,0.000114944174,0.0005130521,0.00012423743,0.000027242884,0.000005963206,0.000109607296,0.000103473634,0.000054840377],"category_scores_gemma":[0.00068878615,0.00006667936,0.00029619716,0.000077962286,0.000061273306,0.00012136583,0.000024440697,0.00015854249,4.1396657e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011451774,0.00097009906,0.3729125,0.00011036501,0.0003051067,0.0000055891715,0.00045575688,0.00018832803,0.00004436488,0.00012840179,0.0022543662,0.6214799],"study_design_scores_gemma":[0.030843362,0.009964333,0.9076481,0.010576236,0.0006349929,0.0002042403,0.0005764403,0.013601374,0.014342384,0.0016413026,0.009597134,0.0003701024],"about_ca_topic_score_codex":0.000098458826,"about_ca_topic_score_gemma":0.0000143046145,"teacher_disagreement_score":0.62110984,"about_ca_system_score_codex":0.00067413336,"about_ca_system_score_gemma":0.0003490663,"threshold_uncertainty_score":0.27191055},"labels":[],"label_agreement":null},{"id":"W2065318007","doi":"10.3111/13696998.2011.653511","title":"Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Medical Research Council","keywords":"Medicine; Zoledronic acid; Multiple myeloma; Incidence (geometry); Internal medicine; Cost effectiveness; Adverse effect; Oncology","score_opus":0.09017863653723394,"score_gpt":0.3739058121697349,"score_spread":0.28372717563250094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065318007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98713225,0.0034515967,0.0018898882,0.0050230124,0.000752002,0.0015178119,0.00018598657,0.000017425595,0.000030003712],"genre_scores_gemma":[0.9969846,0.00064907945,0.00066378043,0.00031426756,0.0011747119,0.00008680888,0.00007825518,0.000044270884,0.0000042528704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99720764,0.0004877857,0.00087407825,0.00022226135,0.00058358145,0.00062466366],"domain_scores_gemma":[0.9941356,0.003270803,0.00066911,0.0003715576,0.0005390799,0.0010138226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028416396,0.00024572798,0.0009577197,0.00020183256,0.00013839387,0.000024714545,0.00043876882,0.00029571194,0.000079034675],"category_scores_gemma":[0.0028490985,0.00016063724,0.0004312999,0.00016929496,0.00020910219,0.00019005996,0.00009740995,0.0007407101,0.000015086274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07253187,0.0055330223,0.7894772,0.0041551,0.012651121,0.0007488594,0.007544115,0.00043948455,0.0021931576,0.029536871,0.0024785409,0.072710656],"study_design_scores_gemma":[0.1459879,0.008331329,0.71105474,0.008304262,0.0018240869,0.0020225209,0.02212016,0.03534463,0.039243672,0.00082114595,0.024026584,0.00091893895],"about_ca_topic_score_codex":0.0015392149,"about_ca_topic_score_gemma":0.0002479552,"teacher_disagreement_score":0.078422435,"about_ca_system_score_codex":0.001955937,"about_ca_system_score_gemma":0.0013996313,"threshold_uncertainty_score":0.6550597},"labels":[],"label_agreement":null},{"id":"W2067254496","doi":"10.3111/13696998.2013.858634","title":"Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Rivaroxaban; Vitamin K antagonist; Pulmonary embolism; Low molecular weight heparin; Enoxaparin sodium; Deep vein; Cost effectiveness; Venous thrombosis; Thrombosis; Cost-effectiveness analysis; Anticoagulant; Anesthesia; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.04347617111276509,"score_gpt":0.3114251669344934,"score_spread":0.2679489958217283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067254496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924916,0.0006541664,0.002100875,0.002187637,0.00038550753,0.001908237,0.000019294994,0.0000053450553,0.00024730669],"genre_scores_gemma":[0.99389654,0.0047097793,0.0007680418,0.00018702305,0.00027005738,0.0001177582,0.000008640548,0.000026734117,0.000015409434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984212,0.000066669396,0.00079148,0.00015230682,0.0003258135,0.00024253233],"domain_scores_gemma":[0.99766654,0.0008527899,0.000702711,0.0002945007,0.0002338716,0.00024959646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083250424,0.0001853984,0.0015664514,0.00010686934,0.000063159576,0.000021126518,0.00028250273,0.000107800945,0.0001533544],"category_scores_gemma":[0.00008652987,0.00010538568,0.00028069204,0.00006912235,0.00029749327,0.00008318797,0.000033884146,0.00014069042,0.0000036301124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01895629,0.0825842,0.025391307,0.0076384903,0.040284418,0.00039721577,0.024660738,0.019361027,0.0042445236,0.041982234,0.020417191,0.71408236],"study_design_scores_gemma":[0.07958453,0.05067951,0.7165972,0.0035278618,0.00575638,0.000999614,0.007657136,0.026970498,0.024218014,0.0022408278,0.08091071,0.00085774204],"about_ca_topic_score_codex":0.0004647588,"about_ca_topic_score_gemma":0.000061857325,"teacher_disagreement_score":0.71322465,"about_ca_system_score_codex":0.0003170142,"about_ca_system_score_gemma":0.000513188,"threshold_uncertainty_score":0.42975032},"labels":[],"label_agreement":null},{"id":"W2069848730","doi":"10.3111/13696998.2014.914032","title":"A cost-analysis model for anticoagulant treatment in the hospital setting","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Rivaroxaban; Medicine; Deep vein; Pulmonary embolism; Anticoagulant; Atrial fibrillation; Thrombosis; Stroke (engine); Emergency medicine; Cost effectiveness; Intensive care medicine; Surgery; Internal medicine; Warfarin","score_opus":0.0905700533176745,"score_gpt":0.3698003849969684,"score_spread":0.2792303316792939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069848730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.860651,0.000057813377,0.063069426,0.07546729,0.00017435313,0.00035711224,0.0000025543916,0.0000034975105,0.00021691222],"genre_scores_gemma":[0.99528867,0.00023578438,0.0023582103,0.0011135136,0.0008809876,0.0000019670808,0.0000059883664,0.0000060634325,0.00010881625],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990866,0.00003198779,0.00050799496,0.00007361849,0.00018296261,0.00011680668],"domain_scores_gemma":[0.99911314,0.00039152417,0.00026102838,0.00010436725,0.000032221717,0.00009770406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016813043,0.00007064383,0.0004140391,0.00015191724,0.00002711148,0.00002244609,0.000113732305,0.000060371618,0.00002429548],"category_scores_gemma":[0.0004803632,0.000039847557,0.00038838436,0.00007431569,0.000022043669,0.000051303596,0.000012615902,0.00008589991,0.0000019214515],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007290645,0.00029144165,0.59569824,0.000083347644,0.0038071452,0.00006192286,0.0050010732,0.0910701,0.0000070046895,0.01763159,0.0030748155,0.28254429],"study_design_scores_gemma":[0.0030412746,0.0003208759,0.015511235,0.00001617136,0.0010389737,0.000015014615,0.00030604895,0.9643666,0.0000046713863,0.000640003,0.01468721,0.00005191306],"about_ca_topic_score_codex":0.0000053223325,"about_ca_topic_score_gemma":0.000021900463,"teacher_disagreement_score":0.8732965,"about_ca_system_score_codex":0.00008690921,"about_ca_system_score_gemma":0.00010272916,"threshold_uncertainty_score":0.16249362},"labels":[],"label_agreement":null},{"id":"W2071344217","doi":"10.3111/13696998.2011.653726","title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Merz Pharmaceuticals","keywords":"Medicine; Cervical dystonia; Botulinum toxin; Patient satisfaction; Cross-sectional study; Quality of life (healthcare); Adverse effect; Physical therapy; Visual analogue scale; Internal medicine; Anesthesia; Surgery","score_opus":0.03516939767736518,"score_gpt":0.2643901803924858,"score_spread":0.2292207827151206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071344217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987499,0.000053370164,0.00017740871,0.00026258107,0.00022336617,0.00014184165,0.000020484742,0.000008563566,0.00036250043],"genre_scores_gemma":[0.9986541,0.0004207031,0.0004603367,0.00033008115,0.00006744517,0.0000017262023,0.00001323777,0.00001895649,0.000033415014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845356,0.00007848494,0.0007069201,0.00017685593,0.000397632,0.00018652048],"domain_scores_gemma":[0.9985741,0.00014360505,0.0005036559,0.00013433472,0.0002473422,0.00039701042],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043335377,0.00015819502,0.0004923579,0.000098893695,0.000039989915,0.000010281136,0.000116207935,0.00033044463,0.0010997024],"category_scores_gemma":[0.00014410012,0.00008742704,0.0001172971,0.00010527889,0.00028793683,0.0001096728,0.000018028517,0.00047365046,0.000009207477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006366101,0.0008332961,0.9894052,0.000016455046,0.0003279009,0.000052040705,0.00006745823,0.00004804011,0.000002576698,0.00005770998,0.000022310274,0.0028008968],"study_design_scores_gemma":[0.008514037,0.0065981755,0.9839581,0.000038129812,0.00007636485,0.00023745098,0.000011749394,0.0002100707,0.000045563647,0.00007356137,0.00014614251,0.00009065524],"about_ca_topic_score_codex":0.00022684532,"about_ca_topic_score_gemma":0.00038365475,"teacher_disagreement_score":0.0057648793,"about_ca_system_score_codex":0.00010471677,"about_ca_system_score_gemma":0.00040941962,"threshold_uncertainty_score":0.99981344},"labels":[],"label_agreement":null},{"id":"W2072574820","doi":"10.3111/13696998.2013.772058","title":"Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"GlaxoSmithKline","keywords":"Medicine; Lupus nephritis; Systemic lupus erythematosus; Population; Internal medicine; Health care; Lupus erythematosus; Disease; Immunology","score_opus":0.014061235590230087,"score_gpt":0.27046570220216126,"score_spread":0.25640446661193117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072574820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991041,0.000584794,0.0000038969397,0.007570885,0.00031524795,0.00045739886,0.0000029770106,0.0000058994124,0.000017904194],"genre_scores_gemma":[0.9974052,0.0011022269,0.00022247713,0.0010141013,0.0001939134,0.000005789626,0.000011720586,0.000028701226,0.000015925236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972939,0.00028524076,0.0009949746,0.00024224965,0.0008779514,0.00030570128],"domain_scores_gemma":[0.9979733,0.00028863244,0.00029611232,0.00018350643,0.00013837703,0.0011200219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013451809,0.0001475407,0.0005974906,0.0005114962,0.000030971663,0.000065434455,0.0001628204,0.0003105987,0.000067021705],"category_scores_gemma":[0.0011203276,0.00011183943,0.000030523282,0.00019191657,0.00011349366,0.0004284482,0.00007480247,0.0009029962,0.0000020660423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047872224,0.00018045545,0.967855,0.0001425617,0.000014358898,0.00012322677,0.00029932504,0.0000021986064,3.9338542e-7,0.000038492362,0.00032986733,0.030535426],"study_design_scores_gemma":[0.01111258,0.0010095459,0.9754395,0.001029005,0.000010270127,0.008549682,0.00035095902,0.0020520259,1.7933218e-7,0.00005947594,0.00028608146,0.000100722515],"about_ca_topic_score_codex":0.0010077865,"about_ca_topic_score_gemma":0.0026730266,"teacher_disagreement_score":0.030434703,"about_ca_system_score_codex":0.00029613927,"about_ca_system_score_gemma":0.00036463307,"threshold_uncertainty_score":0.45606795},"labels":[],"label_agreement":null},{"id":"W2083738707","doi":"10.3111/13696998.2011.578698","title":"Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Pulmonary embolism; Major bleeding; Deep vein; Knee replacement; Thrombosis; Population; Venous thromboembolism; Diagnosis code; Surgery; Arthroplasty; Internal medicine","score_opus":0.04853567880147308,"score_gpt":0.2993872589950098,"score_spread":0.2508515801935367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083738707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978815,0.0003225817,0.00009877906,0.00044941378,0.00030644555,0.00058109453,0.000004747836,0.0000037476505,0.0003517069],"genre_scores_gemma":[0.9955554,0.002719996,0.0013345225,0.00016609757,0.00017952787,0.000010612941,0.0000069394114,0.000017321328,0.000009561134],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987357,0.000022996805,0.00070530595,0.00015445908,0.00020363544,0.0001778515],"domain_scores_gemma":[0.9990367,0.00014177074,0.00045515067,0.00009682419,0.00007479035,0.00019475083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068614085,0.000114275404,0.00064691005,0.00019366674,0.000042391668,0.00001522277,0.00007090538,0.00011824342,0.00007263344],"category_scores_gemma":[0.0003369152,0.000093660026,0.00006358006,0.000040720846,0.00004864686,0.00013457793,0.000086227774,0.00017193895,4.0481265e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046628467,0.0036405937,0.38962933,0.0045447303,0.0017276048,0.00014082638,0.031439923,0.0003739098,0.000018456161,0.007866756,0.001303552,0.5546515],"study_design_scores_gemma":[0.014962533,0.006483154,0.96148664,0.0017571469,0.0006248214,0.000105441584,0.009239031,0.0029732566,0.00004176934,0.0012563466,0.0008410536,0.00022879665],"about_ca_topic_score_codex":0.00025339413,"about_ca_topic_score_gemma":0.00011772244,"teacher_disagreement_score":0.57185733,"about_ca_system_score_codex":0.00015759737,"about_ca_system_score_gemma":0.00009549527,"threshold_uncertainty_score":0.3819345},"labels":[],"label_agreement":null},{"id":"W2087722862","doi":"10.3111/13696998.2013.820193","title":"Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University; University of Toronto","funders":"","keywords":"Medicine; Risperidone; Czech; Paliperidone; Paliperidone Palmitate; Atypical antipsychotic; Antipsychotic; Schizophrenia (object-oriented programming); Psychiatry","score_opus":0.05098097676767101,"score_gpt":0.3923835462629965,"score_spread":0.3414025694953255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087722862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98612654,0.0025206937,0.000043242213,0.010457775,0.00022811661,0.00058266794,0.0000071107524,0.0000022924687,0.000031538304],"genre_scores_gemma":[0.9915213,0.0060399724,0.0018336031,0.00007384266,0.00048687877,0.000017936594,0.00000531088,0.0000128663105,0.000008296326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99760014,0.00011976949,0.0016059394,0.0001838213,0.00024718788,0.0002431335],"domain_scores_gemma":[0.9974615,0.0012044342,0.00059476914,0.000268722,0.00008098735,0.00038960105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013110099,0.00014277673,0.0010109625,0.0001813142,0.000026711406,0.000022574663,0.00024504063,0.00019543566,0.00018991267],"category_scores_gemma":[0.0003443483,0.00008506353,0.00033177278,0.00005331476,0.0002986776,0.00009759058,0.000028797904,0.00026048397,0.000007296164],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022128271,0.0058108475,0.26447573,0.00020266924,0.0012664539,0.000037358965,0.00051235664,0.000032258522,0.000023293896,0.0049488437,0.002260436,0.6983015],"study_design_scores_gemma":[0.07195869,0.024384592,0.8549186,0.00045224457,0.0005040492,0.00069914537,0.0010126574,0.037645467,0.00060501625,0.0050878036,0.0025145977,0.00021712777],"about_ca_topic_score_codex":0.00007921251,"about_ca_topic_score_gemma":0.00034708768,"teacher_disagreement_score":0.69808435,"about_ca_system_score_codex":0.00027864784,"about_ca_system_score_gemma":0.0012838083,"threshold_uncertainty_score":0.34687904},"labels":[],"label_agreement":null},{"id":"W2088026712","doi":"10.3111/13696998.2012.693896","title":"The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Lethbridge","keywords":"Medicine; Internal medicine; Confounding; Medical prescription; Myeloid leukemia; Pleural effusion","score_opus":0.007333948391764676,"score_gpt":0.23089702428171546,"score_spread":0.22356307588995078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088026712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971484,0.0008478068,0.000004312214,0.001184993,0.00027833955,0.00032691378,0.000011589908,0.0000071718023,0.00019050346],"genre_scores_gemma":[0.9979015,0.00093681866,0.0001654003,0.00007235787,0.0007786921,0.000006888539,0.000018055433,0.000040460593,0.00007981982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997901,0.000060752904,0.0010066843,0.00016268654,0.00040164503,0.00046717928],"domain_scores_gemma":[0.99798393,0.00026672726,0.000768365,0.00032083463,0.00008806056,0.00057206274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007228498,0.00024622417,0.0006871079,0.00017793247,0.00006896729,0.000016857815,0.00027213304,0.00018565505,0.00022329696],"category_scores_gemma":[0.00013186657,0.00013569415,0.00012905792,0.00010944227,0.00030884412,0.00023881049,0.000072041395,0.0005918982,0.000016877491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004772211,0.00057303207,0.9589664,0.00011049134,0.00087045005,0.00009469194,0.0006207452,0.0021586088,0.00006990546,0.00024435532,0.0011590947,0.030360026],"study_design_scores_gemma":[0.08141906,0.007911034,0.88241285,0.002341131,0.0008165782,0.00081430934,0.00055957044,0.0047035734,0.0033401435,0.000026830288,0.015064002,0.00059088727],"about_ca_topic_score_codex":0.00044195965,"about_ca_topic_score_gemma":0.00035386794,"teacher_disagreement_score":0.07664685,"about_ca_system_score_codex":0.006500185,"about_ca_system_score_gemma":0.0035519775,"threshold_uncertainty_score":0.9973137},"labels":[],"label_agreement":null},{"id":"W2089796211","doi":"10.3111/13696998.2013.802239","title":"Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Fingolimod; Multiple sclerosis; Randomized controlled trial; Natalizumab; Physical therapy; Disease; Internal medicine","score_opus":0.17371279418505037,"score_gpt":0.369475554435499,"score_spread":0.19576276025044864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089796211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97746754,0.000664545,0.0040402426,0.0052071144,0.0001928396,0.012398819,0.0000126434525,0.000012385266,0.0000038919525],"genre_scores_gemma":[0.9850336,0.0006085658,0.01123615,0.0011196941,0.00019735374,0.0017177875,0.0000038944304,0.000049979422,0.000032977085],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964777,0.00044060906,0.0013310675,0.00042730066,0.000910369,0.0004129096],"domain_scores_gemma":[0.9949118,0.00274356,0.00065743265,0.0003148588,0.0005502662,0.0008220943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049622105,0.0002905412,0.0014049001,0.00030706538,0.00026273582,0.0002783651,0.0003032576,0.000060399987,0.00010440469],"category_scores_gemma":[0.0061381715,0.00018288246,0.00012430854,0.00011502268,0.00012036538,0.00045244643,0.0003131629,0.00033280472,0.0000040033065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41885647,0.015675006,0.38576636,0.000088481276,0.009451104,0.00018438826,0.034342084,0.00073280913,0.00024875705,0.0000043889518,0.0006922559,0.13395791],"study_design_scores_gemma":[0.6706075,0.004054136,0.26647347,0.0008772755,0.0006468349,0.000015455777,0.010997685,0.045797795,0.00003749914,0.00010566844,0.000056474524,0.00033019372],"about_ca_topic_score_codex":0.00021109264,"about_ca_topic_score_gemma":0.00007729472,"teacher_disagreement_score":0.25175104,"about_ca_system_score_codex":0.0001796417,"about_ca_system_score_gemma":0.0004912918,"threshold_uncertainty_score":0.745773},"labels":[],"label_agreement":null},{"id":"W2090977676","doi":"10.3111/13696998.2015.1025793","title":"Utilities for asthma and COPD according to category of severity: a comprehensive literature review","year":2015,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; COPD; Asthma; Pulmonary disease; Quality of life (healthcare); MEDLINE; Internal medicine; Severity of illness; Physical therapy; Disease; Intensive care medicine","score_opus":0.07019135828087612,"score_gpt":0.39095609226121186,"score_spread":0.3207647339803357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090977676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038827068,0.99511534,0.000028954086,0.0020678227,0.00045038492,0.0014564644,0.00031325387,0.000005295001,0.00017421352],"genre_scores_gemma":[0.000014904197,0.99718815,0.00056207937,0.0009352582,0.00097498356,0.00003530956,0.000079297715,0.000058349928,0.00015167748],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967363,0.0001912716,0.0017393702,0.0003366103,0.000642307,0.00035417147],"domain_scores_gemma":[0.9956174,0.0006675276,0.0010360348,0.0003563522,0.0009819904,0.001340679],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019127242,0.00038939007,0.0042528403,0.00038854327,0.00003682858,0.000037608483,0.00045711512,0.00046703056,0.00013840418],"category_scores_gemma":[0.001607332,0.00029415317,0.0008331254,0.00020751763,0.00025097953,0.00014782998,0.000295894,0.0011993534,0.0000060779234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014026099,0.00006817696,0.000009545101,0.2094837,0.00045792919,0.00017293931,0.000065563996,1.5670012e-7,5.449879e-8,0.00015792619,0.012855066,0.7765887],"study_design_scores_gemma":[0.000976673,0.00028434326,0.000026263973,0.14745246,0.0008098457,0.0034278298,0.0002496685,0.000048594215,1.602913e-7,0.00018135615,0.84636843,0.00017436604],"about_ca_topic_score_codex":0.0000057064517,"about_ca_topic_score_gemma":0.000002214626,"teacher_disagreement_score":0.8335134,"about_ca_system_score_codex":0.0006705873,"about_ca_system_score_gemma":0.0050157914,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W2091519380","doi":"10.3111/13696998.2014.925464","title":"Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Medicine; Prior authorization; Pharmacy; Oxycodone; Medical prescription; Health care; Health plan; Emergency medicine; Retrospective cohort study; Medicare Advantage; Medical costs; Cohort; Family medicine; Internal medicine; Opioid; Pharmacology","score_opus":0.03254786490543145,"score_gpt":0.3375770262442395,"score_spread":0.3050291613388081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091519380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576302,0.00050732197,0.00018928084,0.040965814,0.00027606366,0.00031543226,0.0000227691,0.0000054425072,0.0000876881],"genre_scores_gemma":[0.9883386,0.006911611,0.00019201996,0.0044405987,0.00008308865,0.0000067924125,0.000012393619,0.000011606431,0.0000033241358],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99831045,0.00010494087,0.00089971535,0.00016668253,0.00032058096,0.0001976629],"domain_scores_gemma":[0.99843067,0.00022177731,0.0004755226,0.00014493187,0.00008215511,0.0006449471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059806014,0.00011822051,0.00052715186,0.00032148152,0.00004357787,0.000015833255,0.00011746947,0.000102445236,0.000027080067],"category_scores_gemma":[0.00063426537,0.00009818746,0.000050456434,0.00014133927,0.00007104838,0.00009422511,0.000033784872,0.0002751507,0.0000018274599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005916188,0.004548987,0.35079178,0.0010153552,0.00037914934,0.00024174844,0.0047782464,0.0044201417,0.00013151394,0.009236316,0.003399509,0.6151411],"study_design_scores_gemma":[0.026936492,0.022004215,0.9081588,0.007558252,0.00020228513,0.0012417051,0.0033072103,0.0089227995,0.00436564,0.0032006605,0.013505663,0.0005962877],"about_ca_topic_score_codex":0.0011596752,"about_ca_topic_score_gemma":0.0011337221,"teacher_disagreement_score":0.6145448,"about_ca_system_score_codex":0.000397361,"about_ca_system_score_gemma":0.0009866382,"threshold_uncertainty_score":0.40039685},"labels":[],"label_agreement":null},{"id":"W2091908067","doi":"10.3111/200407067083","title":"Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients","year":2004,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Toronto General Hospital","funders":"","keywords":"Medicine; Oseltamivir; Health care; Univariate; Population; Quality-adjusted life year; Intensive care medicine; Emergency medicine; Public health; Cost effectiveness; Internal medicine; Environmental health; Multivariate statistics; Risk analysis (engineering); Disease; Statistics","score_opus":0.042468196841185774,"score_gpt":0.3852910886054576,"score_spread":0.34282289176427183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091908067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966579,0.0006987578,0.000008879641,0.0023115156,0.00003782694,0.00022983864,0.000024359222,0.0000022061752,0.000028684091],"genre_scores_gemma":[0.9904891,0.008291324,0.00028066925,0.00086738967,0.000054697233,0.0000021387757,0.0000010916013,0.000011683624,0.0000019083927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998521,0.000053074178,0.0007244381,0.00012251959,0.00034765742,0.00023131988],"domain_scores_gemma":[0.9986706,0.00021564652,0.00045325066,0.00010612167,0.00008311224,0.000471286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000733619,0.00014487751,0.00072080304,0.00023213944,0.00003532572,0.000010481515,0.00006338415,0.00008370337,0.000011498117],"category_scores_gemma":[0.00039588846,0.000083249084,0.00005639502,0.000058019585,0.00017991982,0.00008822516,0.000031360425,0.00037944314,0.0000012627131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018278165,0.0005371047,0.8554494,0.000040961037,0.00023868303,0.00003900451,0.00047694054,0.00018037151,9.775657e-7,0.00008794284,0.0000227798,0.14109807],"study_design_scores_gemma":[0.025806606,0.022574952,0.95032364,0.000500746,0.00003874402,0.000056912446,0.00014572692,0.000051024123,0.000020551797,0.000108901804,0.00029750555,0.00007471002],"about_ca_topic_score_codex":0.001294688,"about_ca_topic_score_gemma":0.000496941,"teacher_disagreement_score":0.14102335,"about_ca_system_score_codex":0.0009620342,"about_ca_system_score_gemma":0.0006779641,"threshold_uncertainty_score":0.33947992},"labels":[],"label_agreement":null},{"id":"W2095016204","doi":"10.3111/13696990903288970","title":"Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective","year":2009,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Pfizer (Canada); Université Laval; Sunnybrook Health Science Centre; Centre hospitalier de l'Université Laval","funders":"","keywords":"Celecoxib; Medicine; Rheumatoid arthritis; Osteoarthritis; Internal medicine; Physical therapy; Alternative medicine","score_opus":0.027049251592629796,"score_gpt":0.28250903364859586,"score_spread":0.2554597820559661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095016204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867433,0.004640935,0.00010152326,0.00747413,0.00031138436,0.0006353538,0.00006750922,0.0000058744718,0.00001999091],"genre_scores_gemma":[0.9929455,0.0062970943,0.000086853106,0.00029343023,0.00034353824,0.000013876288,0.000007007637,0.000009594855,0.0000031193701],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99851966,0.00012484378,0.0007927105,0.00015652274,0.00020328857,0.00020295127],"domain_scores_gemma":[0.9982903,0.0007274269,0.0003849137,0.00015772865,0.00013435977,0.0003052696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006257994,0.00016171952,0.0008088266,0.0000685194,0.000047035024,0.000036472666,0.00009503716,0.00017185048,0.000022240438],"category_scores_gemma":[0.0002838306,0.00010040772,0.00016990182,0.000030975487,0.00011866019,0.00014200297,0.000012822779,0.00027568804,4.3548405e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007690254,0.0015139921,0.1232613,0.0005441985,0.00059853785,0.0007224861,0.020311197,0.000036492875,0.00022565629,0.028559621,0.0016463452,0.8148899],"study_design_scores_gemma":[0.060629085,0.01496729,0.8059224,0.009442233,0.00023061389,0.0015747123,0.08306838,0.008411252,0.0030894428,0.005240562,0.00679665,0.00062737725],"about_ca_topic_score_codex":0.0031935037,"about_ca_topic_score_gemma":0.022234285,"teacher_disagreement_score":0.8142625,"about_ca_system_score_codex":0.0004576301,"about_ca_system_score_gemma":0.0008264966,"threshold_uncertainty_score":0.9956074},"labels":[],"label_agreement":null},{"id":"W2097511134","doi":"10.3111/13696998.2013.857676","title":"Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Nocturnal; Diabetes mellitus; Diabetes management; Type 1 diabetes; Pediatrics; Gerontology; Intensive care medicine; Internal medicine; Endocrinology","score_opus":0.039867397513276434,"score_gpt":0.25278472761986875,"score_spread":0.2129173301065923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097511134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99453837,0.00027931522,0.000018883478,0.0039237104,0.00030963065,0.00016076706,0.0000012172968,0.0000010880931,0.0007670083],"genre_scores_gemma":[0.9977299,0.0016603268,0.000050462957,0.0001342137,0.00021761854,0.000001219967,0.0000016954846,0.0000082034085,0.00019637593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989665,0.00003047442,0.0004600961,0.00010685209,0.00023532624,0.00020074283],"domain_scores_gemma":[0.99922305,0.00021175659,0.00022848092,0.00008969477,0.000040667135,0.00020634643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006704184,0.00009406999,0.00035548166,0.00014277872,0.000041946427,0.000024108394,0.00018133828,0.00006054992,0.0003034899],"category_scores_gemma":[0.000070343616,0.000060847266,0.00002775006,0.000064021275,0.00010343277,0.0001140006,0.00013496462,0.00031874486,0.00000336161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006953721,0.000012036915,0.97995543,0.00013337008,0.00040846065,0.0000068171234,0.00009505759,0.00010795446,0.000006410996,0.00014332315,0.00241129,0.016650332],"study_design_scores_gemma":[0.0023793594,0.0003568064,0.9820659,0.00036298082,0.00012424047,0.0000107638425,0.002052466,0.010050762,0.0000079164765,0.001746836,0.00073924987,0.00010267225],"about_ca_topic_score_codex":0.0094168335,"about_ca_topic_score_gemma":0.0071218032,"teacher_disagreement_score":0.016547661,"about_ca_system_score_codex":0.00045770322,"about_ca_system_score_gemma":0.00054229604,"threshold_uncertainty_score":0.99717957},"labels":[],"label_agreement":null},{"id":"W2100428999","doi":"10.3111/13696998.2011.564699","title":"An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rivaroxaban; Dabigatran; Venous thromboembolism; Knee replacement; Hip replacement; Surgery; Internal medicine; Atrial fibrillation; Warfarin; Arthroplasty; Thrombosis","score_opus":0.03965693725439577,"score_gpt":0.29923342596447877,"score_spread":0.259576488710083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100428999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972151,0.0002635475,0.00054425624,0.00056307355,0.00019843143,0.00043781416,0.000002737509,0.0000045903985,0.00077043695],"genre_scores_gemma":[0.9973857,0.0005911895,0.0013347687,0.0004746146,0.0001647526,0.000016242391,0.00000391024,0.000020395752,0.000008426479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997638,0.00014808238,0.0013015975,0.00017274334,0.0005142636,0.00022533239],"domain_scores_gemma":[0.9982776,0.000084859144,0.0009444713,0.0003898558,0.00009604877,0.00020717642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002301629,0.00016398127,0.001191466,0.00021214494,0.00002404364,0.000010015583,0.0003794273,0.00014042699,0.0006457108],"category_scores_gemma":[0.00007228053,0.000096993994,0.00014857182,0.0001244514,0.00018458493,0.00014810247,0.000045186316,0.00039895307,0.0000021470914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030651875,0.09850555,0.3892422,0.0034143827,0.007922681,0.0016653804,0.15770452,0.00076272007,0.0008300254,0.0065095653,0.0050537623,0.29773736],"study_design_scores_gemma":[0.010035036,0.028907632,0.939931,0.0017725585,0.0015995981,0.0007455677,0.006825529,0.00096214074,0.004886562,0.0016870747,0.0022986461,0.00034865417],"about_ca_topic_score_codex":0.00018060335,"about_ca_topic_score_gemma":0.00048834685,"teacher_disagreement_score":0.5506888,"about_ca_system_score_codex":0.000085669286,"about_ca_system_score_gemma":0.00034881834,"threshold_uncertainty_score":0.70700806},"labels":[],"label_agreement":null},{"id":"W2103138885","doi":"10.3111/13696990801954780","title":"Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease: a commentary","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University","funders":"","keywords":"Medicine; Coronary artery disease; Cardiology; Internal medicine; Coronary disease; Surgery; Coronary heart disease","score_opus":0.08246746776260393,"score_gpt":0.35269854481115326,"score_spread":0.2702310770485493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103138885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794407,0.0037474772,0.00410035,0.011863453,0.00026265986,0.00052127754,0.000053258584,0.0000023647037,0.000008441871],"genre_scores_gemma":[0.9878366,0.010554892,0.00085750065,0.00041185008,0.00026382756,0.000019069494,0.000024862125,0.000009189379,0.00002223743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880695,0.000028421011,0.0007920992,0.00007195293,0.00021166763,0.0000888911],"domain_scores_gemma":[0.99820083,0.00080595195,0.0005133874,0.00014307178,0.00015211692,0.00018465238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026686458,0.000086989865,0.0004272467,0.000063106105,0.000052497246,0.0000028226311,0.00011228825,0.00005768977,0.00010677517],"category_scores_gemma":[0.0003997141,0.00005632062,0.0003909395,0.000027811499,0.00016633596,0.000052003146,0.000014147201,0.00009538497,5.948287e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064098127,0.0151471775,0.7619236,0.00080347416,0.0028349478,0.00021858941,0.0034336091,0.0017638153,0.00004379092,0.00031196655,0.04686368,0.16024555],"study_design_scores_gemma":[0.015262587,0.0069442336,0.8905865,0.0010393483,0.0014945691,0.0009930504,0.002383,0.043158296,0.00042266696,0.00022821708,0.037345264,0.00014227958],"about_ca_topic_score_codex":0.00001478137,"about_ca_topic_score_gemma":0.000029821193,"teacher_disagreement_score":0.16010328,"about_ca_system_score_codex":0.000121492965,"about_ca_system_score_gemma":0.00036041375,"threshold_uncertainty_score":0.22966883},"labels":[],"label_agreement":null},{"id":"W2104230558","doi":"10.3111/13696998.2012.669438","title":"In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Venous thromboembolism; Total knee arthroplasty; Arthroplasty; Major bleeding; Surgery; Total hip replacement; Total hip arthroplasty; Thrombosis; Internal medicine","score_opus":0.010209279603239595,"score_gpt":0.25533348836190894,"score_spread":0.24512420875866936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104230558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966468,0.00055122457,0.000045992394,0.0012475434,0.001070117,0.00031634865,0.000013672735,0.0000037633165,0.000104529514],"genre_scores_gemma":[0.99192953,0.0070484052,0.0003564695,0.00024384154,0.00038216493,0.0000046395917,0.00000320143,0.000020217874,0.000011545634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863696,0.00003485758,0.0006795314,0.00011862139,0.00023423156,0.0002958012],"domain_scores_gemma":[0.9983277,0.0005364538,0.00061818206,0.000071530005,0.00008501809,0.00036116745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012219122,0.0001321888,0.00080432964,0.00014135701,0.000051309296,0.000017679296,0.000051967483,0.000166303,0.00006180108],"category_scores_gemma":[0.0016319588,0.000104120634,0.00008788206,0.00005073463,0.000096395306,0.00028672806,0.000084388324,0.00026537883,9.3146105e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009771894,0.015159766,0.83803886,0.00088095985,0.0032062824,0.000059953218,0.006901704,0.00006468501,0.000019803925,0.0045078075,0.010413324,0.11976968],"study_design_scores_gemma":[0.013302863,0.0067505036,0.97314125,0.00071148167,0.00074504805,0.00008615326,0.0014851952,0.0010100167,0.000034314042,0.00048217425,0.0020287586,0.00022223087],"about_ca_topic_score_codex":0.000029376224,"about_ca_topic_score_gemma":0.000044463217,"teacher_disagreement_score":0.13510242,"about_ca_system_score_codex":0.00018890148,"about_ca_system_score_gemma":0.00016354297,"threshold_uncertainty_score":0.42459163},"labels":[],"label_agreement":null},{"id":"W2105831881","doi":"10.3111/13696998.2012.718019","title":"A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Parathyroid Disorders and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Sevelamer; Medicine; Hyperphosphatemia; Dialysis; Kidney disease; Intensive care medicine; Internal medicine; Cost effectiveness; Quality-adjusted life year; Emergency medicine","score_opus":0.04638274081642033,"score_gpt":0.3175203668618774,"score_spread":0.27113762604545705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105831881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983304,0.00040686145,0.00002547262,0.0004952152,0.000099696605,0.0005382578,0.00004839342,0.0000013446048,0.000054367792],"genre_scores_gemma":[0.9992548,0.00032580833,0.000024086623,0.00013320401,0.00008097995,0.000036939375,0.00012486265,0.00001320594,0.000006086448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986568,0.00010797913,0.000619738,0.00009358967,0.000347204,0.00017466949],"domain_scores_gemma":[0.9984623,0.00022645436,0.00072817266,0.00014430478,0.00013610009,0.000302622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010260065,0.00012919329,0.00050447317,0.00017838764,0.000022376069,0.0000049635964,0.00009594606,0.000089093955,0.00003939729],"category_scores_gemma":[0.0004313332,0.000075035954,0.00018023142,0.0000793032,0.000069722955,0.00010108455,0.000006451174,0.0000691908,0.0000011975452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021918789,0.004644832,0.9777964,0.000016320868,0.0012168381,0.000003472267,0.00070126733,0.009545412,0.0000022622753,0.00019047178,0.0003615399,0.0033293315],"study_design_scores_gemma":[0.055334475,0.003743997,0.76768374,0.0002580641,0.0029498604,0.0000039574225,0.00012558908,0.16903873,0.00016337552,0.00019007725,0.000368154,0.00013996311],"about_ca_topic_score_codex":0.00013941345,"about_ca_topic_score_gemma":0.000069173126,"teacher_disagreement_score":0.21011262,"about_ca_system_score_codex":0.0010289758,"about_ca_system_score_gemma":0.0010426744,"threshold_uncertainty_score":0.30598775},"labels":[],"label_agreement":null},{"id":"W2106512674","doi":"10.3111/13696990701438629","title":"Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Johns Hopkins University; Sanofi","keywords":"Medicine; Rimonabant; Overweight; Quality-adjusted life year; Cost effectiveness; Obesity; Internal medicine; Risk analysis (engineering)","score_opus":0.01895269973768576,"score_gpt":0.2711988113097658,"score_spread":0.25224611157208005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106512674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982004,0.00021170334,0.00079995074,0.0000487331,0.00019932058,0.00030239837,0.000036843998,0.000004448292,0.00019620922],"genre_scores_gemma":[0.9966826,0.0006236213,0.0024558946,0.000100348254,0.00007021211,0.000003391071,0.000036307338,0.000016975628,0.0000106853095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985364,0.000065389344,0.0007101918,0.00013900733,0.00033170814,0.00021726578],"domain_scores_gemma":[0.99824095,0.0007429911,0.00044675317,0.00016676809,0.000063310945,0.0003392494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018174471,0.00013925193,0.000766677,0.0003063364,0.000017593631,0.000010297356,0.00013527944,0.00012144805,0.000049317165],"category_scores_gemma":[0.00062374317,0.000109842156,0.00019076625,0.000086820575,0.00007187927,0.00013685426,0.000097973345,0.000217404,0.0000036274243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023184884,0.0007594267,0.9646004,0.000060836417,0.0006270522,0.00006636236,0.000053106985,0.0006343874,0.00003604591,0.00003572683,0.000095226074,0.030712947],"study_design_scores_gemma":[0.011590485,0.00029824988,0.97091687,0.00032683223,0.00048862223,0.000003893524,0.000023299146,0.014850814,0.0010189535,0.0001828696,0.0002093316,0.00008977365],"about_ca_topic_score_codex":0.00022982832,"about_ca_topic_score_gemma":0.00005635939,"teacher_disagreement_score":0.030623173,"about_ca_system_score_codex":0.00031695204,"about_ca_system_score_gemma":0.00011926,"threshold_uncertainty_score":0.44792333},"labels":[],"label_agreement":null},{"id":"W2107285363","doi":"10.3111/13696998.2014.923892","title":"A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"MitraClip; Medicine; Mitral regurgitation; Quality-adjusted life year; Mitral valve; Mitral valve repair; Quality of life (healthcare); Heart failure; Cost–utility analysis; Cardiology; Surgery; Cost effectiveness; Intensive care medicine; Internal medicine; Risk analysis (engineering)","score_opus":0.005844515260005902,"score_gpt":0.253686271921591,"score_spread":0.2478417566615851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107285363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99863124,0.00012940835,0.00012301389,0.00038085025,0.000094623734,0.00044304284,0.00010373226,0.000005521752,0.00008855963],"genre_scores_gemma":[0.9996323,0.000049407216,0.00007746079,0.00006932644,0.00008573281,0.000017297736,0.000046958852,0.0000180744,0.000003449464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820626,0.0003085836,0.00058559416,0.00019626544,0.00045194488,0.00025135642],"domain_scores_gemma":[0.9980149,0.0005055488,0.00045558982,0.00022270424,0.0002045275,0.00059671386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001313758,0.00016791007,0.0008593441,0.00036156597,0.00004439273,0.00001632452,0.00012210703,0.0001270141,0.000030054423],"category_scores_gemma":[0.000081606035,0.000092366616,0.003898649,0.00028480816,0.0001176681,0.00008014123,0.0000058702385,0.0003105034,0.0000010600361],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022649833,0.00034833443,0.9737966,0.000068276226,0.018265475,0.000057737714,0.00015963918,0.002047576,1.0370233e-7,0.0001686491,0.000013314967,0.002809279],"study_design_scores_gemma":[0.008761932,0.0009820171,0.97305053,0.00026919396,0.014685562,0.00003122611,0.00024660194,0.0016865518,0.0000030791434,0.000008638878,0.00017402552,0.00010060942],"about_ca_topic_score_codex":0.0108018,"about_ca_topic_score_gemma":0.008831537,"teacher_disagreement_score":0.0064969487,"about_ca_system_score_codex":0.0005610962,"about_ca_system_score_gemma":0.00059105456,"threshold_uncertainty_score":0.99578536},"labels":[],"label_agreement":null},{"id":"W2108384961","doi":"10.3111/13696998.2011.629015","title":"Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Microsoft","keywords":"Medicine; Probiotic; Lactobacillus casei; Placebo; Diarrhea; Lactobacillus acidophilus; Context (archaeology); Antibiotic-associated diarrhea; Incidence (geometry); Antibiotics; Internal medicine; Clostridium difficile; Microbiology; Food science; Biology; Fermentation; Alternative medicine","score_opus":0.09765356787881542,"score_gpt":0.28696049757163605,"score_spread":0.18930692969282065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108384961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961604,0.00025454804,0.000011289154,0.0030243993,0.00011774837,0.0002794685,0.000024325476,0.00000213199,0.00012567137],"genre_scores_gemma":[0.99823964,0.0011072098,0.000178163,0.00029757453,0.00014451897,8.327942e-7,0.0000039535157,0.0000130989,0.000015007063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791825,0.0001490099,0.0010266053,0.00011398585,0.0005607886,0.00023138219],"domain_scores_gemma":[0.9978314,0.00093951245,0.00059186114,0.00029446132,0.00019094681,0.00015179784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019592948,0.00011494806,0.0005463359,0.000114994655,0.000027888791,0.000015357216,0.0005209923,0.00018378143,0.00020542715],"category_scores_gemma":[0.0033173556,0.000060122708,0.00023603684,0.00021143533,0.0002768148,0.00009298886,0.00008463874,0.00081145787,0.000003294907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009286565,0.018071389,0.74341804,0.0012212306,0.0037262633,0.0016355879,0.040376067,0.00014632779,0.021953197,0.0027741066,0.01744344,0.13994779],"study_design_scores_gemma":[0.020983327,0.011744413,0.75851816,0.0055659786,0.0010422163,0.0009855478,0.006842665,0.008123558,0.17781109,0.0012317834,0.006491749,0.0006595226],"about_ca_topic_score_codex":0.0009045465,"about_ca_topic_score_gemma":0.00023007128,"teacher_disagreement_score":0.15585789,"about_ca_system_score_codex":0.000114204704,"about_ca_system_score_gemma":0.00068532676,"threshold_uncertainty_score":0.3971424},"labels":[],"label_agreement":null},{"id":"W2109736015","doi":"10.3111/13696990701679230","title":"Contingent valuation of inhaled insulin: a Canadian perspective","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Healthcare cost, quality, practices","field":"Health Professions","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Medtronic (Canada)","funders":"","keywords":"Medicine; Insulin; Contingent valuation; Willingness to pay; Diabetes mellitus; Confidence interval; Valuation (finance); Internal medicine; Environmental health; Endocrinology; Economics; Finance","score_opus":0.5709903698322264,"score_gpt":0.555987075065585,"score_spread":0.015003294766641417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109736015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92550826,0.0005924706,0.00076781487,0.066002674,0.0017891435,0.00027465002,0.000009655719,0.000005474358,0.0050498466],"genre_scores_gemma":[0.98820454,0.0008665041,0.0007084026,0.008874923,0.0012840342,0.0000022255406,0.0000017645078,0.000015382439,0.000042201824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961836,0.0008433375,0.0019391777,0.00012692946,0.000485343,0.00042164733],"domain_scores_gemma":[0.9931689,0.0023630662,0.0019943407,0.0001641989,0.0011286198,0.0011808603],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.026490966,0.00009743373,0.00045826804,0.00033371398,0.00018305107,0.0000065439285,0.00031997726,0.00042282298,0.0008797674],"category_scores_gemma":[0.015883207,0.000088277426,0.000102373975,0.000117966236,0.00010230573,0.00023280832,0.000048861384,0.0015424007,0.000052216586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022838013,0.0011549252,0.31491953,0.0011199281,0.0012877469,0.0011107904,0.13444318,0.00009444542,0.000086149514,0.28776798,0.017196853,0.23853466],"study_design_scores_gemma":[0.015812121,0.0018401241,0.3868808,0.0026930985,0.000338503,0.000670788,0.23898436,0.0033854793,0.00024510606,0.04228067,0.30603364,0.00083532115],"about_ca_topic_score_codex":0.088052414,"about_ca_topic_score_gemma":0.33055317,"teacher_disagreement_score":0.28883678,"about_ca_system_score_codex":0.0019506575,"about_ca_system_score_gemma":0.010399148,"threshold_uncertainty_score":0.99521095},"labels":[],"label_agreement":null},{"id":"W2116314191","doi":"10.3111/13696998.2014.964720","title":"Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Cohort; Hepatitis C; Health care; Pegylated interferon; Cohort study; Retrospective cohort study; Chronic hepatitis; Ribavirin; Immunology; Virus","score_opus":0.0645373882287213,"score_gpt":0.40240155889075957,"score_spread":0.3378641706620383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116314191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859521,0.00045247443,0.00008381947,0.012413181,0.00019605417,0.00026475987,0.000036326608,0.0000064412534,0.00059483974],"genre_scores_gemma":[0.9810211,0.0167805,0.00018494512,0.0009650923,0.0009734102,0.000004161575,0.00001521738,0.000029716904,0.00002584715],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978801,0.00018057271,0.00090196944,0.0001474391,0.00055019517,0.00033971138],"domain_scores_gemma":[0.9977076,0.00045481283,0.00047778126,0.0002513856,0.0002772975,0.00083114515],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012773144,0.00016136981,0.0007910524,0.00022421574,0.00004801038,0.000016692838,0.00021858209,0.00017554782,0.001232276],"category_scores_gemma":[0.00077840494,0.00011346694,0.00038616543,0.00006904847,0.00012895177,0.00006097622,0.000027338692,0.0005085081,0.000040982464],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066361646,0.00052243,0.1913144,0.00006807549,0.00041193934,0.00008669989,0.0001979363,0.00012916813,0.00019160807,0.00028530555,0.0009779276,0.80515087],"study_design_scores_gemma":[0.03411487,0.11242988,0.6193241,0.0022042498,0.00010108215,0.0011402287,0.00009348307,0.042697925,0.00213731,0.000256284,0.18497643,0.00052415574],"about_ca_topic_score_codex":0.0037538449,"about_ca_topic_score_gemma":0.0010896928,"teacher_disagreement_score":0.80462676,"about_ca_system_score_codex":0.0018533742,"about_ca_system_score_gemma":0.002285283,"threshold_uncertainty_score":0.99968076},"labels":[],"label_agreement":null},{"id":"W2118409839","doi":"10.3111/13696991003723999","title":"Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting","year":2010,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Insulin aspart; Life expectancy; Diabetes mellitus; Insulin; Type 2 diabetes; Cohort; Observational study; Cost effectiveness; Quality of life (healthcare); Internal medicine; Human insulin; Incidence (geometry); Endocrinology; Environmental health; Population; Risk analysis (engineering)","score_opus":0.03662680478415936,"score_gpt":0.3590542527169888,"score_spread":0.32242744793282946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118409839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958002,0.0001048961,0.00021693207,0.0022282517,0.0005050131,0.00039894838,0.0000040627324,0.0000059193626,0.0007358042],"genre_scores_gemma":[0.9980109,0.00008781169,0.0009166249,0.0003573005,0.0005719585,0.000007337392,0.000006106471,0.00002033259,0.0000216831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811035,0.00012072454,0.00087300135,0.0001751779,0.0004454572,0.000275256],"domain_scores_gemma":[0.9983243,0.0005839128,0.00033070828,0.00020044071,0.0001022074,0.00045848056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054404684,0.00012232267,0.0006072391,0.00042449476,0.00003264423,0.0000299898,0.00038167922,0.00019791974,0.00030903984],"category_scores_gemma":[0.0018289444,0.00010082598,0.0001269868,0.0001604371,0.000065752654,0.00013685902,0.00017880036,0.0012650975,0.00001641154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001546341,0.0011542679,0.54433465,0.0006180927,0.0005273964,0.000370557,0.0009804842,0.000597168,0.0371501,0.0008795041,0.0006170797,0.41122434],"study_design_scores_gemma":[0.016544342,0.001337627,0.9412085,0.00319863,0.00014051345,0.000041287654,0.00033960424,0.010427479,0.009851121,0.0027706707,0.013811852,0.00032838955],"about_ca_topic_score_codex":0.000092287526,"about_ca_topic_score_gemma":0.00017504662,"teacher_disagreement_score":0.41089594,"about_ca_system_score_codex":0.00011990885,"about_ca_system_score_gemma":0.0003378968,"threshold_uncertainty_score":0.549629},"labels":[],"label_agreement":null},{"id":"W2122195110","doi":"10.3111/13696998.2015.1038270","title":"Inhaled nitric oxide in term/late preterm neonates with hypoxic respiratory failure: estimating the financial impact of earlier use","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital","funders":"","keywords":"Medicine; Respiratory failure; Respiratory system; Term (time); Nitric oxide; Intensive care medicine; Pediatrics; Emergency medicine; Anesthesia; Cardiology; Internal medicine","score_opus":0.06481795895339988,"score_gpt":0.36080283751962877,"score_spread":0.2959848785662289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122195110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725527,0.0009776417,0.00012405199,0.0011632976,0.00009354623,0.00033044434,0.00000491331,0.00000545487,0.000045389934],"genre_scores_gemma":[0.996393,0.00012938706,0.002100311,0.0009399831,0.00037758437,0.000006860366,0.0000010052659,0.000033000844,0.000018842858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706775,0.0002155416,0.0012310408,0.00017779673,0.0008826193,0.00042527408],"domain_scores_gemma":[0.99684536,0.00081285555,0.0007446571,0.00031064177,0.00033774244,0.00094874756],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0043191887,0.00018530847,0.0006922844,0.00041729573,0.00004082624,0.000037114118,0.00043230518,0.00024240097,0.000072786555],"category_scores_gemma":[0.008521201,0.000107628504,0.0001692268,0.0002958604,0.0003105785,0.0003610982,0.00010977607,0.0014214742,0.000008609436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016748436,0.0009474381,0.5916615,0.0010809349,0.00058237504,0.0072822776,0.002013701,0.010187494,0.0013445935,0.00015885191,0.002398939,0.36559346],"study_design_scores_gemma":[0.026065862,0.006903454,0.9141309,0.0024004688,0.00015389585,0.0037633916,0.00026714912,0.037536543,0.00081331906,0.0007357318,0.006735133,0.0004941407],"about_ca_topic_score_codex":0.000105123494,"about_ca_topic_score_gemma":0.00009900016,"teacher_disagreement_score":0.3650993,"about_ca_system_score_codex":0.00061884307,"about_ca_system_score_gemma":0.0066178897,"threshold_uncertainty_score":0.9998304},"labels":[],"label_agreement":null},{"id":"W2123354253","doi":"10.3111/13696998.2015.1012513","title":"Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Golimumab; Adalimumab; Infliximab; Medicine; Ulcerative colitis; Internal medicine; Gastroenterology; Surgery; Tumor necrosis factor alpha; Disease","score_opus":0.02776260451921954,"score_gpt":0.2931311973706892,"score_spread":0.2653685928514697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123354253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962557,0.0002571335,0.00081752735,0.0020043317,0.000075017444,0.0004626586,0.00008498198,0.0000012348595,0.000041419975],"genre_scores_gemma":[0.9971176,0.001314757,0.00065928535,0.0004926147,0.00021692003,0.00003368298,0.000007917619,0.000019613006,0.0001376436],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991295,0.00011139081,0.00030866917,0.00015889601,0.00014265937,0.00014888539],"domain_scores_gemma":[0.9987411,0.00015549245,0.00022554901,0.00013850993,0.00024434307,0.0004950345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006012071,0.00013690053,0.00023938304,0.000036613834,0.0000680442,0.000029661665,0.00011216709,0.0001363267,0.000017046734],"category_scores_gemma":[0.000308532,0.00008554632,0.000058922946,0.000013164979,0.00018640279,0.000014439999,0.000041339696,0.00008349478,7.135607e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89623797,0.00085019384,0.0022450357,0.000078099794,0.0014922102,0.00018366717,0.00958983,0.0033767193,0.001673953,0.00038893585,0.0058701704,0.078013234],"study_design_scores_gemma":[0.06442954,0.02170778,0.37714556,0.0003627821,0.0007372287,0.0017915078,0.011518408,0.018668601,0.02700946,0.00064118736,0.47486898,0.0011189657],"about_ca_topic_score_codex":0.000007476192,"about_ca_topic_score_gemma":0.000072918294,"teacher_disagreement_score":0.8318084,"about_ca_system_score_codex":0.00012780407,"about_ca_system_score_gemma":0.0008864719,"threshold_uncertainty_score":0.34884778},"labels":[],"label_agreement":null},{"id":"W2124326496","doi":"10.3111/13696998.2012.734886","title":"The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence","year":2012,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Sunnybrook Hospital","funders":"","keywords":"Palivizumab; Medicine; Heart disease; Cost effectiveness; Pediatrics; Quality of life (healthcare); Quality-adjusted life year; MEDLINE; Cost–utility analysis; Intensive care medicine; Internal medicine","score_opus":0.09559665054788327,"score_gpt":0.41252653627758495,"score_spread":0.3169298857297017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124326496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085136073,0.99491113,0.0000016387778,0.0012556937,0.0012817356,0.0015992909,0.000059859074,0.0000019551128,0.000037313188],"genre_scores_gemma":[0.0037247029,0.9956551,0.0000041427957,0.000119980235,0.00039819468,0.000059404978,0.0000027566202,0.000027344653,0.000008373349],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99544626,0.0010152496,0.002265713,0.00017942912,0.00080133474,0.00029198133],"domain_scores_gemma":[0.99290204,0.0044147377,0.0012771093,0.00053794746,0.00034549236,0.00052269374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0059905625,0.00030399926,0.0029479777,0.00011194582,0.000049128084,0.000010995494,0.00063761335,0.00013341465,0.00007523737],"category_scores_gemma":[0.00736696,0.00015035343,0.0014618854,0.00024485248,0.0005722735,0.000121462894,0.00034376234,0.0012125608,0.000008779013],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016394358,0.00019277837,0.0009024299,0.17282884,0.00031849594,0.000013166783,0.000011344263,5.7828043e-8,2.4345113e-8,0.000049352617,0.0004059764,0.8251136],"study_design_scores_gemma":[0.0004610727,0.00008134867,0.003696836,0.42101163,0.0028196047,0.00018121826,0.0000071504683,0.000004559138,2.4853995e-7,0.000034266246,0.57160276,0.000099278346],"about_ca_topic_score_codex":0.000005545574,"about_ca_topic_score_gemma":0.000016499062,"teacher_disagreement_score":0.8250143,"about_ca_system_score_codex":0.00042907655,"about_ca_system_score_gemma":0.0044747875,"threshold_uncertainty_score":0.8819471},"labels":[],"label_agreement":null},{"id":"W2124828164","doi":"10.3111/13696990802125760","title":"Cost comparison of prostaglandin analogues: a Canadian population-based analysis","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Brock University; PharmIdeas (Canada)","funders":"","keywords":"Travoprost; Bimatoprost; Latanoprost; Medicine; Pharmacoeconomics; Indirect costs; Internal medicine; Glaucoma; Ophthalmology; Intensive care medicine","score_opus":0.035128986850056866,"score_gpt":0.30721743348013675,"score_spread":0.27208844663007986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124828164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939199,0.00021495794,0.00039977694,0.004947371,0.00012994217,0.000100885816,0.000013056844,0.000002803842,0.00027128772],"genre_scores_gemma":[0.9985844,0.00016700084,0.000455458,0.0005994053,0.0001008845,8.4583405e-7,0.000059362337,0.0000078014955,0.000024836436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858326,0.00003437831,0.0008076713,0.000086926586,0.00031649074,0.00017124623],"domain_scores_gemma":[0.9985192,0.00009841985,0.00044155508,0.000119413766,0.00012560001,0.00069584884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045537992,0.00008832997,0.0006811546,0.00059898477,0.000052321207,0.0000051865545,0.00013957158,0.00015442436,0.00043971767],"category_scores_gemma":[0.00033868116,0.00006891474,0.00031494882,0.00026775114,0.000098839344,0.000038083665,0.0000071094323,0.00029917996,0.000004331068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011651264,0.00013962839,0.99590766,0.000025776988,0.00036758278,0.000075847885,0.00017988449,0.0007230162,0.000001665051,0.00004647193,0.0010932643,0.0013226859],"study_design_scores_gemma":[0.0017266038,0.00031549795,0.9553748,0.0000737147,0.00053074415,0.00013951086,0.00030127395,0.03764652,0.000022408434,0.00002518815,0.003767233,0.00007655182],"about_ca_topic_score_codex":0.020305453,"about_ca_topic_score_gemma":0.06086202,"teacher_disagreement_score":0.04055657,"about_ca_system_score_codex":0.00018843725,"about_ca_system_score_gemma":0.0013956599,"threshold_uncertainty_score":0.9862184},"labels":[],"label_agreement":null},{"id":"W2124964258","doi":"10.3111/13696998.2011.646045","title":"Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Blood Services; McMaster University; Ottawa Hospital; University of Ottawa; PharmIdeas (Canada)","funders":"","keywords":"Romiplostim; Medicine; Public health; Respondent; Quality of life (healthcare); Time-trade-off; Family medicine; Quality-adjusted life year; Pediatrics; Cost effectiveness; Thrombopoietin; Nursing","score_opus":0.0371163062270349,"score_gpt":0.26398500437051975,"score_spread":0.22686869814348484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124964258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985692,0.00019502825,0.000032691623,0.0009076214,0.000037386133,0.00017433135,0.000011812942,0.0000010290819,0.00007091308],"genre_scores_gemma":[0.99814284,0.00078880205,0.00093174,0.00009276857,0.000015276337,0.0000012723974,0.0000055921787,0.000007710779,0.000014010405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991933,0.000015123038,0.00048232064,0.00007923104,0.00012023148,0.00010978059],"domain_scores_gemma":[0.9994192,0.00012595675,0.00017183389,0.00007261103,0.00006644484,0.00014396614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029292432,0.00007675206,0.00053092587,0.000042582167,0.000013606295,0.000002848449,0.00006441251,0.000060719503,0.00011099417],"category_scores_gemma":[0.00021688323,0.000046345416,0.000032136704,0.000038036156,0.000056221877,0.00006989775,0.000011116346,0.0001139938,1.6532589e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030444046,0.001594421,0.85963786,0.00047127632,0.0015278177,0.0020426111,0.002374802,0.00004977423,0.00022878726,0.00021375724,0.0005929678,0.10082186],"study_design_scores_gemma":[0.021624226,0.002905317,0.9614917,0.00064127776,0.00028349055,0.00070087356,0.0012418833,0.0052680415,0.005012874,0.00046852234,0.0002206329,0.00014114611],"about_ca_topic_score_codex":0.24071285,"about_ca_topic_score_gemma":0.6103479,"teacher_disagreement_score":0.36963508,"about_ca_system_score_codex":0.00013791097,"about_ca_system_score_gemma":0.0014217852,"threshold_uncertainty_score":0.7643433},"labels":[],"label_agreement":null},{"id":"W2125903849","doi":"10.3111/13696990701646825","title":"Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia","year":2007,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; McGill University","funders":"Janssen Canada","keywords":"Risperidone; Medicine; Tolerability; Confidence interval; Schizophrenia (object-oriented programming); Pediatrics; Psychosis; Internal medicine; Psychiatry; Adverse effect","score_opus":0.014956056495635849,"score_gpt":0.2908552119073994,"score_spread":0.2758991554117635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125903849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988898,0.000067871006,0.000036936373,0.00072290003,0.00006392531,0.00015160929,0.0000064268565,0.0000017757819,0.000058725236],"genre_scores_gemma":[0.9989208,0.00021368293,0.0006736397,0.0000615415,0.00010116794,8.375911e-7,0.000014683493,0.000010755207,0.0000028843574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987943,0.000023051183,0.00045831877,0.00010274899,0.00037391775,0.00024765704],"domain_scores_gemma":[0.9984055,0.00018917005,0.00027439688,0.00010404394,0.000120210985,0.00090665073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001009687,0.0000930911,0.00029189608,0.00044082323,0.00002578647,0.000016951695,0.00006766295,0.00010703036,0.000087168824],"category_scores_gemma":[0.0008951879,0.00006326396,0.000053339263,0.00010542398,0.000075635064,0.00019851958,0.000011049034,0.00032809412,0.0000014976114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009265117,0.00024056887,0.95500565,0.000012791467,0.00013235913,0.00008927573,0.00010128217,0.000029805045,0.0000028071627,0.000087004875,0.000033861877,0.034999464],"study_design_scores_gemma":[0.0091803,0.0021147782,0.9878414,0.00022456859,0.000027131095,0.00005869543,0.000041517604,0.00032007403,0.000079622965,0.000043159445,0.000017264272,0.000051468178],"about_ca_topic_score_codex":0.030082107,"about_ca_topic_score_gemma":0.11366259,"teacher_disagreement_score":0.08358048,"about_ca_system_score_codex":0.0007636896,"about_ca_system_score_gemma":0.0016873045,"threshold_uncertainty_score":0.97637665},"labels":[],"label_agreement":null},{"id":"W2128124805","doi":"10.3111/13696998.2013.770747","title":"Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Université Laval; Toronto General Hospital; University of Toronto","funders":"Edwards Lifesciences","keywords":"Medicine; Valve replacement; Stenosis; Emergency medicine; Cost effectiveness; Quality-adjusted life year; Cost-effectiveness analysis; Aortic valve replacement; Economic evaluation; Randomized controlled trial; Incremental cost-effectiveness ratio; Cohort; Cost–benefit analysis; Surgery; Internal medicine","score_opus":0.01543467519830726,"score_gpt":0.29550042294699397,"score_spread":0.2800657477486867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128124805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954147,0.000013499562,0.000058990874,0.0020288373,0.00015137518,0.0020046192,0.00002182515,0.000002526243,0.0003036458],"genre_scores_gemma":[0.99785924,0.00004046422,0.00003384485,0.0017915426,0.00003877056,0.00017391617,0.000035022575,0.000016519634,0.000010655492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754137,0.00020095095,0.00080098043,0.00023068752,0.0009197935,0.00030624348],"domain_scores_gemma":[0.99783444,0.0003392221,0.00019211821,0.00029972265,0.00014198953,0.0011924932],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015692754,0.00018302248,0.0008344441,0.0004212446,0.000044410353,0.000028578877,0.00021529438,0.000106659296,0.0015674679],"category_scores_gemma":[0.00022221699,0.00010899233,0.00092579017,0.000291918,0.00006393361,0.000060457645,0.000021952877,0.00026384764,0.0000128226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009888724,0.0012157059,0.97666067,0.000064985004,0.008009934,0.000012626081,0.00008609215,0.0019293727,9.955338e-8,0.000020534368,0.00023493332,0.0018763494],"study_design_scores_gemma":[0.035923854,0.0011876163,0.9542501,0.00050652004,0.0035076975,0.0000017840688,0.000120838864,0.0042963317,0.000006118264,0.000010379121,0.00007454654,0.00011421003],"about_ca_topic_score_codex":0.0035197118,"about_ca_topic_score_gemma":0.0008268078,"teacher_disagreement_score":0.02603513,"about_ca_system_score_codex":0.0006778995,"about_ca_system_score_gemma":0.0006973228,"threshold_uncertainty_score":0.99934524},"labels":[],"label_agreement":null},{"id":"W2128721688","doi":"10.3111/13696998.2012.756400","title":"Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Hôpital Maisonneuve-Rosemont","funders":"Amgen Canada; Forskningsrådet om Hälsa, Arbetsliv och Välfärd","keywords":"Romiplostim; Medicine; Thrombopoietin; Immune thrombocytopenia; Pediatrics; Emergency medicine; Internal medicine; Platelet","score_opus":0.02503802264846425,"score_gpt":0.28753250658038776,"score_spread":0.2624944839319235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128721688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996556,0.0023037363,0.000020234742,0.00050765346,0.000073930016,0.00045672272,0.00006344915,2.8692517e-7,0.000018011926],"genre_scores_gemma":[0.9985608,0.0013251276,0.00004655789,0.000027685206,0.000017707827,0.0000031787572,0.000009851947,0.000005563304,0.0000035183418],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999182,0.000025357744,0.00049437385,0.00004315402,0.00014527509,0.00010984914],"domain_scores_gemma":[0.9989478,0.00023310851,0.0005509621,0.00010071911,0.00008639714,0.00008098961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016228504,0.00008891213,0.0006146144,0.000027667198,0.000022382854,0.0000021646752,0.00008559257,0.00004452479,0.000036703303],"category_scores_gemma":[0.000051695748,0.000039637842,0.0000791795,0.000043629538,0.0001150604,0.00004854997,0.000011645115,0.00007041777,5.099103e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003937611,0.0033910729,0.96471727,0.000055097258,0.0020282762,0.0000053377057,0.0031607714,0.0007574894,0.000032457057,0.000043164167,0.00023988941,0.021631554],"study_design_scores_gemma":[0.008463183,0.00212212,0.9866966,0.00011185585,0.0002311218,0.000028982071,0.00035550736,0.00086943177,0.00065216684,0.000011057152,0.00042036176,0.000037593185],"about_ca_topic_score_codex":0.10106601,"about_ca_topic_score_gemma":0.13319568,"teacher_disagreement_score":0.03212968,"about_ca_system_score_codex":0.00035121676,"about_ca_system_score_gemma":0.0012820842,"threshold_uncertainty_score":0.9049201},"labels":[],"label_agreement":null},{"id":"W2130922075","doi":"10.3111/13696998.2012.737393","title":"Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Programs for Assessment of Technology in Health Research Institute; McMaster University; St. Joseph’s Healthcare Hamilton; Amgen (Canada)","funders":"","keywords":"Medicine; Denosumab; Discontinuation; Osteoporosis; Femoral neck; Cost effectiveness; Internal medicine; Teriparatide; Cost-effectiveness analysis; Cohort; Adverse effect; Bone mineral","score_opus":0.055857514077070944,"score_gpt":0.35734132471385055,"score_spread":0.3014838106367796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130922075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948417,0.0021561913,0.0000022674028,0.0021831542,0.0002339561,0.00041373642,0.000010154571,4.3786432e-7,0.00015840562],"genre_scores_gemma":[0.9960073,0.0035178126,0.000058133297,0.00027323194,0.00011703247,0.000011796026,0.0000034080108,0.000008048304,0.0000032183527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979947,0.00026156026,0.00088660524,0.00006926472,0.0004750543,0.00031278539],"domain_scores_gemma":[0.99803674,0.0010526256,0.000309449,0.00014912542,0.000076290875,0.00037578898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028503938,0.000092022165,0.00063565973,0.00015689101,0.00001209561,0.0000025061015,0.0001702784,0.00010140139,0.0001100749],"category_scores_gemma":[0.00032681774,0.00005727419,0.0000702482,0.00012932024,0.00007329329,0.00006798516,0.0000151980375,0.00030169694,9.754774e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026392126,0.0025226248,0.92550886,0.00048046937,0.00009786666,0.00013849398,0.0019918776,0.00005639367,0.00018079966,0.00020123339,0.00021516814,0.06596702],"study_design_scores_gemma":[0.008427892,0.00288236,0.97937757,0.00035696026,0.000046864625,0.00036938235,0.0024312872,0.00015750046,0.0023164165,0.00003685551,0.0035311836,0.00006575239],"about_ca_topic_score_codex":0.25545,"about_ca_topic_score_gemma":0.33969215,"teacher_disagreement_score":0.08424211,"about_ca_system_score_codex":0.0014251504,"about_ca_system_score_gemma":0.0049174293,"threshold_uncertainty_score":0.87233084},"labels":[],"label_agreement":null},{"id":"W2132129334","doi":"10.3111/13696990801954756","title":"Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Coronary Interventions and Diagnostics","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Conventional PCI; Medicine; Percutaneous coronary intervention; Coronary artery disease; Cardiology; Internal medicine; Bypass grafting; Artery; Surgery; Myocardial infarction","score_opus":0.09029051761902525,"score_gpt":0.35397319119057075,"score_spread":0.2636826735715455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132129334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98743236,0.0028706475,0.0056150393,0.0033577136,0.00025224657,0.00042511872,0.00003060598,0.0000020987607,0.000014145504],"genre_scores_gemma":[0.9898361,0.008996067,0.00074939005,0.000097467,0.00024337457,0.0000145371705,0.000011193433,0.000008210436,0.000043689713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988836,0.000021723816,0.00074657006,0.0000685038,0.00019780059,0.000081825456],"domain_scores_gemma":[0.9982928,0.00069754286,0.0005025852,0.00013355186,0.00018394625,0.00018956873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025280702,0.00007798472,0.00039413766,0.000060487622,0.000043462926,0.000002694099,0.000098573175,0.00005976884,0.00010091876],"category_scores_gemma":[0.0007605031,0.00004925828,0.00038497368,0.000026350464,0.00014943862,0.000047716912,0.000010300552,0.000083763705,8.6994174e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00709119,0.014937786,0.7335068,0.00091006624,0.0024853735,0.00025941085,0.0037383963,0.0034996856,0.00006304964,0.0008097839,0.012449631,0.22024882],"study_design_scores_gemma":[0.011013266,0.005253112,0.9174166,0.00072343677,0.0011012075,0.0008081779,0.0014436905,0.046151992,0.0004189065,0.00025692026,0.015302928,0.00010976153],"about_ca_topic_score_codex":0.0000074179384,"about_ca_topic_score_gemma":0.000018871242,"teacher_disagreement_score":0.22013906,"about_ca_system_score_codex":0.00009197667,"about_ca_system_score_gemma":0.0005399329,"threshold_uncertainty_score":0.20086944},"labels":[],"label_agreement":null},{"id":"W2132266888","doi":"10.3111/13696998.2013.851082","title":"Prevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Constipation; Cross-sectional study; Internal medicine; Cancer; Colorectal cancer; Physical therapy; Pathology","score_opus":0.022796946312457416,"score_gpt":0.29946144952046405,"score_spread":0.2766645032080066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132266888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99915314,0.00009854609,0.00025565154,0.00008935429,0.000064364576,0.00029435934,0.00003581758,0.0000017543787,0.000007025691],"genre_scores_gemma":[0.9997733,0.0000929061,0.000054035714,0.00003436697,0.000024628285,0.0000037524367,0.000007444795,0.0000059464087,0.0000035798462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883413,0.000101585414,0.00057018804,0.00011809686,0.00027535303,0.00010062648],"domain_scores_gemma":[0.99846745,0.0002505494,0.00052884914,0.00006747558,0.00046272264,0.00022296114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011462237,0.00009348895,0.00029621398,0.00006892636,0.000027279344,0.000018229688,0.00005477286,0.00007289011,0.00018769743],"category_scores_gemma":[0.0011723118,0.00006731278,0.00003737621,0.00004251166,0.00020143791,0.0002024649,0.00002112111,0.00022277763,1.883972e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007892701,0.0005266199,0.995445,0.00010583696,0.00012375986,4.2947804e-7,0.00007768761,0.00006591361,0.000023824852,0.0000011832198,0.00005227247,0.002788205],"study_design_scores_gemma":[0.0046477276,0.004831709,0.98810065,0.00013917591,0.00003463745,0.000015529358,0.0001237021,0.0020445308,0.0000053060267,0.000012650515,4.605206e-7,0.00004394607],"about_ca_topic_score_codex":0.0018777107,"about_ca_topic_score_gemma":0.00015622166,"teacher_disagreement_score":0.007344372,"about_ca_system_score_codex":0.00008244983,"about_ca_system_score_gemma":0.00041655888,"threshold_uncertainty_score":0.28385493},"labels":[],"label_agreement":null},{"id":"W2134289044","doi":"10.3111/13696998.2011.561390","title":"Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis","year":2011,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Insulin detemir; Medicine; Insulin glargine; Type 1 diabetes; Type 2 Diabetes Mellitus; Type 2 diabetes; Insulin; Internal medicine; Cost-minimization analysis; Diabetes mellitus; Hypoglycemia; Endocrinology","score_opus":0.06545180482882385,"score_gpt":0.31225013221462644,"score_spread":0.2467983273858026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134289044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15219593,0.8470458,0.000015639667,0.00027436254,0.00004666071,0.00038208714,0.000017364613,8.8377544e-7,0.00002130725],"genre_scores_gemma":[0.044644948,0.95502055,0.00010324529,0.00011541936,0.000033423265,0.0000064289907,0.00004793387,0.000015685053,0.00001237533],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9975373,0.00023445312,0.0014340511,0.00022609225,0.0003541959,0.00021386945],"domain_scores_gemma":[0.998239,0.0004096163,0.00066440675,0.0001864878,0.00023193976,0.0002685911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022033944,0.0002150154,0.0031808722,0.0012229797,0.000019453715,0.000024047482,0.00021229274,0.00020669063,0.00011697157],"category_scores_gemma":[0.0010896096,0.00012850763,0.00029950944,0.0013510224,0.00008876348,0.00007674444,0.00017226432,0.00054722035,3.35087e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013734144,0.00020487729,0.05439978,0.002276273,0.0874177,0.000024127374,0.00011919975,0.00090102456,1.3787299e-8,0.000024361321,0.000068587025,0.85442674],"study_design_scores_gemma":[0.00439847,0.000638593,0.01594932,0.002383993,0.45210865,0.0000072468933,0.00015943321,0.48317066,3.6955564e-7,0.000058873084,0.040583298,0.0005411102],"about_ca_topic_score_codex":0.016896311,"about_ca_topic_score_gemma":0.16183864,"teacher_disagreement_score":0.8538856,"about_ca_system_score_codex":0.0002519065,"about_ca_system_score_gemma":0.0012090023,"threshold_uncertainty_score":0.98965025},"labels":[],"label_agreement":null},{"id":"W2136970911","doi":"10.3111/13696998.2014.953680","title":"Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data","year":2014,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spasmodic Torticollis; Medicine; Quality of life (healthcare); Cervical dystonia; Physical therapy; Rating scale; Severity of illness; Clinical trial; Disease; Placebo; Botulinum toxin; Internal medicine; Dystonia; Psychiatry; Psychology; Surgery","score_opus":0.49010930002830455,"score_gpt":0.4986480290291424,"score_spread":0.008538729000837852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136970911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05025592,0.93780017,0.0021147914,0.007839517,0.00080437056,0.00087904517,0.0002902514,0.0000054735788,0.000010458517],"genre_scores_gemma":[0.021351608,0.9753094,0.0008867878,0.0012963141,0.0010163938,0.000004538964,0.000094464674,0.00003671005,0.000003790545],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9897204,0.0025493952,0.006020182,0.0005474569,0.00086641754,0.00029617312],"domain_scores_gemma":[0.9868745,0.005249432,0.0060471226,0.0011559768,0.00016304776,0.00050990225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013364297,0.00039503135,0.0077657322,0.00012118119,0.00013832527,0.0000780785,0.0011617747,0.00079139264,0.00038187622],"category_scores_gemma":[0.0028185567,0.00017546753,0.0024873873,0.00023743119,0.0007244802,0.00018025274,0.0006037713,0.0017136796,4.4982428e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011075143,0.0006307328,0.00022407087,0.001947347,0.07336566,0.000027002388,0.00040649108,0.00015298447,1.4085661e-7,0.0000106459265,0.00024810823,0.9218793],"study_design_scores_gemma":[0.014503346,0.0020175008,0.00045728232,0.0041615744,0.62754375,0.00028252922,0.0014493896,0.20378189,4.8014226e-7,0.00008206883,0.14519759,0.0005225856],"about_ca_topic_score_codex":0.0014798566,"about_ca_topic_score_gemma":0.0006255223,"teacher_disagreement_score":0.92135674,"about_ca_system_score_codex":0.00009793436,"about_ca_system_score_gemma":0.0018284492,"threshold_uncertainty_score":0.74451804},"labels":[],"label_agreement":null},{"id":"W2137881910","doi":"10.3111/13696990802579966","title":"Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmes","year":2008,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Medicine; Medical prescription; Principal (computer security); Quarter (Canadian coin); Drug; Demography; Gerontology; Actuarial science; Business; Economic growth; Pharmacology; Geography; Economics; Computer science; Health care","score_opus":0.06650273456870241,"score_gpt":0.33881254415486517,"score_spread":0.27230980958616274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137881910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911053,0.00084977405,0.00059264875,0.007021336,0.00014760304,0.00012639472,0.0000051595634,0.00000418161,0.00014760399],"genre_scores_gemma":[0.99611795,0.0018549385,0.00090815674,0.00075391313,0.00015176504,0.00001166357,0.000026145663,0.0000072817284,0.00016820809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984471,0.000041842315,0.0008423907,0.00013565808,0.00038491993,0.00014808404],"domain_scores_gemma":[0.99872947,0.00020710658,0.00055749854,0.00013084973,0.00008477964,0.00029030733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000841849,0.00009949082,0.0006309579,0.00043674783,0.000029556473,0.000006179676,0.00017251438,0.00012752949,0.00049081596],"category_scores_gemma":[0.00021038625,0.00007629143,0.00016909975,0.00021629364,0.00020984384,0.00009014624,0.00001995205,0.0002546841,0.0000014748757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001122435,0.0012666124,0.84416527,0.00023237198,0.0023317616,0.00008111909,0.0024329426,0.000066475666,0.0002091683,0.0011355382,0.002950455,0.14400586],"study_design_scores_gemma":[0.006593782,0.00043252754,0.941156,0.000245285,0.00086184475,0.0003099515,0.0008416119,0.02490037,0.00022745448,0.00025970238,0.024037613,0.00013382932],"about_ca_topic_score_codex":0.000026010892,"about_ca_topic_score_gemma":0.000052271054,"teacher_disagreement_score":0.14387204,"about_ca_system_score_codex":0.000060678045,"about_ca_system_score_gemma":0.00032025133,"threshold_uncertainty_score":0.53740907},"labels":[],"label_agreement":null},{"id":"W2141205234","doi":"10.3111/13696998.2013.846262","title":"Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Diabetes mellitus; Dosing; Basal (medicine); Population; Regimen; Type 2 diabetes; Basal insulin; Bolus (digestion); Quality of life (healthcare); Internal medicine; Endocrinology; Environmental health; Nursing","score_opus":0.061067269851679346,"score_gpt":0.34540855673629106,"score_spread":0.2843412868846117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141205234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583423,0.0026487578,0.000062456566,0.037131693,0.00037916662,0.00028900348,0.000005249624,0.0000142102535,0.0011271226],"genre_scores_gemma":[0.9926553,0.0023658476,0.00047718114,0.0026991684,0.000348936,0.0000031059644,0.000024256116,0.000037218942,0.0013889846],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99657005,0.00032614774,0.0019414666,0.00015887321,0.00061733846,0.0003861443],"domain_scores_gemma":[0.9972667,0.0006327339,0.00096672075,0.00021090865,0.00012797456,0.0007949487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008465467,0.00014054812,0.0009968992,0.00029406845,0.000052421547,0.000047255322,0.00035321622,0.00021473948,0.0018415963],"category_scores_gemma":[0.0023394935,0.000106913954,0.00022514028,0.00018504274,0.00020047932,0.00022614874,0.00010052286,0.00076515856,0.00013468249],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010805222,0.001458991,0.020879917,0.00097362965,0.0014741112,0.000025121139,0.0006182377,0.00007066011,0.00064072874,0.0007780726,0.05932503,0.91267496],"study_design_scores_gemma":[0.023932396,0.0041365805,0.88602585,0.0015462245,0.00014106097,0.0000766241,0.0007101009,0.040238347,0.0004135214,0.0028725406,0.039269466,0.0006372672],"about_ca_topic_score_codex":0.00027741553,"about_ca_topic_score_gemma":0.000013304929,"teacher_disagreement_score":0.91203773,"about_ca_system_score_codex":0.00013654106,"about_ca_system_score_gemma":0.0011449552,"threshold_uncertainty_score":0.9990709},"labels":[],"label_agreement":null},{"id":"W2141479869","doi":"10.3111/13696998.2013.852097","title":"Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Cetuximab; Medicine; Panitumumab; Bevacizumab; KRAS; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Cancer","score_opus":0.020973881015520494,"score_gpt":0.2953600767874404,"score_spread":0.2743861957719199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141479869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890127,0.0021482971,0.000013662691,0.008310235,0.00007567208,0.00033666744,0.000023065242,0.0000022935606,0.000077389195],"genre_scores_gemma":[0.9916903,0.0075444146,0.00026000844,0.0003725082,0.0000760896,0.000028106511,0.0000065177724,0.000013529742,0.000008566343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986379,0.000039539198,0.00077423267,0.00015786885,0.00022140889,0.00016906168],"domain_scores_gemma":[0.9987316,0.00030824883,0.0005701199,0.00014285067,0.00011559541,0.0001315953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030829437,0.00019082756,0.0012026059,0.0002781005,0.000034111083,0.000013797063,0.00012930864,0.00006427021,0.00054477045],"category_scores_gemma":[0.000036692163,0.00010262738,0.0002163063,0.00020479357,0.00022597681,0.0000737831,0.000013380074,0.00012162211,8.3855696e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016477901,0.006072223,0.7049829,0.00038996982,0.03084568,0.00020810269,0.007882775,0.011319119,0.00020253785,0.0001935896,0.0005440841,0.22088113],"study_design_scores_gemma":[0.05597882,0.031679116,0.8100026,0.00042452727,0.013370396,0.0002672481,0.00287642,0.07680028,0.004154343,0.00022322098,0.003735891,0.00048714326],"about_ca_topic_score_codex":0.0020201793,"about_ca_topic_score_gemma":0.006602013,"teacher_disagreement_score":0.22039399,"about_ca_system_score_codex":0.00044988192,"about_ca_system_score_gemma":0.00058580627,"threshold_uncertainty_score":0.59648544},"labels":[],"label_agreement":null},{"id":"W2141519001","doi":"10.3111/13696998.2011.650521","title":"Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Swiss children","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Food Allergy and Anaphylaxis Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; PharmIdeas (Canada)","funders":"Bundesamt für Sozialversicherungen","keywords":"Medicine; Atopic dermatitis; Infant formula; Pediatrics; Dermatology","score_opus":0.04012483709666384,"score_gpt":0.3182215672743979,"score_spread":0.27809673017773406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141519001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748796,0.00022023673,0.00010976294,0.0013217223,0.00008369517,0.0002570755,0.0000027286217,0.0000015322552,0.00051530945],"genre_scores_gemma":[0.99927104,0.00031031863,0.00015306218,0.00012946126,0.000112208305,0.000006007641,0.000006721323,0.0000073172423,0.000003886976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981088,0.0002026411,0.00097432197,0.00008728736,0.00048458023,0.00014235367],"domain_scores_gemma":[0.9989076,0.000081370534,0.0006011497,0.00017338192,0.000110178786,0.0001262835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041655474,0.00008214007,0.0003803301,0.00021449935,0.000018677536,0.000006505854,0.00027898187,0.00014110269,0.00065181864],"category_scores_gemma":[0.00031576215,0.00005855441,0.00020085198,0.000061609215,0.00013308563,0.00014346176,0.000025437988,0.00032304702,0.0000030692768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015044296,0.0032643708,0.75421816,0.000513383,0.0016491319,0.00006803274,0.0057426104,0.005445656,0.00025654119,0.004234243,0.0010968554,0.22200656],"study_design_scores_gemma":[0.0072177667,0.0011218125,0.93010205,0.00047142396,0.000075020645,0.00008799336,0.00016918837,0.05489719,0.003070069,0.002570457,0.00013475007,0.0000822647],"about_ca_topic_score_codex":0.00023221015,"about_ca_topic_score_gemma":0.0013079158,"teacher_disagreement_score":0.22192429,"about_ca_system_score_codex":0.00009480621,"about_ca_system_score_gemma":0.0011184347,"threshold_uncertainty_score":0.7136957},"labels":[],"label_agreement":null},{"id":"W2160034796","doi":"10.3111/13696998.2014.909435","title":"A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO)","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Ranibizumab; Medicine; Branch retinal vein occlusion; Central retinal vein occlusion; Macular edema; Cost effectiveness; Retinal Vein; Occlusion; Quality of life (healthcare); Quality-adjusted life year; Ophthalmology; Incremental cost-effectiveness ratio; Surgery; Retinal; Bevacizumab","score_opus":0.025160850929691527,"score_gpt":0.3111070444981639,"score_spread":0.2859461935684724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160034796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968601,0.00003075355,0.00096865045,0.001388484,0.00020017955,0.000366399,0.000020078927,0.000003669676,0.00016168681],"genre_scores_gemma":[0.9981991,0.000025707195,0.001147394,0.0003101284,0.00020614234,0.000004728189,0.000082191524,0.00001913565,0.0000054747916],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984719,0.00008662996,0.00066142733,0.00013374617,0.0005019479,0.00014436051],"domain_scores_gemma":[0.9981275,0.00021993772,0.00074105134,0.00015576549,0.00043550075,0.00032020098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015694774,0.0001223165,0.00043450744,0.00019260339,0.000038895112,0.000011116557,0.00012572821,0.00010776593,0.0002687022],"category_scores_gemma":[0.00068024674,0.00008649049,0.00018808898,0.00004336191,0.00007251091,0.00007025756,0.000017151557,0.0001314169,0.000004250532],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06744987,0.007829081,0.7180759,0.0010771686,0.002286168,0.000056158267,0.00026603896,0.015306213,0.00004405925,0.005038713,0.0043480857,0.17822258],"study_design_scores_gemma":[0.11036997,0.014844836,0.32549003,0.0014471391,0.0029373942,0.00011485478,0.00006350644,0.5327417,0.00029938517,0.0014405334,0.009925601,0.00032500867],"about_ca_topic_score_codex":0.00002264478,"about_ca_topic_score_gemma":0.000007826085,"teacher_disagreement_score":0.51743555,"about_ca_system_score_codex":0.00033682658,"about_ca_system_score_gemma":0.0009046665,"threshold_uncertainty_score":0.35269797},"labels":[],"label_agreement":null},{"id":"W2160861863","doi":"10.3111/13696998.2011.571328","title":"Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review","year":2011,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anemia; Health care; Upper gastrointestinal bleeding; Blood loss; Gastrointestinal bleeding; Retrospective cohort study; Emergency medicine; Intensive care medicine; Medical record; MEDLINE; Disease; Blood transfusion; Systematic review; Surgery; Internal medicine; Endoscopy","score_opus":0.06400063312899791,"score_gpt":0.3410981287151585,"score_spread":0.2770974955861606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160861863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004210703,0.99773437,0.000019670571,0.000849847,0.00016692796,0.00045657853,0.000007652165,0.0000052236956,0.0003386733],"genre_scores_gemma":[0.00035953338,0.99837285,0.000050026294,0.00091437326,0.00026085178,0.000004959259,0.000008153409,0.000023023547,0.0000062048553],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9978485,0.00007967904,0.0015292589,0.00016300341,0.00025097237,0.00012855094],"domain_scores_gemma":[0.9962797,0.00030704436,0.0029551238,0.0001427351,0.00023034759,0.00008506141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020203574,0.0002376315,0.001806824,0.00029599888,0.00003981461,0.00008494756,0.00024171875,0.00014344938,0.0003569854],"category_scores_gemma":[0.001364673,0.00015342343,0.00034482338,0.00012106126,0.00007110523,0.00048468748,0.00007730334,0.00048756012,0.00001070719],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033962602,0.0002642161,0.00021016305,0.79240906,0.0003824641,0.000053020187,0.000007277875,8.748883e-8,3.9275725e-9,0.0070588244,0.0002566069,0.19932432],"study_design_scores_gemma":[0.00084635266,0.00026226387,0.000056368244,0.92029184,0.004619705,0.003252932,0.00002399004,0.000057007484,1.2404312e-8,0.00016182699,0.07021522,0.00021249207],"about_ca_topic_score_codex":0.0000479496,"about_ca_topic_score_gemma":0.000012056293,"teacher_disagreement_score":0.19911183,"about_ca_system_score_codex":0.00004438669,"about_ca_system_score_gemma":0.00028111652,"threshold_uncertainty_score":0.62564266},"labels":[],"label_agreement":null},{"id":"W2166937404","doi":"10.3111/13696998.2010.499749","title":"The cost effectiveness of palivizumab: a systematic review of the evidence","year":2010,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Palivizumab; Medicine; Cost effectiveness; Population; Pediatrics; MEDLINE; Cost-effectiveness analysis; Cost–utility analysis; Intensive care medicine; Environmental health; Risk analysis (engineering); Internal medicine; Respiratory system","score_opus":0.1409699726642448,"score_gpt":0.47145864189459175,"score_spread":0.3304886692303469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166937404","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012496636,0.9956689,0.000025082165,0.0004567509,0.0007714325,0.002821536,0.0000072919884,0.000002152867,0.00012192393],"genre_scores_gemma":[0.000072759685,0.999371,0.0000105176205,0.00014581025,0.00024750654,0.00008438435,6.387334e-7,0.000030734318,0.000036650144],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99271345,0.0024945182,0.0033469426,0.00015902433,0.0010724644,0.00021357516],"domain_scores_gemma":[0.9846046,0.009405837,0.00401483,0.0010231728,0.0006620672,0.00028951518],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.023781935,0.00025110046,0.004300967,0.00016335465,0.00007704846,0.000024594245,0.0014479815,0.00045364627,0.00009863979],"category_scores_gemma":[0.040400244,0.000103650775,0.0016282591,0.000346564,0.00060353207,0.0000887923,0.00023105921,0.002445377,0.000015238587],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025155281,0.000059673526,0.000011838942,0.88988155,0.00044102833,0.000010820226,0.000003664468,2.403045e-7,7.338612e-7,0.00023122565,0.00020733113,0.10912672],"study_design_scores_gemma":[0.00023735294,0.00022455321,0.0000145685635,0.80198276,0.0020759774,0.0011155047,0.0000049021032,0.000007994197,0.000008956428,0.000020499992,0.19424383,0.00006313246],"about_ca_topic_score_codex":0.000007744312,"about_ca_topic_score_gemma":0.000007612888,"teacher_disagreement_score":0.1940365,"about_ca_system_score_codex":0.00039347657,"about_ca_system_score_gemma":0.0049597304,"threshold_uncertainty_score":0.999856},"labels":[],"label_agreement":null},{"id":"W2166962814","doi":"10.3111/13696998.2013.851083","title":"Further validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC)","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Constipation; Quality of life (healthcare); Physical therapy; Functional constipation; Opioid; Psychometrics; Internal medicine; Clinical psychology; Nursing","score_opus":0.06586046611436944,"score_gpt":0.2959547595350054,"score_spread":0.23009429342063595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166962814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894125,0.000074805066,0.0020862352,0.0077982442,0.0005553757,0.0004505327,0.000001141821,0.0000021679073,0.000090221176],"genre_scores_gemma":[0.999217,0.00001826328,0.0002607975,0.0003500785,0.000120315744,0.0000074007075,5.895255e-7,0.0000071032277,0.000018464438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987103,0.00007351441,0.00069286453,0.00007262595,0.0003579637,0.00009276313],"domain_scores_gemma":[0.9983702,0.00015365412,0.0008317067,0.00014946748,0.00041977657,0.000075196294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012758784,0.000070318965,0.00022646438,0.000100964106,0.00004125463,0.000010337412,0.00017024939,0.000090304435,0.00012110331],"category_scores_gemma":[0.004460111,0.000037106536,0.00018036716,0.00013583075,0.0001211357,0.00011816831,0.00002720488,0.00023409938,0.0000013609075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021232886,0.0011666637,0.76803404,0.0010519145,0.00043835482,2.1214485e-7,0.0017172714,0.0027930592,0.032134186,0.0005514007,0.001439513,0.18855007],"study_design_scores_gemma":[0.0070510805,0.0019821953,0.91813946,0.0013066131,0.0003301224,0.00012004573,0.0024518408,0.049220566,0.01477386,0.0043545784,0.00016012111,0.00010953446],"about_ca_topic_score_codex":0.000044415356,"about_ca_topic_score_gemma":0.000008490865,"teacher_disagreement_score":0.18844055,"about_ca_system_score_codex":0.000055813965,"about_ca_system_score_gemma":0.0004506006,"threshold_uncertainty_score":0.53394914},"labels":[],"label_agreement":null},{"id":"W2168221836","doi":"10.3111/13696998.2013.779277","title":"Medical resource use and costs associated with chylomicronemia","year":2013,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Acute pancreatitis; Hypertriglyceridemia; Pancreatitis; Internal medicine; Medical costs; Demographics; Gastroenterology; Pediatrics; Triglyceride; Cholesterol; Demography; Health care","score_opus":0.010336646389222208,"score_gpt":0.22747254911971737,"score_spread":0.21713590273049516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168221836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97455126,0.000520637,0.000067838024,0.023769572,0.00019233866,0.00012339742,0.0000024812944,0.0000105854115,0.0007619141],"genre_scores_gemma":[0.9790203,0.0029386166,0.00049894623,0.0164308,0.0007948246,0.0000031062507,0.000009517671,0.00003531393,0.0002685636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983707,0.00006323305,0.00059803686,0.00013892744,0.00058406463,0.000245022],"domain_scores_gemma":[0.9976648,0.00043817464,0.00033262768,0.00014224809,0.00018550693,0.0012366043],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012042113,0.00013485781,0.0005476771,0.00010902874,0.000038790262,0.0000606375,0.00017922166,0.00032352348,0.0012124585],"category_scores_gemma":[0.004882923,0.000089792156,0.00008138413,0.00006406628,0.0002711482,0.0002713268,0.00006285509,0.00066277746,0.000018483486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016241801,0.0017400755,0.34939268,0.00014120765,0.0018931997,0.0008550236,0.0011540275,0.000018975386,0.00022760202,0.0027519064,0.33071026,0.30949086],"study_design_scores_gemma":[0.04812511,0.0020789835,0.6022875,0.00257612,0.0008769897,0.0073796334,0.0024039706,0.0063887807,0.00030616924,0.0004701977,0.32626393,0.00084262626],"about_ca_topic_score_codex":0.00007523015,"about_ca_topic_score_gemma":0.000042604388,"teacher_disagreement_score":0.30864823,"about_ca_system_score_codex":0.000096467054,"about_ca_system_score_gemma":0.00074045354,"threshold_uncertainty_score":0.99970055},"labels":[],"label_agreement":null},{"id":"W2171819381","doi":"10.3111/13696998.2012.684116","title":"Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Bayer (Canada)","funders":"Bayer","keywords":"Rivaroxaban; Medicine; Cost-effectiveness analysis; Cost effectiveness; Time horizon; Pulmonary embolism; Emergency medicine; Intensive care medicine; Surgery; Internal medicine; Atrial fibrillation; Warfarin; Risk analysis (engineering)","score_opus":0.07944289797029809,"score_gpt":0.37235758021225135,"score_spread":0.2929146822419533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171819381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956258,0.0008245578,0.00034833755,0.002112541,0.00021248039,0.00047087058,0.000008824426,7.188188e-7,0.00039587595],"genre_scores_gemma":[0.9989815,0.00041982677,0.00019044528,0.00028142307,0.000107509855,0.000004483451,0.0000036063432,0.000008212447,0.0000030396507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795294,0.0003909548,0.0009415576,0.000094384166,0.00036675268,0.00025342876],"domain_scores_gemma":[0.9980776,0.00028147182,0.0010363875,0.00024504244,0.00014629672,0.0002132068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064165383,0.00010680683,0.0012053632,0.0003387532,0.000047332625,0.00000634282,0.00029689478,0.000103069506,0.00013081319],"category_scores_gemma":[0.00021371068,0.000068014815,0.00034986058,0.00028658143,0.00017117981,0.00008850031,0.000036486384,0.00035418224,2.7354116e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093442685,0.019315995,0.6438515,0.002162642,0.020139722,0.000082758634,0.23388529,0.009107885,0.00020864127,0.043211035,0.0008702776,0.026229834],"study_design_scores_gemma":[0.0014183881,0.0008056065,0.9748146,0.00058435113,0.0017423419,0.000094464114,0.018711329,0.0003939766,0.00018724261,0.00062571955,0.0005432866,0.000078700126],"about_ca_topic_score_codex":0.28731787,"about_ca_topic_score_gemma":0.23298968,"teacher_disagreement_score":0.3309631,"about_ca_system_score_codex":0.0010686187,"about_ca_system_score_gemma":0.0023531995,"threshold_uncertainty_score":0.7810063},"labels":[],"label_agreement":null},{"id":"W2171964208","doi":"10.3111/13696998.2012.667028","title":"Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thomson Reuters (Canada)","funders":"","keywords":"Medicine; Etanercept; Adalimumab; Infliximab; Rheumatoid arthritis; Internal medicine; Tumor necrosis factor alpha; Surgery","score_opus":0.020433945557357704,"score_gpt":0.2750843191235194,"score_spread":0.25465037356616166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171964208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960486,0.0022070406,0.00001004032,0.0009502516,0.0003972752,0.00028919228,0.000012064517,0.0000055995515,0.000079903235],"genre_scores_gemma":[0.9633316,0.03581036,0.00006160364,0.0005868452,0.00015606478,0.000010466541,0.000028309469,0.000014037957,7.561475e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982023,0.00022532861,0.00072003686,0.000102655686,0.0004227596,0.00032691172],"domain_scores_gemma":[0.99910134,0.00026541806,0.00025853098,0.000115828814,0.000045834648,0.00021303313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012559224,0.00012338998,0.00039153395,0.00025385676,0.000056634137,0.00005023769,0.00021339043,0.0001462217,0.00014340457],"category_scores_gemma":[0.00045083815,0.00008863707,0.00016233456,0.0001197531,0.00009061203,0.00040868737,0.000031628653,0.0006437255,0.0000103350585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001937794,0.00026864593,0.8716848,0.00000589005,0.000037913425,0.000047226782,0.004324669,0.0000037134948,0.0000050445788,0.0000407943,0.00011080492,0.12327673],"study_design_scores_gemma":[0.006482623,0.00031486122,0.98946106,0.00037825303,0.0000014474663,0.000042737844,0.0015554533,0.00012089041,0.000025501231,0.00010349678,0.0014251305,0.000088546956],"about_ca_topic_score_codex":0.0001122684,"about_ca_topic_score_gemma":0.0005457014,"teacher_disagreement_score":0.12318818,"about_ca_system_score_codex":0.00014385708,"about_ca_system_score_gemma":0.00011919004,"threshold_uncertainty_score":0.36145148},"labels":[],"label_agreement":null},{"id":"W2207823877","doi":"10.3111/13696998.2015.1131705","title":"Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Comprehensive Cancer Network; Canadian Centre for Applied Research in Cancer Control","keywords":"Axitinib; Everolimus; Medicine; Sunitinib; Hazard ratio; Internal medicine; Renal cell carcinoma; Pazopanib; Oncology; Sorafenib; Retrospective cohort study; Dosing; Discontinuation; Confidence interval; Hepatocellular carcinoma","score_opus":0.023934877566439083,"score_gpt":0.2883542912529376,"score_spread":0.2644194136864985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2207823877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737985,0.012402569,0.000011031149,0.010881143,0.00014103614,0.0008376799,0.000012351537,0.0000057261605,0.0019099471],"genre_scores_gemma":[0.98621565,0.008591291,0.0009939955,0.003399654,0.00036854824,0.00003501349,0.000010965369,0.000032203832,0.00035270068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981198,0.00013789914,0.0007647077,0.00024004042,0.00045054444,0.00028701755],"domain_scores_gemma":[0.9981249,0.00037731763,0.0005905625,0.00022661635,0.00021899743,0.00046162686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022319283,0.00022867306,0.0008593616,0.00014441642,0.00005078765,0.00003176047,0.00020305601,0.00008275562,0.00015543624],"category_scores_gemma":[0.00032094284,0.0001221952,0.00012962944,0.0001437961,0.00014122877,0.00016292458,0.00003193492,0.0005299489,0.0000031222216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13314392,0.0070843655,0.47686177,0.012366036,0.004187103,0.022438444,0.052496724,0.00017739981,0.0018207863,0.003754621,0.16318841,0.122480415],"study_design_scores_gemma":[0.17369263,0.0430742,0.525924,0.020246722,0.0035527758,0.024975419,0.012503121,0.0012557076,0.013096419,0.0038178917,0.17564508,0.0022160278],"about_ca_topic_score_codex":0.00008884254,"about_ca_topic_score_gemma":0.0007292544,"teacher_disagreement_score":0.12026438,"about_ca_system_score_codex":0.0007096101,"about_ca_system_score_gemma":0.0010997173,"threshold_uncertainty_score":0.4982975},"labels":[],"label_agreement":null},{"id":"W2252889185","doi":"10.3111/13696998.2015.1100115","title":"Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Risperidone; Aripiprazole; Tolerability; Paliperidone; Olanzapine; Internal medicine; Schizophrenia (object-oriented programming); Adverse effect; Psychiatry","score_opus":0.059788747396948526,"score_gpt":0.37644823819064643,"score_spread":0.31665949079369793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252889185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022514,0.0010470587,0.0009327366,0.0067542973,0.00065424683,0.00028583498,0.000013765384,0.000004360358,0.000082550076],"genre_scores_gemma":[0.9883433,0.0021957066,0.008163552,0.00021329094,0.0010088766,0.000005438191,0.000009208543,0.000027462174,0.00003318483],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980537,0.000048527785,0.0010839697,0.0001740823,0.0003120738,0.00032762863],"domain_scores_gemma":[0.9978872,0.00040737918,0.00049142266,0.00017661048,0.00016904225,0.0008683405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017720052,0.0001556895,0.0007338215,0.00025747516,0.000021972975,0.000019749825,0.00026702927,0.00021602742,0.00013412806],"category_scores_gemma":[0.00096363405,0.00012724714,0.00024459805,0.00008642412,0.00011966871,0.0001451863,0.00005094894,0.0006191191,0.000014476628],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40184367,0.0029923595,0.09573212,0.0006415495,0.002225089,0.0015196063,0.00051894906,0.0014929238,0.00018277553,0.0030964906,0.012470916,0.47728357],"study_design_scores_gemma":[0.50445104,0.023669377,0.21564393,0.0032908302,0.0014135445,0.008084528,0.000997833,0.18387403,0.012418945,0.013474344,0.03133541,0.0013462228],"about_ca_topic_score_codex":0.000005807428,"about_ca_topic_score_gemma":0.000099538716,"teacher_disagreement_score":0.47593734,"about_ca_system_score_codex":0.000548484,"about_ca_system_score_gemma":0.0031780077,"threshold_uncertainty_score":0.56376487},"labels":[],"label_agreement":null},{"id":"W2262803926","doi":"10.3111/13696998.2016.1141780","title":"Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Pfizer (Canada)","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Apixaban; Venous thromboembolism; Intensive care medicine; Internal medicine; Warfarin; Atrial fibrillation; Rivaroxaban; Thrombosis","score_opus":0.03019685173148177,"score_gpt":0.30518240421543796,"score_spread":0.2749855524839562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2262803926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244106,0.0024277628,0.000050879997,0.00427244,0.0002761816,0.00047807844,0.000024953993,9.4998956e-7,0.000027716353],"genre_scores_gemma":[0.9131542,0.08632721,0.00024134733,0.00007250827,0.0001656013,0.000016320786,0.0000011889049,0.000010442444,0.000011218567],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987147,0.000034743494,0.0008524227,0.00014639786,0.000109595036,0.0001421439],"domain_scores_gemma":[0.99863863,0.00046351049,0.0005327008,0.00014382882,0.000037704325,0.00018359703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059314526,0.00012236978,0.0009203509,0.00006327592,0.000020625102,0.000004580135,0.0000813521,0.000062948755,0.000035171866],"category_scores_gemma":[0.000041648615,0.00005898662,0.00010612425,0.000015898526,0.00014015101,0.00004651133,0.000020505891,0.000059511007,1.4471992e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005742957,0.0012018876,0.02324362,0.00005931984,0.00086761964,0.000006838858,0.00024773204,0.00004740537,0.000003779297,0.0012215788,0.00016473966,0.9723612],"study_design_scores_gemma":[0.027955439,0.032068342,0.9203218,0.0016353993,0.0016309753,0.00019666864,0.00093989813,0.0008515541,0.00049553945,0.001104533,0.012585069,0.00021477626],"about_ca_topic_score_codex":0.023467682,"about_ca_topic_score_gemma":0.27895764,"teacher_disagreement_score":0.9721464,"about_ca_system_score_codex":0.00047350654,"about_ca_system_score_gemma":0.0013885153,"threshold_uncertainty_score":0.98303515},"labels":[],"label_agreement":null},{"id":"W2264465777","doi":"10.3111/13696998.2016.1151432","title":"Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; McGill University; Golder Associates (Canada)","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Erlotinib; Nivolumab; Docetaxel; Quality-adjusted life year; Oncology; Lung cancer; Quality of life (healthcare); Cost effectiveness; Survival analysis; Internal medicine; Cancer; Immunotherapy; Epidermal growth factor receptor; Risk analysis (engineering)","score_opus":0.13854774319199728,"score_gpt":0.36274728020138175,"score_spread":0.22419953700938447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264465777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279994,0.0018801275,0.0012908233,0.0033703344,0.00024729886,0.00036224106,0.000035436886,7.0382316e-7,0.000013110409],"genre_scores_gemma":[0.9987219,0.0006617942,0.0005178958,0.000029311419,0.000042942313,0.000008869304,0.0000012700423,0.0000089619725,0.0000070674655],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99852467,0.000035841735,0.0010345259,0.000095996336,0.00019539565,0.00011354943],"domain_scores_gemma":[0.9987001,0.00047879387,0.00053883856,0.00012102991,0.00006669628,0.00009457331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013373378,0.00009611607,0.000693582,0.0000850237,0.000013288797,0.0000023034513,0.0000997529,0.000055148153,0.000051289888],"category_scores_gemma":[0.00011935863,0.00005413628,0.00011767705,0.000023076438,0.000058718208,0.000048896185,0.00000976942,0.0000508001,4.9336847e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008029884,0.00040045913,0.061296925,0.00012915075,0.0007106159,0.000001152422,0.0010097591,0.05062151,0.00086037425,0.00011197902,0.0000276606,0.87680054],"study_design_scores_gemma":[0.030407859,0.0024688123,0.047741685,0.00036560107,0.00038847598,0.00002455189,0.0014272777,0.9121131,0.0043873736,0.0002214359,0.00032011216,0.00013372698],"about_ca_topic_score_codex":0.018301222,"about_ca_topic_score_gemma":0.37507817,"teacher_disagreement_score":0.8766668,"about_ca_system_score_codex":0.000792122,"about_ca_system_score_gemma":0.0019365749,"threshold_uncertainty_score":0.988236},"labels":[],"label_agreement":null},{"id":"W2280216291","doi":"10.3111/13696998.2016.1154566","title":"Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharmaceuticals Canada; Public Health Agency of Canada","keywords":"Medicine; Ranibizumab; Diabetic macular edema; Ophthalmology; Edema; Visual impairment; Macular edema; Diabetic retinopathy; Diabetes mellitus; Visual acuity; Surgery; Bevacizumab; Chemotherapy","score_opus":0.02298697161475093,"score_gpt":0.33643614135231387,"score_spread":0.3134491697375629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280216291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627674,0.00041925025,0.00017398444,0.002391724,0.0001243925,0.0005444676,0.0000129353475,0.0000011978423,0.00005531486],"genre_scores_gemma":[0.99828,0.0013849674,0.00006927948,0.00012393648,0.00010260619,0.000019580079,0.0000017219476,0.000009601934,0.000008327092],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986538,0.00015405746,0.00061350816,0.000104640676,0.00031828237,0.00015568329],"domain_scores_gemma":[0.99877536,0.0004690415,0.000258729,0.00014709681,0.00006393327,0.0002858483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008064645,0.000115405106,0.000629583,0.00010905513,0.000011166015,0.0000041067187,0.00013455297,0.0000715732,0.00014469589],"category_scores_gemma":[0.00015441763,0.000053065258,0.0002785949,0.00006087511,0.00007415078,0.00003617628,0.0000160336,0.000054956807,0.0000068447434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02377015,0.03546651,0.3551626,0.00091193756,0.0031239523,0.0041142567,0.002502872,0.00016251081,0.0018869491,0.0011268315,0.00033598964,0.57143545],"study_design_scores_gemma":[0.035745427,0.027748795,0.9197586,0.0024613834,0.0007153248,0.0008165087,0.0005674877,0.00025547892,0.008788954,0.00075985026,0.002221159,0.00016103679],"about_ca_topic_score_codex":0.00002557509,"about_ca_topic_score_gemma":0.0000060023244,"teacher_disagreement_score":0.5712744,"about_ca_system_score_codex":0.000354964,"about_ca_system_score_gemma":0.00029658113,"threshold_uncertainty_score":0.21639384},"labels":[],"label_agreement":null},{"id":"W2288006965","doi":"10.3111/13696998.2015.1116992","title":"Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Gastrointestinal motility and disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"Purdue Pharma","keywords":"Oxycodone; Medicine; Opioid; Chronic pain; (+)-Naloxone; Analgesic; Constipation; Anesthesia; Cost effectiveness; Physical therapy; Internal medicine","score_opus":0.042985781415556146,"score_gpt":0.2773973107426432,"score_spread":0.23441152932708703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288006965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874092,0.0000313102,0.010823898,0.0008642246,0.00007590532,0.0007472936,0.000018484077,0.000001134857,0.000028581153],"genre_scores_gemma":[0.9979778,0.00001936388,0.0018051412,0.00013949808,0.000012158025,0.000018645453,0.000016986467,0.000009092946,0.0000013247443],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984274,0.00010342047,0.00067620416,0.00013861553,0.0004772742,0.00017711658],"domain_scores_gemma":[0.9981711,0.0006670702,0.00042145507,0.00015576965,0.00032702327,0.00025759044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002197343,0.00012087573,0.0007174031,0.0002591409,0.000014398228,0.0000052317205,0.00015211743,0.000049206094,0.000013517435],"category_scores_gemma":[0.0005125822,0.0000806187,0.00006285025,0.00040078044,0.00006387411,0.00006920219,0.000027423905,0.00020977976,1.07636644e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05106046,0.0008425704,0.7686637,0.0003109155,0.002124911,0.00004473794,0.00027332513,0.15203887,0.000003030331,0.00010288932,0.000036038768,0.024498533],"study_design_scores_gemma":[0.034084167,0.0038797029,0.9095267,0.00082239404,0.0009143339,0.000008861105,0.0021703574,0.048368547,0.000043379667,0.00003581,0.000033590393,0.00011215797],"about_ca_topic_score_codex":0.045960866,"about_ca_topic_score_gemma":0.33069736,"teacher_disagreement_score":0.28473648,"about_ca_system_score_codex":0.0006498954,"about_ca_system_score_gemma":0.0015280611,"threshold_uncertainty_score":0.9603922},"labels":[],"label_agreement":null},{"id":"W2290821530","doi":"10.3111/13696998.2016.1151431","title":"A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Notre-Dame; Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Letrozole; Anastrozole; Breast cancer; Quality-adjusted life year; Context (archaeology); Cost effectiveness; Metastatic breast cancer; Oncology; Internal medicine; Pharmacoeconomics; Economic evaluation; Quality of life (healthcare); Tamoxifen; Cancer; Trastuzumab; Intensive care medicine","score_opus":0.05054085207464628,"score_gpt":0.31177162081062276,"score_spread":0.2612307687359765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290821530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692291,0.0007064055,0.015087043,0.010085154,0.0014697637,0.00056653755,0.0023294867,0.0000025696008,0.00052396394],"genre_scores_gemma":[0.99653804,0.00209191,0.00030292073,0.00061735546,0.00028659843,0.00005122728,0.0000011611494,0.000023370761,0.000087420776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793065,0.000020712025,0.0013399728,0.0002686864,0.000057968195,0.00038201796],"domain_scores_gemma":[0.9979212,0.00035813206,0.0009979692,0.00023554155,0.000056091852,0.00043103244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013105598,0.00019472328,0.00091068394,0.000109025925,0.000033084627,0.000023099417,0.000682001,0.00012677768,0.0002261877],"category_scores_gemma":[0.00023602117,0.00014337686,0.00019907302,0.00007216427,0.000057501496,0.0003750114,0.000067312525,0.000110488574,0.000008654775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029151223,0.00018546174,0.40098447,0.00008304968,0.0007187783,0.000009592787,0.00015492378,0.16547228,0.000018065146,0.12141832,0.0065962537,0.3014437],"study_design_scores_gemma":[0.025929522,0.0005876102,0.7744437,0.0011155726,0.00010970556,0.00013120026,0.0002028998,0.039886273,0.0003409133,0.12340161,0.032729805,0.0011211876],"about_ca_topic_score_codex":0.158168,"about_ca_topic_score_gemma":0.44629443,"teacher_disagreement_score":0.37345925,"about_ca_system_score_codex":0.0054906607,"about_ca_system_score_gemma":0.0056114565,"threshold_uncertainty_score":0.9983271},"labels":[],"label_agreement":null},{"id":"W2292517844","doi":"10.3111/13696998.2015.1106546","title":"Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada","year":2015,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hepatitis C virus research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Sofosbuvir; Medicine; Daclatasvir; Internal medicine; Regimen; Ribavirin; Quality-adjusted life year; Cost effectiveness; Hepatitis C; Hepatitis C virus; Gastroenterology; Virology; Virus","score_opus":0.10394248166757698,"score_gpt":0.36719780092797444,"score_spread":0.26325531926039747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292517844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658746,0.0002875553,0.0013242121,0.0005779218,0.00034040437,0.00064129324,0.00008334972,0.000001991674,0.00015579269],"genre_scores_gemma":[0.9967996,0.002418118,0.00046209988,0.00008997254,0.00014485166,0.000030129691,0.00002589669,0.000019639834,0.000009676157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981754,0.0001712025,0.0008392827,0.00012305158,0.00047772625,0.00021337971],"domain_scores_gemma":[0.99792016,0.00067690347,0.00043084368,0.00017818433,0.0003216361,0.0004722684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017696313,0.00011635451,0.0008054558,0.000223968,0.000013296851,0.000004719158,0.00012457951,0.00013933156,0.00007972642],"category_scores_gemma":[0.001205883,0.000098674645,0.00012234983,0.00010876287,0.00008495446,0.00008081305,0.000020129253,0.00015983524,0.0000014408894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009098963,0.0011434975,0.8221652,0.00077875156,0.00060784596,0.00033387108,0.0003353467,0.009399346,0.0005043409,0.00018599373,0.0019781347,0.15346873],"study_design_scores_gemma":[0.10132071,0.023032857,0.4913841,0.0024226117,0.0005412311,0.0002883751,0.00023978995,0.1731808,0.095102265,0.0008635846,0.110962376,0.00066130847],"about_ca_topic_score_codex":0.73071176,"about_ca_topic_score_gemma":0.7818226,"teacher_disagreement_score":0.33078107,"about_ca_system_score_codex":0.0047723516,"about_ca_system_score_gemma":0.016536523,"threshold_uncertainty_score":0.9990482},"labels":[],"label_agreement":null},{"id":"W2292965968","doi":"10.3111/13696998.2016.1148043","title":"Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Society for Medical Oncology; Amgen","keywords":"Medicine; Palliative care; Health care; Radiation oncologist; Delphi method; Disease; Family medicine; Intensive care medicine; Internal medicine; Oncology; Radiation therapy; Nursing","score_opus":0.02535785315555483,"score_gpt":0.2717050905676122,"score_spread":0.24634723741205738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292965968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95927197,0.00019904292,0.00046074617,0.039693132,0.00012989776,0.00016491614,0.000007457557,0.0000044925287,0.000068341644],"genre_scores_gemma":[0.9973613,0.0007144364,0.00058393856,0.0008386242,0.00012828008,0.0000037111677,0.0000015161153,0.000013149931,0.00035504246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885863,0.00008645613,0.00054961094,0.00008390096,0.00028049338,0.00014090148],"domain_scores_gemma":[0.9984442,0.00069008896,0.0005088815,0.00012694231,0.00007170681,0.00015818953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071462983,0.00009276598,0.00041901084,0.000114591785,0.000030380086,0.000013370969,0.00008856403,0.000052802563,0.00012412366],"category_scores_gemma":[0.00038031465,0.000041090232,0.00008066575,0.000061430015,0.00010678864,0.00005810173,0.000011842344,0.00011008686,0.000002417258],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012142783,0.0056226267,0.19706154,0.0006537153,0.0077069784,0.00821548,0.013078666,0.0017927116,0.0001663011,0.0067801233,0.013420771,0.7333583],"study_design_scores_gemma":[0.06469387,0.03742568,0.095659554,0.007891824,0.0022691076,0.010510006,0.006611423,0.023305435,0.001845591,0.00092618074,0.74800426,0.0008570802],"about_ca_topic_score_codex":0.000052443254,"about_ca_topic_score_gemma":0.0005208059,"teacher_disagreement_score":0.7345835,"about_ca_system_score_codex":0.00042358332,"about_ca_system_score_gemma":0.00025792306,"threshold_uncertainty_score":0.1675611},"labels":[],"label_agreement":null},{"id":"W2325992311","doi":"10.3111/13696998.2012.726674","title":"Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain","year":2012,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Casa","funders":"European Commission","keywords":"Rosuvastatin; Medicine; Atorvastatin; Statin; Rosuvastatin Calcium; Cost effectiveness; Internal medicine; Risk analysis (engineering)","score_opus":0.040634616720675476,"score_gpt":0.3254239922523687,"score_spread":0.2847893755316932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325992311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911016,0.0012432939,0.00636789,0.0006959099,0.0002780228,0.00021337572,0.00000756034,0.0000028443083,0.00008948348],"genre_scores_gemma":[0.9962117,0.0012456458,0.001626332,0.00043445622,0.00044737753,0.000006943402,0.0000066710854,0.000015123236,0.0000057536104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978874,0.00029289856,0.0009304598,0.00010489543,0.0005066522,0.00027774353],"domain_scores_gemma":[0.9983919,0.0002716306,0.0004691055,0.00021877901,0.00009839432,0.00055018347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008553614,0.000110836154,0.0011379959,0.00047760768,0.0000150232545,0.000006296112,0.00013018724,0.00014456263,0.0002756673],"category_scores_gemma":[0.0006494744,0.00008868261,0.0005531392,0.00044060964,0.00006640101,0.0001143723,0.000035323643,0.00038125995,0.0000035880364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010116242,0.0010786011,0.6005901,0.0004944448,0.0049879146,0.00014713041,0.0010448248,0.0034137256,0.00013563677,0.00091398205,0.0001788063,0.3860032],"study_design_scores_gemma":[0.005194176,0.00046805205,0.9736828,0.0002770647,0.0015344948,0.00030396794,0.00050679233,0.008772899,0.0006441241,0.000049036935,0.008407252,0.00015930423],"about_ca_topic_score_codex":0.00017508036,"about_ca_topic_score_gemma":0.00006185329,"teacher_disagreement_score":0.38584387,"about_ca_system_score_codex":0.00028236405,"about_ca_system_score_gemma":0.0006074591,"threshold_uncertainty_score":0.36163718},"labels":[],"label_agreement":null},{"id":"W2337280501","doi":"10.3111/13696998.2016.1164174","title":"The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Biogen","keywords":"Dimethyl fumarate; Relapsing remitting; Medicine; Multiple sclerosis; Cost effectiveness; Internal medicine; Oncology; Immunology","score_opus":0.08091913144112999,"score_gpt":0.3192051370431769,"score_spread":0.23828600560204688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337280501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911569,0.0024063855,0.00055989507,0.004717917,0.00038117575,0.0007138982,0.00004406562,0.0000013562801,0.000018406445],"genre_scores_gemma":[0.9689439,0.03063407,0.00015142819,0.000045973407,0.00014313214,0.00004864775,7.396898e-7,0.000014563278,0.000017571225],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99809384,0.00015941262,0.0009224181,0.00012321112,0.00041285664,0.0002882877],"domain_scores_gemma":[0.98301303,0.015690312,0.00057877664,0.00022794415,0.00026616946,0.00022379286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031656232,0.00012595992,0.00060947525,0.000067250454,0.0000967082,0.000006660636,0.00027190777,0.00006969858,0.000021279073],"category_scores_gemma":[0.0056884103,0.000053534015,0.00021387359,0.00007935752,0.00027090512,0.000053348227,0.000048116628,0.00017213968,4.315462e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060294885,0.00054212584,0.12152693,0.00017023181,0.0013495196,0.0000124787575,0.0003138927,0.0009345289,0.005372843,0.00010050053,0.0007751029,0.86287236],"study_design_scores_gemma":[0.057879947,0.00505056,0.79251605,0.0056045637,0.0005093418,0.00006423115,0.0027095338,0.048352104,0.063881904,0.00027285967,0.022799049,0.00035987404],"about_ca_topic_score_codex":0.08760181,"about_ca_topic_score_gemma":0.25611678,"teacher_disagreement_score":0.86251247,"about_ca_system_score_codex":0.0013403143,"about_ca_system_score_gemma":0.002211653,"threshold_uncertainty_score":0.91847396},"labels":[],"label_agreement":null},{"id":"W2546071416","doi":"10.1080/13696998.2016.1254090","title":"Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Uterine Myomas and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Ulipristal acetate; Medicine; Uterine fibroids; Reimbursement; Gynecology; Population; Obstetrics; Health care; Family planning; Research methodology; Environmental health","score_opus":0.014795165088812998,"score_gpt":0.33683622796714313,"score_spread":0.3220410628783301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546071416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951634,0.00007050529,0.0019548924,0.0023331763,0.000018953002,0.00034464875,0.00009933612,9.3167097e-7,0.000014200533],"genre_scores_gemma":[0.99768734,0.0011134474,0.000975464,0.000053035103,0.000060683087,0.000022878128,0.000016634904,0.0000074295403,0.00006307883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987396,0.000079984624,0.0007091394,0.00017964194,0.00014575516,0.00014589004],"domain_scores_gemma":[0.9990197,0.00019621139,0.00036725332,0.00018828634,0.00008131436,0.00014725735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000599097,0.00012792481,0.0009101227,0.00046639654,0.000012609011,0.000010849837,0.00008531649,0.0000652037,0.000075355674],"category_scores_gemma":[0.00015379366,0.00006254366,0.00022009965,0.00035099016,0.00006283296,0.00009530775,0.000020053612,0.000052039864,1.341463e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020987583,0.0023971996,0.8231273,0.00008553187,0.021789884,0.00020319744,0.025132423,0.016777309,0.0004792054,0.000030033285,0.00007612627,0.08891415],"study_design_scores_gemma":[0.018927677,0.007231818,0.9561293,0.00013167209,0.0023575919,0.00008836377,0.0010809791,0.01191797,0.001416674,0.00020432199,0.000356774,0.0001568297],"about_ca_topic_score_codex":0.00012681472,"about_ca_topic_score_gemma":0.00039611277,"teacher_disagreement_score":0.13300197,"about_ca_system_score_codex":0.0003067911,"about_ca_system_score_gemma":0.00013797602,"threshold_uncertainty_score":0.25504565},"labels":[],"label_agreement":null},{"id":"W2564573601","doi":"10.1080/13696998.2016.1273229","title":"Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study","year":2016,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Medicines Company; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Idarucizumab; Dabigatran; Anticoagulant; Surgery; Interim analysis; Psychological intervention; Intensive care unit; Emergency medicine; Anesthesia; Randomized controlled trial; Intensive care medicine; Warfarin; Internal medicine","score_opus":0.17826688296940718,"score_gpt":0.3904857417989905,"score_spread":0.2122188588295833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564573601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94188756,0.000042873857,0.0009131477,0.055578668,0.0006361983,0.00089501875,0.000031156458,0.0000069658818,0.000008395827],"genre_scores_gemma":[0.99845606,0.00014728411,0.000365664,0.000436912,0.00046613114,0.0000030577398,0.000027098376,0.000016678165,0.00008112703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736184,0.00013044095,0.0018024509,0.0001872018,0.00035989002,0.00015819511],"domain_scores_gemma":[0.997231,0.0011908864,0.0009907531,0.00017504986,0.00020357841,0.0002086972],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025721013,0.00011604371,0.0005453265,0.00023975507,0.00004798549,0.000021024714,0.0001722493,0.00009513824,0.00011540377],"category_scores_gemma":[0.010725509,0.00006731801,0.00025534554,0.0001497999,0.000037262398,0.00020717115,0.00007258248,0.00012102074,0.0000016298613],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030968392,0.00046629034,0.75794405,0.0005083176,0.00055065885,0.00003154427,0.005701748,0.00008366516,0.00003806171,0.00009391611,0.014993696,0.18861966],"study_design_scores_gemma":[0.017101133,0.0021932628,0.9612874,0.0059031565,0.0002774163,0.000011045736,0.005767804,0.0006420551,0.00012403539,0.00015204377,0.006368598,0.00017205454],"about_ca_topic_score_codex":0.000057570633,"about_ca_topic_score_gemma":0.00074826146,"teacher_disagreement_score":0.20334335,"about_ca_system_score_codex":0.00023875898,"about_ca_system_score_gemma":0.00029212888,"threshold_uncertainty_score":0.9976076},"labels":[],"label_agreement":null},{"id":"W2704483287","doi":"10.1080/13696998.2017.1347792","title":"Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective","year":2017,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute for Clinical Evaluative Sciences; University of Ottawa","funders":"","keywords":"Medicine; Insulin detemir; Insulin glargine; Type 2 diabetes; Context (archaeology); Type 2 Diabetes Mellitus; Cost effectiveness; Diabetes mellitus; Cohort; Intensive care medicine; Internal medicine; Endocrinology; Risk analysis (engineering)","score_opus":0.08740198163052294,"score_gpt":0.3885485808099122,"score_spread":0.3011465991793893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2704483287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908723,0.0014110184,0.00019178497,0.004553661,0.0013650302,0.00053394254,0.000030106668,0.000005977737,0.0010361304],"genre_scores_gemma":[0.9966315,0.0016220182,0.00063146703,0.00011525299,0.00088850467,0.000012675704,0.000012778087,0.000025137419,0.000060660106],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985679,0.000079372825,0.000512622,0.00018471343,0.00038104298,0.00027435736],"domain_scores_gemma":[0.9970822,0.0011789063,0.00059755926,0.00034115845,0.00045061723,0.00034956326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025769125,0.00013998838,0.00071730214,0.00015777288,0.00008888732,0.000053207783,0.0005720582,0.00019909379,0.0002236211],"category_scores_gemma":[0.0055770357,0.00010719032,0.0002442109,0.000047734164,0.0002654548,0.00019663142,0.0001818426,0.00044913136,0.000012316075],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07117514,0.004632389,0.19251056,0.0026819732,0.013042804,0.00031893383,0.0017802924,0.0002666755,0.0026040273,0.013629562,0.007346998,0.69001067],"study_design_scores_gemma":[0.17282066,0.019553902,0.6099501,0.0058864863,0.0023480852,0.000017877042,0.0038822007,0.04869764,0.022376236,0.025870154,0.08740875,0.0011878745],"about_ca_topic_score_codex":0.000033725497,"about_ca_topic_score_gemma":0.000019835234,"teacher_disagreement_score":0.68882275,"about_ca_system_score_codex":0.00024546863,"about_ca_system_score_gemma":0.00051117525,"threshold_uncertainty_score":0.6676636},"labels":[],"label_agreement":null},{"id":"W2740431138","doi":"10.1080/13696998.2017.1363050","title":"Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands","year":2017,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Paliperidone Palmitate; Paliperidone; Risperidone; Cost effectiveness; Olanzapine; Quality-adjusted life year; Emergency medicine; Schizophrenia (object-oriented programming); Psychiatry","score_opus":0.0715635955191591,"score_gpt":0.38269670465807637,"score_spread":0.3111331091389173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740431138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884544,0.0016965211,0.00016890028,0.008668249,0.00023003404,0.0006617473,0.000009650898,0.0000017000323,0.00010880866],"genre_scores_gemma":[0.99379504,0.0049573346,0.0004028496,0.00010714889,0.00066790724,0.0000441456,0.000004558142,0.0000128063975,0.000008238581],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988096,0.00011628312,0.0004381643,0.00010739832,0.00032186086,0.00020669217],"domain_scores_gemma":[0.99829257,0.00067686185,0.00037605493,0.00035577733,0.00009187042,0.00020686854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034324662,0.00010653881,0.000496032,0.00009078222,0.000081355254,0.000039912746,0.0005202617,0.00012095309,0.00007831559],"category_scores_gemma":[0.0007040059,0.00005880701,0.00022367253,0.000027667124,0.00019107955,0.000093581875,0.0000319852,0.00035971482,0.0000019166484],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12085227,0.0019554847,0.052791007,0.00036453072,0.0011555854,0.00039184742,0.00043198068,0.0000959997,0.00034677805,0.0052832738,0.00093795126,0.81539327],"study_design_scores_gemma":[0.11972759,0.009643949,0.84356827,0.0011515239,0.000131758,0.0007065941,0.00022227677,0.003821788,0.004237295,0.0065828706,0.010008441,0.00019763561],"about_ca_topic_score_codex":0.000040635987,"about_ca_topic_score_gemma":0.00019636255,"teacher_disagreement_score":0.8151957,"about_ca_system_score_codex":0.00017817057,"about_ca_system_score_gemma":0.0012338872,"threshold_uncertainty_score":0.23980804},"labels":[],"label_agreement":null},{"id":"W2765403114","doi":"10.1080/13696998.2018.1539400","title":"Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); McMaster University","funders":"","keywords":"Medicine; Secukinumab; BASDAI; Golimumab; Adalimumab; BASFI; Ankylosing spondylitis; Certolizumab pegol; Etanercept; Infliximab; Population; Cost effectiveness; Discontinuation; Internal medicine; Tumor necrosis factor alpha; Disease","score_opus":0.03604495381201373,"score_gpt":0.3326350826472689,"score_spread":0.29659012883525515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765403114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928798,0.0010402427,0.000029017045,0.004368834,0.0003084087,0.00015557083,0.00016968511,0.0000015036214,0.0010469566],"genre_scores_gemma":[0.9984055,0.0005522834,0.000103671395,0.00054543186,0.00036365862,0.000002872346,0.000014005621,0.000008401904,0.0000041428934],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886864,0.000093137445,0.00046446713,0.0001328694,0.00024465902,0.00019625174],"domain_scores_gemma":[0.9986206,0.0004365734,0.0002385075,0.00015445164,0.0002563035,0.00029355087],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009312998,0.00009901922,0.0006431846,0.00031141937,0.00008049013,0.000015905656,0.0001508196,0.000119495686,0.0009934738],"category_scores_gemma":[0.00061847595,0.00006874021,0.00023303185,0.00033290745,0.00027219247,0.00005979756,0.000031704596,0.00028094716,0.0000040367486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021813442,0.00051780965,0.9336353,0.000015706504,0.011696438,0.0013474991,0.009511017,0.00009051741,0.000016453983,0.0052249287,0.00045867995,0.035304304],"study_design_scores_gemma":[0.0054596146,0.00060494075,0.9789066,0.00033719794,0.0013217138,0.0001443847,0.004121124,0.001212653,0.00011523023,0.0011040481,0.006580306,0.00009220237],"about_ca_topic_score_codex":0.18536788,"about_ca_topic_score_gemma":0.6378275,"teacher_disagreement_score":0.4524596,"about_ca_system_score_codex":0.0011463991,"about_ca_system_score_gemma":0.0009247513,"threshold_uncertainty_score":0.9999198},"labels":[],"label_agreement":null},{"id":"W2806175845","doi":"10.1080/13696998.2018.1486846","title":"The impact of different scenarios for intermittent bladder catheterization on health state utilities: results from an internet-based time trade-off survey","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Urinary Tract Infections Management","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"International Collaboration On Repair Discoveries; GF Strong Rehabilitation Centre; University of British Columbia","funders":"","keywords":"Medicine; Catheter; The Internet; Time-trade-off; Quality of life (healthcare); Population; Gold standard (test); Intensive care medicine; Emergency medicine; Environmental health; Surgery; Nursing; Internal medicine","score_opus":0.03653573159351569,"score_gpt":0.3403987896737409,"score_spread":0.3038630580802252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806175845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881534,0.000028460217,0.0028514382,0.007884032,0.0004780704,0.00034474613,0.00020467582,0.000008669408,0.00004653337],"genre_scores_gemma":[0.9984133,0.0002276594,0.00008805176,0.0007486453,0.000290354,0.0000038722096,0.00012184889,0.000022422028,0.00008382815],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980289,0.00021441413,0.0011321963,0.00016203901,0.000249357,0.0002131098],"domain_scores_gemma":[0.99753827,0.0008540883,0.0008902326,0.00030282815,0.00011634159,0.0002982531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002165017,0.00015109961,0.0004477534,0.00014108793,0.000062432206,0.000035674188,0.00024885777,0.000075859665,0.00014625727],"category_scores_gemma":[0.00069848937,0.000090805996,0.00024167998,0.00004109853,0.00017222951,0.00008412834,0.00003035339,0.0002713271,0.0000056682516],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05174943,0.019109618,0.012567914,0.0001685378,0.0045855367,0.000033253713,0.0075579854,0.0033264074,0.00008768787,0.000111549794,0.046354488,0.8543476],"study_design_scores_gemma":[0.015029425,0.081445865,0.43372646,0.0009342855,0.00016764092,0.000054770728,0.00032429572,0.45664942,0.00062531297,0.00039412297,0.0103649665,0.00028344267],"about_ca_topic_score_codex":0.00048189034,"about_ca_topic_score_gemma":0.0002517826,"teacher_disagreement_score":0.85406417,"about_ca_system_score_codex":0.0005092373,"about_ca_system_score_gemma":0.000530077,"threshold_uncertainty_score":0.37029612},"labels":[],"label_agreement":null},{"id":"W2887537762","doi":"10.1080/13696998.2018.1511566","title":"Cost consequence analysis of use of a balloon expandable vascular access system and standard vascular sheath for transcatheter aortic valve implantation","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital; Université de Montréal; Montreal Heart Institute","funders":"","keywords":"Medicine; Stenosis; Surgery; Balloon; Retrospective cohort study; Vascular access; Cardiology","score_opus":0.03803053530142948,"score_gpt":0.35875473697368737,"score_spread":0.3207242016722579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887537762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870127,0.0007171562,0.011496676,0.00008085137,0.00012934004,0.00030858238,0.00023977818,0.0000031221919,0.000011783423],"genre_scores_gemma":[0.9974562,0.0017136866,0.0006100863,0.0000894428,0.00008452479,0.000007727572,0.000024734018,0.000011491779,0.0000021234066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861425,0.00004288477,0.00073299784,0.00014051812,0.00033144982,0.00013789076],"domain_scores_gemma":[0.9985453,0.0001899109,0.00044162365,0.00017114134,0.00035155241,0.0003004699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007009466,0.00010948116,0.0008991214,0.00023078949,0.000029742347,0.000027565791,0.000094309944,0.000098151264,0.00005613544],"category_scores_gemma":[0.00015024263,0.000083717714,0.002015348,0.00011563447,0.0001515622,0.00017899579,0.000017390072,0.00007209312,2.5542695e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008909464,0.0014334882,0.7192202,0.0037068129,0.20628217,0.000080585756,0.0023893656,0.0015004025,0.0006866819,0.0009415326,0.00030656837,0.05454271],"study_design_scores_gemma":[0.034413517,0.0056323106,0.7124742,0.0029010288,0.19110763,0.0005722289,0.0017693564,0.043986257,0.0043435483,0.00030063416,0.0019236362,0.0005756341],"about_ca_topic_score_codex":0.00009929297,"about_ca_topic_score_gemma":0.00001301923,"teacher_disagreement_score":0.053967077,"about_ca_system_score_codex":0.000117999625,"about_ca_system_score_gemma":0.0003510494,"threshold_uncertainty_score":0.34139094},"labels":[],"label_agreement":null},{"id":"W2904389052","doi":"10.1080/13696998.2018.1558866","title":"Decrease in American birth rates makes it imperative for the United States to implement state mandated fertility coverage","year":2018,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Assisted Reproductive Technology and Twin Pregnancy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Infertility; Medicine; Fertility; Live birth; Obstetrics; Assisted reproductive technology; Embryo transfer; Single Embryo Transfer; Multiple birth; Pregnancy; Demography; Environmental health; Population","score_opus":0.0235166893265398,"score_gpt":0.3442517936237993,"score_spread":0.32073510429725954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904389052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372707,0.00013173831,0.0045031174,0.05740126,0.00019491346,0.0004164116,0.000043148295,0.000011259121,0.000027443077],"genre_scores_gemma":[0.99251467,0.0012101406,0.0006617601,0.005319525,0.00016382277,0.000019534613,0.000017101183,0.000014552128,0.00007890663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985922,0.00007774468,0.0006978823,0.00020724577,0.00015779691,0.00026715433],"domain_scores_gemma":[0.998348,0.00044361403,0.00033384393,0.00024956465,0.00029977117,0.0003252257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001634843,0.00013674694,0.00043492817,0.00022732887,0.00009335316,0.000017868904,0.00024443044,0.000074276984,0.00035921144],"category_scores_gemma":[0.0020071694,0.00008359731,0.0000904396,0.00024775066,0.00042328783,0.00006541192,0.00007565651,0.00041176184,0.000006395492],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032808308,0.0029590926,0.3915664,0.0002566934,0.004153205,0.0006129576,0.012330827,0.000789922,0.0005247698,0.0024956453,0.03686467,0.51463753],"study_design_scores_gemma":[0.018052472,0.01136831,0.6731588,0.00089703174,0.00039146186,0.0005733994,0.011206942,0.017558763,0.017185068,0.010297341,0.2387226,0.0005877923],"about_ca_topic_score_codex":0.00017195204,"about_ca_topic_score_gemma":0.0006086054,"teacher_disagreement_score":0.5140497,"about_ca_system_score_codex":0.00018279915,"about_ca_system_score_gemma":0.000496429,"threshold_uncertainty_score":0.39331135},"labels":[],"label_agreement":null},{"id":"W2906443950","doi":"10.1080/13696998.2019.1590843","title":"The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina","year":2019,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Latin Americans; Osteoporosis; Environmental health; Medical prescription; Indirect costs; Business","score_opus":0.049133716734967206,"score_gpt":0.3803805302742925,"score_spread":0.33124681353932534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906443950","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017691158,0.971174,0.000002180577,0.009639946,0.0004556139,0.0007413703,0.00003259797,0.0000031829723,0.00025992413],"genre_scores_gemma":[0.00048416574,0.9980843,0.00010636238,0.0004474691,0.000515041,0.0000112642065,0.000007373333,0.000043394408,0.00030064257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99567014,0.00026238553,0.0025531042,0.00024212936,0.0007842004,0.00048802042],"domain_scores_gemma":[0.9941621,0.002203719,0.0023284869,0.00034948697,0.00019804883,0.0007581836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046367315,0.00027177765,0.0032258676,0.00033600375,0.00006440856,0.00004457791,0.0005073888,0.00044960348,0.0001787701],"category_scores_gemma":[0.0018416848,0.00017209424,0.00044178937,0.00023988521,0.0006094011,0.00006511256,0.00017100519,0.001728623,0.00002310243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020280246,0.00006509114,0.0010227045,0.010754461,0.00023485179,0.00006704447,0.00018060833,0.0000015035906,9.882673e-8,0.0001038652,0.0050400477,0.9823269],"study_design_scores_gemma":[0.0015733795,0.0008747772,0.0004582663,0.008822126,0.00032162413,0.00046102196,0.00041731365,0.00016969204,5.7505383e-7,0.000027572043,0.9867419,0.00013176443],"about_ca_topic_score_codex":0.00038467135,"about_ca_topic_score_gemma":0.00016936201,"teacher_disagreement_score":0.98219514,"about_ca_system_score_codex":0.00035252172,"about_ca_system_score_gemma":0.0052708373,"threshold_uncertainty_score":0.9350239},"labels":[],"label_agreement":null},{"id":"W2910482049","doi":"10.1080/13696998.2019.1569446","title":"Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Metastatic melanoma; Cohort; Oncology; Internal medicine; Melanoma; Overall survival; Cancer","score_opus":0.14165245733668508,"score_gpt":0.4049893729289035,"score_spread":0.26333691559221845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910482049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936266,0.0005711721,0.00023697052,0.0021610886,0.0018151444,0.0010775989,0.0000075243884,0.0000021110536,0.00050177734],"genre_scores_gemma":[0.9990137,0.00049739884,0.00021409635,0.00006672275,0.00012925916,0.000021273285,0.000013924983,0.000016748776,0.00002687423],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980988,0.0002054552,0.0008943394,0.00012131106,0.0005207738,0.0001593276],"domain_scores_gemma":[0.9953254,0.003435483,0.00064304477,0.00019239393,0.0003203632,0.00008330319],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0055915685,0.00009822755,0.00046350356,0.0001991524,0.000025573727,0.00001482938,0.0001866755,0.00012342414,0.0018235083],"category_scores_gemma":[0.00095310225,0.00007334269,0.00017249111,0.000053466236,0.00009444278,0.00013153917,0.000031177864,0.0002386387,0.0000081638555],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039132535,0.0008508342,0.0046649226,0.00008334165,0.002282773,0.000004961229,0.0022957257,0.12766252,0.002649857,0.0011141009,0.00020113932,0.8190573],"study_design_scores_gemma":[0.08436578,0.01079635,0.0139626255,0.00009909633,0.0006022279,0.000035601704,0.0029183396,0.8733308,0.0017062307,0.00090314564,0.011129142,0.00015068888],"about_ca_topic_score_codex":0.00005110351,"about_ca_topic_score_gemma":0.00014601304,"teacher_disagreement_score":0.8189066,"about_ca_system_score_codex":0.0019161474,"about_ca_system_score_gemma":0.0014648425,"threshold_uncertainty_score":0.99908894},"labels":[],"label_agreement":null},{"id":"W2911474691","doi":"10.1080/13696998.2019.1582059","title":"CAR T-cells: costs, comparisons, and commentary","year":2019,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Intensive care medicine; Actuarial science; Economics","score_opus":0.033320510649939156,"score_gpt":0.3124527859559872,"score_spread":0.279132275306048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911474691","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034283083,0.0024096677,0.000026477355,0.9598537,0.0018227998,0.00030848067,0.000040295323,0.000007417092,0.0012480925],"genre_scores_gemma":[0.000368138,0.021546422,0.00036158977,0.96285194,0.012173616,0.000002190502,0.000094647075,0.000085159765,0.0025162902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724644,0.00015803339,0.001041985,0.00025264753,0.0008959353,0.00040494918],"domain_scores_gemma":[0.9975965,0.00084041554,0.000584201,0.00038722463,0.00011737286,0.00047430434],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016888024,0.00028055013,0.0013957483,0.0003049131,0.000036845162,0.00006112549,0.0005084986,0.0011326243,0.0048897467],"category_scores_gemma":[0.0001317802,0.00023358918,0.0003330384,0.000045931494,0.0002770686,0.00007235541,0.00018315329,0.006178195,0.000065797765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022606572,0.00007603866,0.00084604236,0.00026124922,0.0006127893,0.001194671,0.00004086013,0.0000012911127,0.00007538485,0.000004460906,0.98490846,0.011752657],"study_design_scores_gemma":[0.0037343903,0.00060334126,0.00005676069,0.0005286482,0.00020446119,0.0021824662,0.000103014216,0.0005472615,0.00010992504,0.000016712478,0.9917281,0.00018486967],"about_ca_topic_score_codex":0.000088782646,"about_ca_topic_score_gemma":0.000012687916,"teacher_disagreement_score":0.033914942,"about_ca_system_score_codex":0.00071931054,"about_ca_system_score_gemma":0.00090427726,"threshold_uncertainty_score":0.9961146},"labels":[],"label_agreement":null},{"id":"W2919228285","doi":"10.1080/13696998.2019.1590842","title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Western University; University of Alberta; William Osler Health System; Roche (Canada)","funders":"","keywords":"Atezolizumab; Docetaxel; Medicine; Nivolumab; Oncology; Lung cancer; Cost effectiveness; Clinical trial; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Risk analysis (engineering)","score_opus":0.016275617865555925,"score_gpt":0.29182496836964344,"score_spread":0.2755493505040875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2919228285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470866,0.0020022935,0.00021192785,0.0008115357,0.0012730194,0.0007304531,0.000043122338,0.0000013949344,0.00021758546],"genre_scores_gemma":[0.9967727,0.0020472517,0.00020122051,0.00067882176,0.00016376375,0.000011443269,0.0000056629356,0.00002120738,0.000097949705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986449,0.000035853063,0.000767669,0.00013719784,0.0001903925,0.00022400176],"domain_scores_gemma":[0.9986664,0.00039396243,0.00048490742,0.00013866412,0.000119967925,0.00019610279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010168912,0.0001269603,0.00068865955,0.00010126957,0.0000113797105,0.0000046396226,0.00019971986,0.00012133332,0.0006998919],"category_scores_gemma":[0.000058197274,0.00010592898,0.0001705418,0.000071917115,0.000033355802,0.00006960239,0.00002171989,0.00030166368,5.542178e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1135269,0.0014690132,0.3815358,0.014854124,0.002774268,0.000328469,0.0015958154,0.013134026,0.059849814,0.00013659954,0.0060452577,0.4047499],"study_design_scores_gemma":[0.24104084,0.0061103455,0.35721663,0.014530039,0.0006625064,0.0006516216,0.003787612,0.059452605,0.2374733,0.00018548631,0.07747146,0.0014175641],"about_ca_topic_score_codex":0.05542929,"about_ca_topic_score_gemma":0.30446956,"teacher_disagreement_score":0.40333235,"about_ca_system_score_codex":0.001482991,"about_ca_system_score_gemma":0.007726778,"threshold_uncertainty_score":0.9978985},"labels":[],"label_agreement":null},{"id":"W2945206773","doi":"10.1080/13696998.2019.1620243","title":"Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Mycobacterium research and diagnosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Mount Sinai Hospital","funders":"Insmed","keywords":"Medicine; Internal medicine; Odds ratio; Nontuberculous mycobacteria; Retrospective cohort study; Cohort; Health care; Emergency medicine; Tuberculosis; Mycobacterium","score_opus":0.01999539016700081,"score_gpt":0.31916590772575676,"score_spread":0.29917051755875596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945206773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868315,0.00011449925,0.000016004053,0.011722111,0.00064752763,0.0004197502,0.00005378294,0.000010505764,0.00018434823],"genre_scores_gemma":[0.9970465,0.0006388708,0.00017906864,0.001410609,0.0004991538,0.000015681298,0.000044494514,0.00003290011,0.00013274261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979735,0.000072379255,0.0010268808,0.00022802617,0.00031440286,0.0003848325],"domain_scores_gemma":[0.99762976,0.00045223435,0.00042683454,0.0002686647,0.00013157676,0.0010909404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009926965,0.00022495363,0.00093582366,0.00024191555,0.00002021535,0.0000504611,0.00021783337,0.000176483,0.0017722554],"category_scores_gemma":[0.001163478,0.00014860905,0.00029161648,0.000050355065,0.000055907367,0.0001576017,0.0000329679,0.00031428502,0.00004888686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004200153,0.0008727461,0.9884346,0.00005185976,0.0005200738,0.00045516453,0.00002678497,0.00041745006,0.00006298688,0.00004818833,0.0007468234,0.0041631763],"study_design_scores_gemma":[0.050613903,0.0040068706,0.81840014,0.0009162648,0.00042999772,0.00011092372,0.000070857874,0.11960084,0.000267501,0.00005893852,0.005069697,0.00045406993],"about_ca_topic_score_codex":0.0001448433,"about_ca_topic_score_gemma":0.00030225766,"teacher_disagreement_score":0.17003445,"about_ca_system_score_codex":0.0014974538,"about_ca_system_score_gemma":0.0035438654,"threshold_uncertainty_score":0.99914026},"labels":[],"label_agreement":null},{"id":"W2948865799","doi":"10.1080/13696998.2019.1627364","title":"Cost of operating room time for endovascular transcatheter aortic valve replacement","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Valve Diseases and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Valve replacement; Comorbidity; Cohort; Charlson comorbidity index; Emergency medicine; Variable cost; Surgery; Cardiology; Internal medicine; Stenosis","score_opus":0.016025664826337587,"score_gpt":0.3164916511245503,"score_spread":0.3004659862982127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948865799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969216,0.0006341625,0.00056111044,0.0008041187,0.0003094038,0.00045977437,0.000022254106,0.0000028913,0.00028470083],"genre_scores_gemma":[0.9979308,0.0003913456,0.00075685047,0.0004805184,0.00025176624,0.000008459828,0.000015532452,0.000019801904,0.0001449019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988146,0.000021274509,0.0006349612,0.00011613117,0.00026531788,0.00014770601],"domain_scores_gemma":[0.99905545,0.000121323734,0.00025864324,0.00017548485,0.00009990056,0.00028920558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069939625,0.00009769594,0.0005539796,0.000059103597,0.00001620545,0.000010341308,0.000092075396,0.00008185561,0.00084939925],"category_scores_gemma":[0.00014370443,0.000074201766,0.0024349813,0.000022228554,0.000021488022,0.000060259437,0.000015983678,0.00012172853,0.000025354013],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007967292,0.007600854,0.5987232,0.0025184257,0.07020319,0.000053750635,0.0025091774,0.0037980403,0.0028307575,0.001270738,0.0067849522,0.29573965],"study_design_scores_gemma":[0.26060036,0.032934994,0.35773557,0.0075524193,0.041023247,0.002786192,0.0034315055,0.17107031,0.01745434,0.0017748603,0.101320565,0.0023156554],"about_ca_topic_score_codex":0.000004785933,"about_ca_topic_score_gemma":2.6315254e-7,"teacher_disagreement_score":0.293424,"about_ca_system_score_codex":0.00010874243,"about_ca_system_score_gemma":0.00029762258,"threshold_uncertainty_score":0.9300326},"labels":[],"label_agreement":null},{"id":"W2988380919","doi":"10.1080/13696998.2019.1686311","title":"Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States–based retrospective claims database analysis","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Brain and Cognition Discovery Foundation","funders":"","keywords":"Medicine; Major depressive disorder; Retrospective cohort study; Depression (economics); Emergency medicine; Fluoxetine; Antidepressant; Myocardial infarction; Emergency department; Internal medicine; Database; Psychiatry; Anxiety","score_opus":0.005058976549069971,"score_gpt":0.23826029643699242,"score_spread":0.23320131988792245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988380919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971272,0.00044779788,0.0008104659,0.00044400478,0.00019095073,0.00065287715,0.00022658404,0.000014505496,0.00008565153],"genre_scores_gemma":[0.9951163,0.0021470762,0.0001936992,0.00055929157,0.00014411294,0.000010875667,0.0017918972,0.000028538818,0.000008194732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975837,0.00017458996,0.0007659255,0.00041275137,0.0007754557,0.00028757064],"domain_scores_gemma":[0.9973195,0.00018590753,0.0007335434,0.0004388382,0.00014935329,0.0011728345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007503757,0.00022089168,0.0011116948,0.00053998205,0.00007950224,0.000031155374,0.00015274089,0.00015390365,0.00010896566],"category_scores_gemma":[0.000066230714,0.00015224563,0.00022927245,0.00026304618,0.0001318846,0.00024333928,0.00007057523,0.00046114344,0.000004579844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015040601,0.00025014623,0.9862767,0.0001428109,0.00431862,0.00009290755,0.00016875281,0.0043806806,2.552319e-7,0.0000130171575,0.00012717945,0.0027248675],"study_design_scores_gemma":[0.013115476,0.0005973214,0.9426175,0.00092333386,0.0038676753,0.000005747438,0.00032537873,0.037601005,0.0000075634694,0.000030088113,0.00073488156,0.00017404552],"about_ca_topic_score_codex":0.0011941843,"about_ca_topic_score_gemma":0.00031547144,"teacher_disagreement_score":0.04365922,"about_ca_system_score_codex":0.0009262306,"about_ca_system_score_gemma":0.0005306634,"threshold_uncertainty_score":0.62083966},"labels":[],"label_agreement":null},{"id":"W3000406225","doi":"10.1080/13696998.2020.1717499","title":"Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fingolimod; Medicine; Cladribine; Multiple sclerosis; Expanded Disability Status Scale; Quality-adjusted life year; Internal medicine; Cost effectiveness; Immunology","score_opus":0.12037512007868408,"score_gpt":0.31522119481138305,"score_spread":0.194846074732699,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3000406225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596786,0.00009584678,0.0000914619,0.0029583883,0.00019797409,0.00054712733,0.000022600474,0.0000048764027,0.00011383991],"genre_scores_gemma":[0.9983033,0.0008202054,0.00050129055,0.00019911537,0.0001296001,0.000010622974,0.000010605534,0.000024303057,9.555274e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976985,0.0001748589,0.0008764916,0.00023214458,0.0006837823,0.0003342658],"domain_scores_gemma":[0.9974412,0.0012136194,0.00047353268,0.00013473978,0.00025357987,0.00048335202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012584826,0.00017418373,0.0009508723,0.00026604912,0.000025980646,0.000010814085,0.00022738364,0.00016773009,0.000057354035],"category_scores_gemma":[0.004949727,0.00013789149,0.00011187496,0.00028178573,0.00018531663,0.00024236289,0.00013645925,0.00091028225,0.0000022997142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059771676,0.0016163514,0.8910245,0.00046425857,0.0005547266,0.00013505972,0.0011664443,0.0024111113,0.00091756595,0.000038710932,0.0002229884,0.041676644],"study_design_scores_gemma":[0.046109397,0.0022748115,0.94273657,0.0019089258,0.000041713356,0.000004072976,0.000337792,0.004887651,0.0013280795,0.000005102898,0.00023904689,0.00012687134],"about_ca_topic_score_codex":0.000112148904,"about_ca_topic_score_gemma":0.00013267939,"teacher_disagreement_score":0.051712073,"about_ca_system_score_codex":0.000592303,"about_ca_system_score_gemma":0.0005873581,"threshold_uncertainty_score":0.5925643},"labels":[],"label_agreement":null},{"id":"W3001381091","doi":"10.1080/13696998.2020.1722138","title":"Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Spasticity; Quality of life (healthcare); Cost effectiveness; Physical medicine and rehabilitation; Physical therapy; Quality-adjusted life year","score_opus":0.0318918515765523,"score_gpt":0.2930713692873646,"score_spread":0.2611795177108123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001381091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994489,0.00058953423,0.0000170707,0.0044968603,0.000036994177,0.00032029877,0.000020620295,9.0426414e-7,0.000028707378],"genre_scores_gemma":[0.99462515,0.004607372,0.000022577024,0.0006986578,0.000035401226,0.0000016033531,0.0000012803595,0.000007698612,2.5460767e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839866,0.00022598146,0.000794144,0.00014562548,0.00029127832,0.00014429656],"domain_scores_gemma":[0.99816996,0.00090658537,0.0004719992,0.00010083915,0.000040788083,0.00030982646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006489029,0.00014919332,0.0009344899,0.000064806285,0.0000098367145,0.000002956498,0.00012078799,0.00013928606,0.000032719476],"category_scores_gemma":[0.00049414375,0.00007656312,0.00009566905,0.00012725516,0.00022626393,0.000029988987,0.000017196366,0.0004220205,1.0025866e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014979448,0.0015502411,0.9700121,0.00017891519,0.00035985318,0.00010335302,0.0005290397,0.003406448,0.00007169365,0.000081090155,0.000024055633,0.008703743],"study_design_scores_gemma":[0.008682467,0.009496469,0.9797904,0.00015846168,0.00006546109,0.000057073958,0.0002477054,0.0012124507,0.0001655516,0.000042264724,0.000013929799,0.00006778423],"about_ca_topic_score_codex":0.027038567,"about_ca_topic_score_gemma":0.024660926,"teacher_disagreement_score":0.009778262,"about_ca_system_score_codex":0.00012457617,"about_ca_system_score_gemma":0.0010531624,"threshold_uncertainty_score":0.99313647},"labels":[],"label_agreement":null},{"id":"W3009349222","doi":"10.1080/13696998.2020.1737536","title":"The burden of osteoporosis in Saudi Arabia: a scorecard and economic model","year":2020,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Bone health and osteoporosis research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Amgen (Canada)","funders":"","keywords":"Medicine; Balanced scorecard; Osteoporosis; Traditional medicine; Environmental health; Internal medicine; Process management","score_opus":0.0604248716602036,"score_gpt":0.3699678145198404,"score_spread":0.3095429428596368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009349222","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033081193,0.9829498,0.000005522709,0.012655132,0.0002896112,0.00049877516,0.000029178887,0.0000029438158,0.0002609121],"genre_scores_gemma":[0.0003376882,0.99823475,0.00022155386,0.00021786541,0.0008713375,0.00001269081,0.000005466754,0.00004327205,0.000055364875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961687,0.00015610657,0.0026183715,0.00025784268,0.00041783895,0.00038116652],"domain_scores_gemma":[0.99634117,0.00090113824,0.0013764757,0.00028283583,0.00007485463,0.0010235137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031772447,0.0002726875,0.0031167944,0.00027483096,0.000050128932,0.000035107663,0.000513841,0.0006011,0.00006061546],"category_scores_gemma":[0.0009929739,0.00017278321,0.0005686992,0.00010113862,0.0003163353,0.00007551536,0.00020425882,0.0019768921,0.000014655022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001593768,0.000033478933,0.00002873171,0.007013581,0.00018187377,0.00006551973,0.0001573679,0.000046055848,7.409929e-8,0.00013930038,0.0022490516,0.98992556],"study_design_scores_gemma":[0.0017764377,0.00050771656,0.000014435276,0.010650751,0.00037987373,0.0010389367,0.00018542822,0.01071906,5.24505e-7,0.00020739013,0.97437006,0.0001493833],"about_ca_topic_score_codex":0.000100508245,"about_ca_topic_score_gemma":0.000079351106,"teacher_disagreement_score":0.9897762,"about_ca_system_score_codex":0.0005452734,"about_ca_system_score_gemma":0.008102925,"threshold_uncertainty_score":0.9975202},"labels":[],"label_agreement":null},{"id":"W3029092466","doi":"10.1080/13696998.2020.1776297","title":"Economic and humanistic burden associated with noncommunicable diseases among adults with depression and anxiety in the United States","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Health and Mental Health","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Medical Expenditure Panel Survey; Depression (economics); Anxiety; Quality of life (healthcare); Obesity; Diabetes mellitus; Cohort; Health care; Internal medicine; Psychiatry","score_opus":0.011528167845995259,"score_gpt":0.27466957368992406,"score_spread":0.2631414058439288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029092466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858845,0.0004929193,0.000009357729,0.013268638,0.000026582127,0.00020657992,0.000015573693,0.000004712686,0.000091136164],"genre_scores_gemma":[0.9889314,0.007021701,0.000051898332,0.0037872097,0.00015584302,0.000003252081,0.000034801313,0.000011394777,0.000002454268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907273,0.00009774879,0.00038580428,0.000113407616,0.0001562226,0.00017409833],"domain_scores_gemma":[0.99859095,0.00032985705,0.00025165913,0.00009437533,0.000023912813,0.00070926873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000612645,0.00009666224,0.00037966674,0.000056303234,0.00006940702,0.000024259962,0.00010302799,0.00007493637,0.000022254753],"category_scores_gemma":[0.00014170188,0.000055153512,0.000027964641,0.000053554588,0.00015574819,0.00008410344,0.000041603227,0.00047546194,4.4706687e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035646711,0.00015034358,0.98358315,0.00036161754,0.000097158736,0.0001481794,0.004793712,0.0005090238,5.519068e-7,0.000033801178,0.00119566,0.0055621536],"study_design_scores_gemma":[0.01760573,0.003350457,0.91620415,0.002304291,0.00026789802,0.00061882,0.010940247,0.04162019,0.000004759484,0.000053954416,0.006832779,0.00019671298],"about_ca_topic_score_codex":0.00055851036,"about_ca_topic_score_gemma":0.000740692,"teacher_disagreement_score":0.06737897,"about_ca_system_score_codex":0.00013223931,"about_ca_system_score_gemma":0.0004096191,"threshold_uncertainty_score":0.2249095},"labels":[],"label_agreement":null},{"id":"W3037379129","doi":"10.1080/13696998.2020.1789152","title":"Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; Roche (Canada); William Osler Health System; Vancouver Coastal Health","funders":"","keywords":"Medicine; Profiling (computer programming); Activity-based costing; Lung cancer; Operations management; Oncology; Business; Accounting; Computer science","score_opus":0.04434937502367767,"score_gpt":0.3662375444127789,"score_spread":0.32188816938910125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037379129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912022,0.0016747656,0.0009577889,0.005179161,0.00011737612,0.00066545716,0.00009659391,0.0000026187693,0.000104073544],"genre_scores_gemma":[0.99482894,0.001355349,0.00317737,0.0003297821,0.00023128021,0.000045788194,0.0000074510567,0.000020347166,0.0000036941724],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989511,0.000018287097,0.000723819,0.0001327021,0.00006888666,0.00010524894],"domain_scores_gemma":[0.9988499,0.00018238545,0.0005087298,0.0000982837,0.00011710456,0.00024356252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052286655,0.00008254098,0.00039699374,0.00008581056,0.00002374001,0.0000066970942,0.000079843216,0.00007719278,0.00006935077],"category_scores_gemma":[0.00008046981,0.0000736928,0.00009102468,0.000033435183,0.000047429203,0.00006412435,0.00002448339,0.000119468925,4.6760888e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022010207,0.0014441742,0.740292,0.003194611,0.002708615,0.000190938,0.013990259,0.024576623,0.008645581,0.003867787,0.003432231,0.19545612],"study_design_scores_gemma":[0.090271756,0.00418758,0.15955001,0.0017713527,0.007623654,0.0031537076,0.0054757376,0.70842856,0.013595795,0.0009713797,0.0041416413,0.0008288433],"about_ca_topic_score_codex":0.000320116,"about_ca_topic_score_gemma":0.0002750681,"teacher_disagreement_score":0.6838519,"about_ca_system_score_codex":0.0004250572,"about_ca_system_score_gemma":0.0021870674,"threshold_uncertainty_score":0.38797635},"labels":[],"label_agreement":null},{"id":"W3039853632","doi":"10.1080/13696998.2020.1791889","title":"The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Medicine; Visual analogue scale; Inflammatory bowel disease; Confidence interval; Quality of life (healthcare); Internal medicine; Ulcerative colitis; Retrospective cohort study; Physical therapy; Adalimumab; Cohort; Infliximab; Disease","score_opus":0.012412975289260783,"score_gpt":0.2572623991760171,"score_spread":0.24484942388675635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039853632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984418,0.00061824935,0.000011849168,0.00025353697,0.00006983436,0.00048895983,0.00011143688,7.670361e-7,0.0000035720714],"genre_scores_gemma":[0.9991523,0.0006414754,0.000010759309,0.000115343086,0.00001930236,0.000013945339,0.00003991753,0.000006818025,1.4193232e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980386,0.0006469886,0.0009050555,0.00014278626,0.00012418856,0.00014236453],"domain_scores_gemma":[0.99829996,0.0003596675,0.0008777499,0.00015017873,0.000085458705,0.00022701177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011660444,0.000118357064,0.00037723666,0.000031766405,0.000025325855,0.0000041609146,0.00023682568,0.00011577188,0.0000036862025],"category_scores_gemma":[0.0013171595,0.000065096916,0.00011173589,0.000034482022,0.000516107,0.000008811699,0.00010028526,0.00016294644,9.3685834e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021536367,0.00013277524,0.9769072,0.00021418242,0.00014711534,0.000006887726,0.0002143914,0.00034888793,0.000024221143,0.000021489446,0.000004030951,0.0004424724],"study_design_scores_gemma":[0.013744004,0.00041646874,0.98510116,0.00011574773,0.000019585908,2.662736e-7,0.00020858433,0.00023853358,0.000047952977,0.000037871963,0.000009189014,0.000060601997],"about_ca_topic_score_codex":0.00009082802,"about_ca_topic_score_gemma":0.00031750693,"teacher_disagreement_score":0.0081940135,"about_ca_system_score_codex":0.000056768513,"about_ca_system_score_gemma":0.0004557403,"threshold_uncertainty_score":0.26545754},"labels":[],"label_agreement":null},{"id":"W3091869780","doi":"10.1080/13696998.2020.1835333","title":"Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; University of Ottawa","funders":"Medtronic","keywords":"Medicine; Cardiac resynchronization therapy; Internal medicine; Algorithm; Heart failure; Cardiology; Intensive care medicine; Ejection fraction; Computer science","score_opus":0.08060196100767866,"score_gpt":0.3311108763835697,"score_spread":0.25050891537589104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091869780","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2027443,0.0016290401,0.77336234,0.020338953,0.0003650311,0.0010642242,0.00037934654,0.000006817792,0.000109965455],"genre_scores_gemma":[0.9359302,0.007872966,0.053111933,0.0009811476,0.0019681614,0.000048496117,0.000027876664,0.000031497762,0.000027714426],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99879026,0.000051947754,0.0008233211,0.00013632566,0.00010967831,0.00008848483],"domain_scores_gemma":[0.9971316,0.0018620422,0.00055873365,0.00013066917,0.0001289386,0.00018802349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013155772,0.00009166853,0.00077354873,0.00016764333,0.000058203765,0.000016392269,0.00005978618,0.0000742428,0.00002999791],"category_scores_gemma":[0.00064295926,0.00007015486,0.00037065457,0.000098133874,0.00007992618,0.0000647543,0.000033386517,0.00008215946,9.3612283e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039861515,0.00011771424,0.0031595682,0.000047228947,0.01165693,6.225543e-7,0.0024756042,0.8798786,0.0005035798,0.001969256,0.009977789,0.050351594],"study_design_scores_gemma":[0.07951986,0.0042748796,0.020678835,0.00013492173,0.0052851485,0.00013942491,0.0024925487,0.8136855,0.0011458201,0.0002745745,0.071885906,0.0004825991],"about_ca_topic_score_codex":0.000015412508,"about_ca_topic_score_gemma":0.0000039278925,"teacher_disagreement_score":0.7331859,"about_ca_system_score_codex":0.00011211553,"about_ca_system_score_gemma":0.0006960241,"threshold_uncertainty_score":0.28608325},"labels":[],"label_agreement":null},{"id":"W3092295665","doi":"10.1080/13696998.2020.1835305","title":"Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. J Med Econ. 2020;23(6):641–649","year":2020,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Betamethasone dipropionate; Medicine; Tazarotene; Lotion; Dermatology; Psoriasis; Pharmacology","score_opus":0.24880238701289326,"score_gpt":0.4378970647347771,"score_spread":0.18909467772188382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092295665","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31742367,0.004071811,0.028796867,0.63969857,0.0016885076,0.0030059272,0.0051999404,0.000049163325,0.00006553273],"genre_scores_gemma":[0.54137385,0.005668076,0.0056694183,0.43803036,0.0026049912,0.000594988,0.0056801373,0.0002678651,0.000110337],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9806497,0.0035164796,0.012281983,0.0017149417,0.0008318312,0.0010050564],"domain_scores_gemma":[0.971821,0.009818516,0.01605108,0.0008728897,0.00048818244,0.0009483196],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.033155587,0.0010982035,0.010913533,0.0033016854,0.00031704197,0.00031675948,0.0013554062,0.0016445998,0.0007139703],"category_scores_gemma":[0.0044065258,0.0012050824,0.002040495,0.0013660326,0.00046295387,0.00087428343,0.00030934854,0.0031659747,0.00006323317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048172353,0.0013486048,0.039340332,0.0038552699,0.099626124,0.00013938692,0.009815545,0.042623878,0.00003176978,0.0020907905,0.795171,0.0011400653],"study_design_scores_gemma":[0.025667723,0.0030942454,0.06518938,0.0018064566,0.01990367,0.00010244776,0.0045280564,0.4036213,0.00032338806,0.0049062427,0.46665353,0.004203565],"about_ca_topic_score_codex":0.00124071,"about_ca_topic_score_gemma":0.0018519408,"teacher_disagreement_score":0.3609974,"about_ca_system_score_codex":0.0021584688,"about_ca_system_score_gemma":0.0013189971,"threshold_uncertainty_score":0.9996515},"labels":[],"label_agreement":null},{"id":"W3093960533","doi":"10.1080/13696998.2020.1840138","title":"Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Alberta Children's Hospital; Children's Hospital of Eastern Ontario; University of Calgary; McGill University; Montreal Children's Hospital; Novartis (Canada)","funders":"","keywords":"Fingolimod; Medicine; Quality-adjusted life year; Expanded Disability Status Scale; Cost effectiveness; Multiple sclerosis; Demography; Pediatrics; Immunology","score_opus":0.22889309778335293,"score_gpt":0.3534979604582821,"score_spread":0.12460486267492915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093960533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925038,0.0010078476,0.0002604861,0.0050571025,0.00037078786,0.00068647746,0.00009984817,0.000001507339,0.000012112842],"genre_scores_gemma":[0.9837397,0.015560101,0.00019084221,0.00010280878,0.00035228717,0.00003677935,0.000003458651,0.000013049002,0.0000010222236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99842197,0.00009703075,0.00076690904,0.00012812811,0.00036809142,0.00021790275],"domain_scores_gemma":[0.99340683,0.005595476,0.00037652976,0.00013724332,0.00017269306,0.00031124597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085835374,0.00012487691,0.0007466873,0.00007917949,0.000027486878,0.000004949736,0.0002582736,0.00006858455,0.000047267637],"category_scores_gemma":[0.0032648044,0.0000806656,0.00020994057,0.000104061364,0.00010015624,0.000042297772,0.00005658045,0.00021635446,4.6826167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074240915,0.002631393,0.67922574,0.0024049703,0.004164854,0.00007498122,0.0046561235,0.008410858,0.00096855557,0.000054012045,0.0070171566,0.21615042],"study_design_scores_gemma":[0.09077234,0.015536357,0.7761835,0.0008457646,0.00076371775,0.000021458503,0.005184931,0.08865266,0.013083427,0.0000169772,0.008613389,0.0003254691],"about_ca_topic_score_codex":0.052918438,"about_ca_topic_score_gemma":0.13432443,"teacher_disagreement_score":0.21582495,"about_ca_system_score_codex":0.00093748636,"about_ca_system_score_gemma":0.0023838894,"threshold_uncertainty_score":0.9533883},"labels":[],"label_agreement":null},{"id":"W3115065302","doi":"10.1080/13696998.2020.1864920","title":"Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina","year":2020,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hip and Femur Fractures","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Amgen (Canada)","funders":"","keywords":"Latin Americans; Medicine; Socioeconomics; Environmental health; Political science","score_opus":0.013916230084183905,"score_gpt":0.27086673988373877,"score_spread":0.25695050979955486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115065302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490498,0.0010771679,0.000058078615,0.04942838,0.00011483239,0.00009035115,0.000012377498,0.000005240449,0.00016382034],"genre_scores_gemma":[0.9745909,0.0041277255,0.00036701045,0.020429932,0.00045315703,7.048022e-7,0.000003451861,0.000016434811,0.000010690374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852407,0.000034013654,0.0007846657,0.00014477395,0.00032885466,0.00018363135],"domain_scores_gemma":[0.9983677,0.00021913966,0.0007045773,0.00009314506,0.00008466839,0.0005307138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050409394,0.00013429482,0.00075747876,0.00010700721,0.000021604636,0.000019162855,0.00019179954,0.00018470234,0.00035943315],"category_scores_gemma":[0.000342298,0.00010842591,0.000098454526,0.00010880045,0.00014773422,0.000112111826,0.000049393442,0.0006103106,0.000005176706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001795073,0.00029213473,0.9495661,0.0007265583,0.0003419698,0.00022597682,0.0064116176,0.0010423769,0.00008673577,0.00038191018,0.006161633,0.032967918],"study_design_scores_gemma":[0.005777322,0.0017903503,0.846968,0.0006977258,0.00017751,0.00024218636,0.0019892326,0.0061171083,0.0010158058,0.00020063839,0.13478456,0.00023957506],"about_ca_topic_score_codex":0.0001223231,"about_ca_topic_score_gemma":0.00019206297,"teacher_disagreement_score":0.12862293,"about_ca_system_score_codex":0.00004144271,"about_ca_system_score_gemma":0.00027529965,"threshold_uncertainty_score":0.44214806},"labels":[],"label_agreement":null},{"id":"W3124381759","doi":"10.1080/13696998.2021.1875743","title":"The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Azacitidine; Cytarabine; Internal medicine; Oncology; Myeloid leukemia; Induction chemotherapy; Cost effectiveness; Clinical trial; Chemotherapy","score_opus":0.01477245771784256,"score_gpt":0.28539256468498775,"score_spread":0.27062010696714517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124381759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986514,0.00011041257,0.00007587045,0.011629778,0.00024350487,0.0013950043,0.000023016288,9.191984e-7,0.0000074942204],"genre_scores_gemma":[0.99078244,0.008103336,0.00009202251,0.00079155044,0.000057194673,0.000116896124,0.000017986364,0.000021339265,0.000017230335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981965,0.0001772986,0.0008059847,0.00017904576,0.00039315782,0.00024802802],"domain_scores_gemma":[0.9963302,0.0017127725,0.0004892549,0.0002020509,0.001117658,0.00014803685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093482377,0.00014877054,0.0007107528,0.00019334472,0.00002898657,0.000010791694,0.00021138861,0.00012161064,0.0000075352077],"category_scores_gemma":[0.0015948922,0.00008850135,0.000081133585,0.0003494086,0.000096824755,0.00009032279,0.000026065582,0.00041596513,2.8285098e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07310354,0.0029066456,0.40965825,0.00058637606,0.0018180346,0.00072346214,0.0073304926,0.020515153,0.00174904,0.0002435931,0.0029447335,0.47842067],"study_design_scores_gemma":[0.06556931,0.0036686598,0.87124,0.0022305835,0.00008235617,0.00006950304,0.006693566,0.009849946,0.039201453,0.000076493525,0.0011575446,0.0001605763],"about_ca_topic_score_codex":0.08446999,"about_ca_topic_score_gemma":0.4079845,"teacher_disagreement_score":0.4782601,"about_ca_system_score_codex":0.009454354,"about_ca_system_score_gemma":0.008125642,"threshold_uncertainty_score":0.9974974},"labels":[],"label_agreement":null},{"id":"W3127334177","doi":"10.1080/13696998.2021.1885194","title":"Influence of neurovascular embolic coil primary wind diameter on aneurysm packing density and case costs","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Intracranial Aneurysms: Treatment and Complications","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Electromagnetic coil; Sphere packing; Neurovascular bundle; Volume (thermodynamics); Materials science; Medicine; Composite material; Physics; Surgery; Electrical engineering; Engineering","score_opus":0.012286893965751996,"score_gpt":0.24602864924688617,"score_spread":0.23374175528113417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127334177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946474,0.0002490925,0.000026331818,0.0046991385,0.00009263593,0.00006727045,0.000003466514,0.000003961175,0.0002107012],"genre_scores_gemma":[0.9954575,0.0010641268,0.0002681334,0.0029875531,0.000189531,6.021516e-7,0.000002990755,0.000010561385,0.0000190332],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9989936,0.000053061165,0.0004731686,0.00014038006,0.00021715148,0.00012267692],"domain_scores_gemma":[0.9988948,0.00022166032,0.00023969667,0.0001912101,0.00017370279,0.0002789406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030511938,0.00010161089,0.00041222607,0.00007039984,0.0000486559,0.0000151974955,0.000075425065,0.000098522396,0.000042850326],"category_scores_gemma":[0.00037563007,0.00008396529,0.0001311255,0.000061138344,0.000112495865,0.00007791876,0.000047083653,0.00034092763,0.0000039330666],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026403884,0.0072427397,0.3066093,0.0015118143,0.0027657798,0.3688244,0.0024795334,0.0022241136,0.020880647,0.011471496,0.001710462,0.27163935],"study_design_scores_gemma":[0.0075441715,0.0016963705,0.5085699,0.0006968025,0.0009050225,0.46828657,0.00020954387,0.0012730411,0.007264967,0.00080606306,0.002426146,0.0003213862],"about_ca_topic_score_codex":0.00002023361,"about_ca_topic_score_gemma":0.000018549543,"teacher_disagreement_score":0.27131796,"about_ca_system_score_codex":0.00008222806,"about_ca_system_score_gemma":0.00029366167,"threshold_uncertainty_score":0.34240052},"labels":[],"label_agreement":null},{"id":"W3130545975","doi":"10.3111/13696998.2013.784591","title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","year":2013,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"","keywords":"Checklist; Government (linguistics); Medicine; Statement (logic); Delphi method; Psychological intervention; Consolidated Standards of Reporting Trials; Systematic review; Economic evaluation; Delphi; MEDLINE; Public relations; Medical education; Political science; Psychology; Nursing; Law; Computer science","score_opus":0.31607405893797513,"score_gpt":0.5300803307364624,"score_spread":0.2140062717984873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130545975","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01274167,0.011235107,0.001921875,0.08751632,0.8784982,0.001960926,0.0037027805,0.00005877311,0.002364331],"genre_scores_gemma":[0.003782509,0.027702216,0.0035877351,0.011353481,0.9505395,0.00021404406,0.0014224169,0.00041018147,0.0009878649],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95203704,0.0014280129,0.042408187,0.0011931859,0.0017751858,0.0011583876],"domain_scores_gemma":[0.89362895,0.0039137155,0.098167256,0.0011499645,0.0014237454,0.0017163577],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.26384518,0.000735586,0.0056966837,0.0011022562,0.00029068856,0.00050944486,0.001556656,0.0018434265,0.009154288],"category_scores_gemma":[0.09262637,0.0008725236,0.0007800011,0.00012603278,0.00024385277,0.0012048743,0.0002523095,0.0025287946,0.001297923],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000044961427,0.00011016275,0.00016931062,0.0005729935,0.0006529965,0.000008096772,0.00066089723,0.0008087307,5.3010382e-8,0.0026537564,0.99212545,0.0021925627],"study_design_scores_gemma":[0.0032429076,0.00040553632,0.000070771064,0.00084341684,0.00006716827,0.000049204653,0.0008604433,0.015107854,0.0000012096187,0.0065347482,0.9721338,0.000682897],"about_ca_topic_score_codex":0.0021138426,"about_ca_topic_score_gemma":0.00059355923,"teacher_disagreement_score":0.1712188,"about_ca_system_score_codex":0.018787486,"about_ca_system_score_gemma":0.03166425,"threshold_uncertainty_score":0.9997724},"labels":[],"label_agreement":null},{"id":"W3153392867","doi":"10.1080/13696998.2021.1915626","title":"A device category economic model of electrosurgery technologies across procedure types: a U.S. hospital budget impact analysis","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Electrosurgery; Single use; Operations management; Emergency medicine; Medical emergency; Surgery","score_opus":0.013049471692332388,"score_gpt":0.2999056111815729,"score_spread":0.2868561394892405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153392867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778075,0.0050934274,0.0003583238,0.0062098512,0.00022737612,0.00006996952,0.00004597218,0.000025947045,0.0001884035],"genre_scores_gemma":[0.9938601,0.00483329,0.0003845282,0.0005365131,0.0002580206,0.0000030514718,0.00001959314,0.000024950756,0.000079903926],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99786067,0.000029021758,0.0011893205,0.0002463828,0.00027803474,0.00039656294],"domain_scores_gemma":[0.99808455,0.0002155616,0.00083942275,0.00032940955,0.0002488081,0.0002822649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011831728,0.00021617227,0.0013341703,0.00034057323,0.000042104268,0.0000375864,0.00028308522,0.0004155142,0.000151522],"category_scores_gemma":[0.0008965202,0.0001747848,0.0010012186,0.0003373482,0.0001800269,0.00021773441,0.00009618315,0.00069060025,0.00001699128],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004934997,0.0055959984,0.6175585,0.0012307437,0.04057931,0.0032446529,0.0049319067,0.13359644,0.015229746,0.0037529126,0.13847898,0.0308658],"study_design_scores_gemma":[0.019438509,0.004221374,0.0731857,0.0011090505,0.011298719,0.011683121,0.014315807,0.7603988,0.07371236,0.009959558,0.017236993,0.0034400185],"about_ca_topic_score_codex":0.000025696272,"about_ca_topic_score_gemma":0.00007110029,"teacher_disagreement_score":0.6268024,"about_ca_system_score_codex":0.00029573846,"about_ca_system_score_gemma":0.004219022,"threshold_uncertainty_score":0.7484364},"labels":[],"label_agreement":null},{"id":"W3154244221","doi":"10.1080/13696998.2021.1917139","title":"Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Medicine; Nivolumab; Docetaxel; Population; Clinical trial; Cost effectiveness; Quality-adjusted life year; Internal medicine; Oncology; Randomized controlled trial; Cost–benefit analysis; Demography; Cancer; Environmental health; Immunotherapy","score_opus":0.02007993074301333,"score_gpt":0.2834601182077676,"score_spread":0.2633801874647543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154244221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591225,0.0027532002,0.00005443905,0.0007821049,0.00019239441,0.00020679564,0.000050319195,8.686876e-7,0.00004762107],"genre_scores_gemma":[0.99350214,0.0058145877,0.00018189623,0.00037740052,0.00008387722,0.000003805765,0.0000133912135,0.000015721316,0.00000715232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881357,0.000077975026,0.00051807874,0.00021448353,0.00019256215,0.0001833127],"domain_scores_gemma":[0.99901235,0.00020093069,0.00024049156,0.00023489847,0.00006407964,0.0002472252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107865,0.00011941904,0.00054871093,0.00009251044,0.00001566903,0.000015256212,0.00018984004,0.00010047181,0.00009904187],"category_scores_gemma":[0.00006052859,0.00009875062,0.000023237062,0.0001022963,0.0000864865,0.00013901659,0.000081684106,0.00037552477,6.2936245e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007148932,0.0003487447,0.9543939,0.0010345805,0.00018633956,0.001482366,0.00046677064,0.0003654203,0.0010149973,0.000004545125,0.00034638835,0.033206977],"study_design_scores_gemma":[0.03468464,0.00083082326,0.93473417,0.0017710201,0.00018191282,0.0010097921,0.0022069511,0.019574258,0.003453656,0.0000128570255,0.0012262944,0.0003136033],"about_ca_topic_score_codex":0.29063806,"about_ca_topic_score_gemma":0.88699496,"teacher_disagreement_score":0.5963569,"about_ca_system_score_codex":0.00053220656,"about_ca_system_score_gemma":0.0057702996,"threshold_uncertainty_score":0.99986607},"labels":[],"label_agreement":null},{"id":"W3155883542","doi":"10.1080/13696998.2021.1917140","title":"Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Endometrial cancer; Microsatellite instability; Oncology; Internal medicine; Chemotherapy; Cost effectiveness; Cancer; Quality of life (healthcare); Clinical trial; Immunotherapy","score_opus":0.0601413884066394,"score_gpt":0.34328911807943985,"score_spread":0.28314772967280044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155883542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959916,0.0010079698,0.00018431192,0.0009307641,0.00014489205,0.0016124952,0.00007842524,0.000007753631,0.00004180741],"genre_scores_gemma":[0.9955874,0.0022817308,0.0011357857,0.0004944733,0.00013085044,0.0002696639,0.000018165107,0.000027973583,0.00005397817],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99750865,0.0003696568,0.00093877886,0.0002804088,0.00051863235,0.00038386162],"domain_scores_gemma":[0.9959385,0.0025872828,0.00052858464,0.00027514403,0.00037316137,0.00029735992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002510124,0.00022589797,0.001401184,0.00018231585,0.00004462119,0.000028922235,0.00022996217,0.00009866251,0.0005672573],"category_scores_gemma":[0.0008413544,0.00010249083,0.00017614114,0.00082342944,0.0001716532,0.00009048696,0.000023930415,0.00031012995,4.108592e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85439306,0.008292967,0.087850116,0.0039102067,0.0051054694,0.0012688579,0.0027150318,0.0020972071,0.0003846169,0.0001013985,0.00010649695,0.033774547],"study_design_scores_gemma":[0.64815485,0.053355765,0.21060812,0.005388281,0.0029252702,0.004025268,0.005776983,0.0018228786,0.040992342,0.0005300992,0.025447669,0.00097248366],"about_ca_topic_score_codex":0.00045186802,"about_ca_topic_score_gemma":0.0011654756,"teacher_disagreement_score":0.20623824,"about_ca_system_score_codex":0.0010199443,"about_ca_system_score_gemma":0.0026979262,"threshold_uncertainty_score":0.621107},"labels":[],"label_agreement":null},{"id":"W3174480137","doi":"10.1080/13696998.2021.1946326","title":"The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best–worst scaling approach","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"Dalhousie University","keywords":"Medicine; Scaling; Family medicine","score_opus":0.23062563386427604,"score_gpt":0.39846172618442116,"score_spread":0.16783609232014512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174480137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6827151,0.005130399,0.0017315298,0.30941287,0.000597579,0.0002560629,0.00010853015,0.000002178402,0.000045738518],"genre_scores_gemma":[0.9603143,0.008935952,0.00652274,0.023895022,0.00021465814,0.00003234399,0.0000053053786,0.000031024174,0.000048680646],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925198,0.000370142,0.006254539,0.00028163593,0.00018349696,0.00039038603],"domain_scores_gemma":[0.99433523,0.0015140752,0.0031154517,0.0003809407,0.00009448743,0.00055983587],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.025868783,0.00013968114,0.0010923315,0.00023120169,0.00022069359,0.000070851645,0.00046981743,0.00013587906,0.00006206265],"category_scores_gemma":[0.012067391,0.000114938666,0.00007950098,0.0002796092,0.00014651731,0.00017776781,0.00013627134,0.000609064,0.0000032838914],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046659537,0.00014714389,0.75518876,0.00037469753,0.00045525024,0.000026916545,0.0032968973,0.016012734,6.066948e-7,0.17604618,0.028518885,0.019885255],"study_design_scores_gemma":[0.0030394904,0.00036043377,0.06948484,0.0006066638,0.000025487449,0.00044805586,0.0939546,0.14494924,0.000006995268,0.008457211,0.67801046,0.00065652124],"about_ca_topic_score_codex":0.12159475,"about_ca_topic_score_gemma":0.3662896,"teacher_disagreement_score":0.68570393,"about_ca_system_score_codex":0.0018974887,"about_ca_system_score_gemma":0.012579682,"threshold_uncertainty_score":0.9962544},"labels":[],"label_agreement":null},{"id":"W3174798083","doi":"10.1080/13696998.2021.1948681","title":"Healthcare costs of patients with cancer stratified by Khorana score risk levels","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Cancer; Health care; Internal medicine; Intensive care medicine; Emergency medicine","score_opus":0.021541374900351698,"score_gpt":0.28961048883788276,"score_spread":0.2680691139375311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174798083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853866,0.0014668229,0.00015131517,0.012151784,0.00036394908,0.0001492795,0.00012849468,0.000003074779,0.00019864376],"genre_scores_gemma":[0.9893954,0.008207874,0.00028150112,0.0018445924,0.00019787494,0.0000029566672,0.000020137164,0.000017011578,0.000032645967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851346,0.00005180672,0.0006703249,0.00013685647,0.00045292146,0.00017465213],"domain_scores_gemma":[0.9983928,0.00007156621,0.00062184583,0.00016402737,0.00034363766,0.00040609422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039101182,0.000109259854,0.00066827866,0.000057274712,0.000034947137,0.000013738024,0.00013310055,0.000112946036,0.00082452846],"category_scores_gemma":[0.00017107994,0.00008134766,0.000104812425,0.0000724972,0.000072395844,0.00007614464,0.00003786554,0.0003649023,0.000001868692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009123587,0.0044546435,0.5483101,0.0008851079,0.002804192,0.0003585755,0.00086752523,0.00026472562,0.000047232188,0.0030733887,0.08498458,0.35303757],"study_design_scores_gemma":[0.015848849,0.0025781228,0.94437903,0.002746261,0.0010526904,0.000073280564,0.0011922371,0.00041277357,0.002255173,0.00038171615,0.028713278,0.0003665693],"about_ca_topic_score_codex":0.0002734021,"about_ca_topic_score_gemma":0.00056739495,"teacher_disagreement_score":0.39606893,"about_ca_system_score_codex":0.00020242528,"about_ca_system_score_gemma":0.0010246466,"threshold_uncertainty_score":0.90280086},"labels":[],"label_agreement":null},{"id":"W3183895493","doi":"10.1080/13696998.2021.1962664","title":"The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico","year":2021,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Amgen (Canada)","funders":"Amgen","keywords":"Latin Americans; Medicine; Demography; Environmental health; Socioeconomics","score_opus":0.032495212423711964,"score_gpt":0.3590363809811568,"score_spread":0.32654116855744486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183895493","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040024925,0.95616937,0.0000038547087,0.0028929648,0.00026759418,0.00048141862,0.000029578463,0.0000029035075,0.0001273709],"genre_scores_gemma":[0.0024212655,0.9968193,0.00009756645,0.00006128546,0.00022214568,0.000010874578,0.000023864559,0.000035653527,0.0003080077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965266,0.0003171474,0.0019043206,0.00022435408,0.0006589841,0.0003685962],"domain_scores_gemma":[0.9959886,0.0013669828,0.0016388567,0.00026775384,0.00015329765,0.0005845181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020639342,0.00026758012,0.0026081796,0.0002475952,0.000057509074,0.000023562265,0.00036598038,0.00031370053,0.00023954322],"category_scores_gemma":[0.0020011389,0.00016927574,0.00051972346,0.00022378787,0.00040864432,0.00005365668,0.00016239869,0.0011404203,0.000012643421],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090709626,0.00016215527,0.0028557885,0.0021310025,0.0019041819,0.0006765242,0.00008819439,0.0000025467625,6.837194e-8,0.00013080762,0.00074565946,0.99121237],"study_design_scores_gemma":[0.0037429656,0.0005642025,0.0013701303,0.012861728,0.00063494674,0.001083122,0.00018380271,0.0003429521,6.9167515e-7,0.00007602264,0.97898626,0.00015314511],"about_ca_topic_score_codex":0.00017833564,"about_ca_topic_score_gemma":0.00007379048,"teacher_disagreement_score":0.99105924,"about_ca_system_score_codex":0.0003468633,"about_ca_system_score_gemma":0.0026119826,"threshold_uncertainty_score":0.69028646},"labels":[],"label_agreement":null},{"id":"W3190179948","doi":"10.1080/13696998.2021.1957582","title":"Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation","year":2021,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Botulinum Toxin and Related Neurological Disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Cost effectiveness; Quality of life (healthcare); Spasticity; Physical therapy; Botulinum toxin; Adverse effect; Randomized controlled trial; Quality-adjusted life year; Indirect costs; Economic evaluation; Surgery; Internal medicine; Nursing","score_opus":0.05089289765251078,"score_gpt":0.3719166455498343,"score_spread":0.3210237478973235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190179948","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05746396,0.9380352,0.0000149562875,0.0003160605,0.000106889434,0.0039815824,0.00003985507,0.0000053131917,0.000036181253],"genre_scores_gemma":[0.008540422,0.9909704,0.00009747738,0.00012140548,0.00008082183,0.00006183562,0.00008715707,0.000035263136,0.000005215695],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9950217,0.0015567385,0.0022797494,0.0005191838,0.00036581315,0.00025679037],"domain_scores_gemma":[0.9953214,0.0020450456,0.0017833246,0.00024674958,0.00014517037,0.00045830244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030734078,0.00055918476,0.0074332133,0.0003719048,0.00004576913,0.000048377926,0.00016441128,0.00073916087,0.00003638284],"category_scores_gemma":[0.0005822072,0.0003473435,0.00036890918,0.00021564252,0.00034448967,0.00009929143,0.00009764396,0.00127524,0.0000017267233],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001960056,0.0022206872,0.0058911764,0.40744135,0.009180263,0.00034717738,0.00073103595,0.00029459695,4.6771535e-7,0.00025940983,0.000078479476,0.5715953],"study_design_scores_gemma":[0.015226488,0.005172806,0.017606687,0.92146623,0.015001494,0.014032439,0.000115415125,0.0024500494,0.0000029613461,0.000037864495,0.008224963,0.0006626155],"about_ca_topic_score_codex":0.0000066281345,"about_ca_topic_score_gemma":0.000025235891,"teacher_disagreement_score":0.5709327,"about_ca_system_score_codex":0.00040965033,"about_ca_system_score_gemma":0.001151114,"threshold_uncertainty_score":0.99989784},"labels":[],"label_agreement":null},{"id":"W3211731066","doi":"10.1080/13696998.2021.2003804","title":"Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; McMaster University; Ted Rogers Centre for Heart Research; Impact","funders":"","keywords":"Medicine; Insulin glargine; Insulin degludec; Confidence interval; Pediatrics; Adverse effect; Type 2 diabetes; Randomized controlled trial; Diabetes mellitus; Internal medicine; Emergency medicine; Endocrinology","score_opus":0.005918474577636413,"score_gpt":0.21089628994057324,"score_spread":0.20497781536293683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211731066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99491245,0.0003656461,0.00029518612,0.0015730289,0.0010337736,0.0015193233,0.000057512574,0.000009151286,0.00023392668],"genre_scores_gemma":[0.9944626,0.00056132284,0.003110363,0.00082992186,0.00039966707,0.0000771331,0.00045577224,0.00004368066,0.000059544476],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984031,0.0000615948,0.000519619,0.00023795942,0.00048595585,0.00029181901],"domain_scores_gemma":[0.99797803,0.00046858005,0.00030133256,0.0002596453,0.00028313996,0.000709242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069307693,0.00020549135,0.0013058601,0.00014627699,0.0000700763,0.00004698215,0.0001311585,0.00011901802,0.00015519117],"category_scores_gemma":[0.000903097,0.00013515637,0.00029548426,0.00010667166,0.000057485253,0.00007477942,0.00004156168,0.00012833605,0.000008934422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75724685,0.0009854253,0.14589313,0.00006578036,0.031795934,0.00014260515,0.00020581303,0.0008457186,0.0000012004731,0.00066096894,0.0043177083,0.057838857],"study_design_scores_gemma":[0.9479259,0.0026898216,0.026940104,0.00016822007,0.004610209,0.0000011175908,0.000074088966,0.00020161856,0.00008226909,0.000040077677,0.017028134,0.00023841455],"about_ca_topic_score_codex":0.0015520228,"about_ca_topic_score_gemma":0.011602466,"teacher_disagreement_score":0.19067906,"about_ca_system_score_codex":0.0010199411,"about_ca_system_score_gemma":0.0006136106,"threshold_uncertainty_score":0.64744484},"labels":[],"label_agreement":null},{"id":"W4200054040","doi":"10.1080/13696998.2021.2007691","title":"The Global South political economy of health financing and spending landscape – history and presence","year":2021,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science Fund of the Republic of Serbia; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja","keywords":"Politics; Multinational corporation; Economic growth; East Asia; Development economics; Medicine; China; Business; Economics; Political science; Finance","score_opus":0.07373820326831175,"score_gpt":0.3464244995850857,"score_spread":0.27268629631677394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200054040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018143801,0.9706395,0.000061301915,0.024406794,0.0010404324,0.00010967931,0.0000057889592,0.0000034831248,0.0035515751],"genre_scores_gemma":[0.00034819022,0.99160117,0.000056885496,0.006420781,0.0015472381,0.000001768659,0.0000042624597,0.000011916579,0.000007779854],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973103,0.000115912626,0.0017594076,0.00018908571,0.00012659829,0.000498743],"domain_scores_gemma":[0.9967109,0.0007133447,0.0021928502,0.00015188179,0.0000631361,0.00016791314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050423536,0.00019395413,0.0018076239,0.00009858264,0.00011363527,0.000080987,0.00038694084,0.00025735,0.000043780765],"category_scores_gemma":[0.002159394,0.00013014067,0.00021465698,0.00006731967,0.00025589604,0.00021970518,0.00037515597,0.00050255534,0.0000026072564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000034308018,0.000013187831,0.00026879527,0.0058283126,0.000080294085,0.000009081212,0.000013056817,0.000004203464,6.9266856e-11,0.58534724,0.03686152,0.37157091],"study_design_scores_gemma":[0.00018879054,0.000017639692,0.000057138135,0.0023607446,0.00007501513,0.00020713589,0.00022148728,0.0013115028,2.4253835e-10,0.003608668,0.9918582,0.00009368473],"about_ca_topic_score_codex":0.0003479551,"about_ca_topic_score_gemma":0.00003326397,"teacher_disagreement_score":0.95499665,"about_ca_system_score_codex":0.00038261144,"about_ca_system_score_gemma":0.0015850139,"threshold_uncertainty_score":0.53069824},"labels":[],"label_agreement":null},{"id":"W4200209188","doi":"10.1080/13696998.2021.2013676","title":"Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Libin Cardiovascular Institute of Alberta; Roche (Canada); University of Calgary","funders":"","keywords":"Medicine; SMA*; Epidemiology; Health care; Spinal muscular atrophy; Ambulatory; Incidence (geometry); Ambulatory care; Healthcare Cost and Utilization Project; Pediatrics; Emergency medicine; Disease; Surgery; Internal medicine","score_opus":0.07006822663938389,"score_gpt":0.37823941091476004,"score_spread":0.30817118427537615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200209188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71892315,0.016098108,0.00038241124,0.2641305,0.00018391588,0.00023594865,0.0000068606437,0.0000013759044,0.00003774591],"genre_scores_gemma":[0.9637472,0.01704862,0.0009315121,0.017766336,0.0003607311,0.00000893497,0.00003305771,0.000025632104,0.00007797972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983026,0.00024499194,0.00071856886,0.00019993795,0.00023578998,0.00029815847],"domain_scores_gemma":[0.9984163,0.00040718133,0.00019229297,0.00014601884,0.00018220444,0.00065598456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013509403,0.00009652041,0.00053408707,0.00008686605,0.000046562764,0.0000048264947,0.00010378137,0.00017196224,0.000030860618],"category_scores_gemma":[0.0029166837,0.000087215456,0.00010937145,0.000083145525,0.00007892254,0.000028321068,0.00004832261,0.00046624854,3.4983904e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028170303,0.00038389585,0.33077544,0.0024976397,0.0003739616,0.0014142958,0.0002826066,0.0001605302,0.000018784447,0.012627608,0.011450515,0.6371977],"study_design_scores_gemma":[0.014668222,0.0029629476,0.21717547,0.0016147512,0.00013693719,0.0053927456,0.0027532496,0.0126663735,0.00024168767,0.0023806414,0.7396152,0.00039175522],"about_ca_topic_score_codex":0.08082015,"about_ca_topic_score_gemma":0.49635476,"teacher_disagreement_score":0.72816473,"about_ca_system_score_codex":0.00032291,"about_ca_system_score_gemma":0.004486494,"threshold_uncertainty_score":0.9253008},"labels":[],"label_agreement":null},{"id":"W4205669185","doi":"10.1080/13696998.2021.2014721","title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Health Economics; University of Ottawa","funders":"National Institute for Health and Care Research","keywords":"Checklist; Economic evaluation; Medicine; Context (archaeology); Public health; Health care; Stakeholder; Psychological intervention; Public relations; Population; Political science; Psychology; Nursing; Environmental health; Law","score_opus":0.319495175828176,"score_gpt":0.5390198283255929,"score_spread":0.21952465249741693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205669185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5198465,0.014868605,0.019969888,0.41604504,0.013905186,0.005472398,0.008499719,0.00013253771,0.0012601202],"genre_scores_gemma":[0.8744665,0.008307046,0.019833462,0.08394798,0.006057261,0.0020155087,0.0036034605,0.0006160869,0.001152705],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9428504,0.002304322,0.050841853,0.001426299,0.0011262876,0.0014508052],"domain_scores_gemma":[0.884603,0.001304953,0.11147113,0.0009545556,0.00052985264,0.0011364758],"candidate_categories":["metaresearch","metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.36176187,0.0005061859,0.0035950362,0.0010948741,0.0014239178,0.00025057662,0.0011471817,0.0002526398,0.009033476],"category_scores_gemma":[0.032729536,0.0006802668,0.000746075,0.0002448367,0.00017295034,0.0010670346,0.00032296378,0.0011520702,0.0001081717],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037110772,0.00041195354,0.0076081282,0.00060524774,0.0012218767,0.000012886245,0.004778471,0.12747897,0.000004685952,0.030027067,0.8162908,0.01118878],"study_design_scores_gemma":[0.00790848,0.0013750953,0.001896324,0.0002775367,0.00007971368,0.00049856666,0.0071273944,0.39372215,0.000016958817,0.016813112,0.5693119,0.0009727193],"about_ca_topic_score_codex":0.001210584,"about_ca_topic_score_gemma":0.0009875362,"teacher_disagreement_score":0.35462,"about_ca_system_score_codex":0.026593806,"about_ca_system_score_gemma":0.026502289,"threshold_uncertainty_score":0.9998761},"labels":[],"label_agreement":null},{"id":"W4205746204","doi":"10.1080/13696998.2022.2030148","title":"Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Population; Mechanical ventilation; Intensive care unit; Emergency medicine; Pneumonia; Clinical trial; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.03335726888210563,"score_gpt":0.381984455753694,"score_spread":0.3486271868715884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205746204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97818154,0.0024997548,0.000076150005,0.01419348,0.00010162286,0.0013070655,0.003633056,0.0000021027458,0.00000521752],"genre_scores_gemma":[0.99136287,0.007903869,0.00018947377,0.00035281666,0.00007849461,0.000026641112,0.00006651236,0.000018221785,0.0000010917402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970522,0.00030080468,0.0014121403,0.00023681996,0.0007950056,0.00020305984],"domain_scores_gemma":[0.98356557,0.013730715,0.0013244926,0.00036561178,0.0007912374,0.00022236606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016732867,0.00018838572,0.0015917227,0.00011712036,0.00011848829,0.0000099671815,0.000469131,0.00007534363,0.000057713194],"category_scores_gemma":[0.0038232382,0.00008689936,0.0002792792,0.00012828206,0.0013689295,0.000046130703,0.00014323037,0.0004255858,3.934561e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09266572,0.0012407065,0.7715501,0.00039804197,0.0031982872,0.000020445968,0.0973947,0.028022354,1.8075623e-7,0.000530947,0.00041437134,0.0045641013],"study_design_scores_gemma":[0.11022376,0.15491292,0.36526924,0.00066096726,0.0016904133,0.0000060428447,0.35314444,0.0027584853,0.000039124436,0.00051212375,0.010510659,0.00027182212],"about_ca_topic_score_codex":0.0024435525,"about_ca_topic_score_gemma":0.0018723871,"teacher_disagreement_score":0.4062809,"about_ca_system_score_codex":0.0016506892,"about_ca_system_score_gemma":0.003298104,"threshold_uncertainty_score":0.5850695},"labels":[],"label_agreement":null},{"id":"W4206083502","doi":"10.1080/13696998.2022.2027706","title":"Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Dalhousie University","funders":"","keywords":"Eculizumab; Atypical hemolytic uremic syndrome; Productivity; Adverse effect; Hemoglobinuria","score_opus":0.015630096427270628,"score_gpt":0.2520832225586991,"score_spread":0.23645312613142846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206083502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639875,0.0009487831,0.000006563554,0.000504135,0.001744446,0.00034057122,0.000027160171,0.00000453882,0.000025047091],"genre_scores_gemma":[0.9997584,0.00007600758,0.000011238826,0.000058637143,0.000029273746,0.00002007842,0.000020319341,0.00001421439,0.000011784911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840534,0.0003148396,0.0007802696,0.00016082061,0.000101336205,0.00023739375],"domain_scores_gemma":[0.99822026,0.000866991,0.000601089,0.00023121321,0.000020628639,0.00005981852],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048556225,0.00015234126,0.0005481438,0.0001412047,0.00010566113,0.000008738093,0.0005390556,0.0000823509,0.0010602471],"category_scores_gemma":[0.00011781725,0.0001026161,0.00016419089,0.00004888663,0.00014692415,0.00006223786,0.00015514056,0.00035791125,0.000021673963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0874872,0.009007047,0.8011049,0.00080680003,0.01091941,0.0011496898,0.0041211173,0.023381757,0.00027090925,0.009378579,0.009259659,0.04311293],"study_design_scores_gemma":[0.19249785,0.032694962,0.7329809,0.00092450844,0.0012486757,0.0027717873,0.0031674667,0.001255617,0.0013281096,0.0003667528,0.029672412,0.0010909329],"about_ca_topic_score_codex":0.0000683924,"about_ca_topic_score_gemma":0.00010174847,"teacher_disagreement_score":0.10501064,"about_ca_system_score_codex":0.0012069087,"about_ca_system_score_gemma":0.00070348283,"threshold_uncertainty_score":0.9998529},"labels":[],"label_agreement":null},{"id":"W4210251137","doi":"10.1080/13696998.2022.2035131","title":"Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modeling analysis","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Eli Lilly (Canada); McMaster University; Impact; McGill University","funders":"Eli Lilly and Company","keywords":"Medicine; Glucagon; Hypoglycemia; Psychological intervention; Emergency medicine; Type 2 diabetes; Diabetes mellitus; Glucagon receptor; Intensive care medicine; Medical emergency; Insulin; Internal medicine; Endocrinology; Nursing","score_opus":0.0448619192863499,"score_gpt":0.29080398657987816,"score_spread":0.24594206729352824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210251137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99694985,0.00015168788,0.000012128383,0.0023218633,0.00005854286,0.00045197058,0.000019406772,0.0000010367248,0.00003348968],"genre_scores_gemma":[0.9997082,0.00006530773,0.000037933005,0.00008713946,0.00001916446,0.00002993488,0.00001770641,0.000010935098,0.000023723156],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9972466,0.00022687105,0.0005979707,0.00013559355,0.0015653644,0.00022755541],"domain_scores_gemma":[0.99828154,0.0008614335,0.00038491076,0.00013486986,0.00017188555,0.00016534896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037209734,0.00010464282,0.000707841,0.00030539112,0.00004263099,0.000010267423,0.00017179144,0.00006317497,0.00008141614],"category_scores_gemma":[0.0015530547,0.00006245322,0.000093144656,0.00043997343,0.000060312923,0.00007453341,0.00007558513,0.00024061228,1.3825003e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016505645,0.0003413694,0.8551747,0.000030855583,0.001695003,0.0000081245935,0.00026585002,0.13392039,0.0000015341456,0.000008954955,0.00003397,0.0068686483],"study_design_scores_gemma":[0.018684352,0.0013112474,0.20002061,0.00014089505,0.0013764019,0.0000022439792,0.001616986,0.7766755,0.000019074316,0.000014921256,0.000068707865,0.00006904534],"about_ca_topic_score_codex":0.03144422,"about_ca_topic_score_gemma":0.62758774,"teacher_disagreement_score":0.6551541,"about_ca_system_score_codex":0.0021376004,"about_ca_system_score_gemma":0.0046457173,"threshold_uncertainty_score":0.97500545},"labels":[],"label_agreement":null},{"id":"W4210759142","doi":"10.1080/13696998.2022.2033493","title":"Epidemiology and economic burden of Huntington’s disease: a Canadian provincial public health system perspective","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Epidemiology; Health care; Public health; Proxy (statistics); Incidence (geometry); Cohort; Disease burden; Retrospective cohort study; Disease; Demography; Indirect costs; Gerontology; Environmental health; Emergency medicine; Surgery; Internal medicine","score_opus":0.044430487514849244,"score_gpt":0.2987692817046934,"score_spread":0.2543387941898442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210759142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.941948,0.00045499622,0.000033489763,0.056221668,0.0007396527,0.00017094461,0.00022916068,0.000005729877,0.0001963775],"genre_scores_gemma":[0.9966291,0.00025320216,0.000057686673,0.0025885843,0.00042565726,0.000009810826,0.0000012935506,0.000016369911,0.000018268964],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973089,0.0009084284,0.00088844163,0.00030382638,0.00020385244,0.00038653502],"domain_scores_gemma":[0.9967141,0.0005345419,0.000941358,0.00016323481,0.000051338804,0.0015953989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024727676,0.00012153644,0.00052532833,0.00028598183,0.0002396002,0.000016677024,0.00053613685,0.00004105732,0.00024210488],"category_scores_gemma":[0.0038230591,0.00012094845,0.00012924803,0.000057480516,0.00024904188,0.000098562035,0.00019243917,0.00036804462,0.0000032708276],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068226387,0.0005959915,0.088945076,0.00057465094,0.0002789129,0.0002817429,0.0070907054,0.0323653,0.0005623233,0.8366209,0.011899428,0.020102685],"study_design_scores_gemma":[0.025410831,0.0122778565,0.21563132,0.00070073636,0.00059977727,0.005990979,0.09856838,0.33734033,0.006829301,0.028895492,0.2634172,0.0043377928],"about_ca_topic_score_codex":0.014561113,"about_ca_topic_score_gemma":0.0060906317,"teacher_disagreement_score":0.8077254,"about_ca_system_score_codex":0.0015903084,"about_ca_system_score_gemma":0.009195038,"threshold_uncertainty_score":0.99642193},"labels":[],"label_agreement":null},{"id":"W4220766721","doi":"10.1080/13696998.2022.2049552","title":"Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Haemophilia; Quality of life (healthcare); Tobit model; Body mass index; Haemophilia A; Population; Haemophilia B; Medical record; EQ-5D; Factor IX; Internal medicine; Health related quality of life; Pediatrics; Physical therapy; Disease; Environmental health","score_opus":0.0532654150044163,"score_gpt":0.34627892845941805,"score_spread":0.29301351345500176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220766721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629526,0.00044828007,0.000076476244,0.035967093,0.000103232676,0.00030299736,0.000075918026,0.0000040315913,0.00006934597],"genre_scores_gemma":[0.998629,0.00046438735,0.00036348504,0.00025228458,0.00009654938,0.000008327071,0.000013679083,0.000014878589,0.00015744918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971853,0.000237846,0.0010232817,0.00013470337,0.0012217057,0.00019718103],"domain_scores_gemma":[0.9968943,0.0010154112,0.0011473275,0.00010997437,0.00018935681,0.00064360845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040496183,0.00010059598,0.00094780524,0.00012476621,0.000080642174,0.000005177192,0.00013703197,0.00014734195,0.0006445276],"category_scores_gemma":[0.0019566491,0.000062769446,0.00010091415,0.00009908084,0.00009627727,0.000069163456,0.00006308144,0.000493927,2.39119e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014337467,0.0025729558,0.9348759,0.0015015388,0.0025493489,0.00007546837,0.003678361,0.00008144132,0.00057924725,0.0002633512,0.009247123,0.030237772],"study_design_scores_gemma":[0.098497465,0.031460613,0.84022504,0.0031264434,0.0004781945,0.0010420849,0.005870403,0.0067959325,0.005350538,0.00040878105,0.006069161,0.00067532033],"about_ca_topic_score_codex":0.0000934532,"about_ca_topic_score_gemma":0.0001225711,"teacher_disagreement_score":0.094650865,"about_ca_system_score_codex":0.00041093418,"about_ca_system_score_gemma":0.0024143364,"threshold_uncertainty_score":0.70571256},"labels":[],"label_agreement":null},{"id":"W4220928355","doi":"10.1080/13696998.2022.2053403","title":"Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; KRAS; Internal medicine; Oncology; Personalized medicine; Polymerase chain reaction; Genetic testing; Cancer; Bioinformatics; Gene; Genetics; Colorectal cancer","score_opus":0.057040984885594635,"score_gpt":0.2991262615221178,"score_spread":0.24208527663652316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220928355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963695,0.00012268325,0.002164352,0.00021277624,0.0003163497,0.000597553,0.00009400896,0.0000068698687,0.00011591525],"genre_scores_gemma":[0.9957918,0.000012558356,0.003640558,0.000074706826,0.00019444313,0.00009515857,0.00013655634,0.000026826227,0.000027420709],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99882567,0.0000429135,0.0005501324,0.00014358084,0.0002636249,0.00017405026],"domain_scores_gemma":[0.99806535,0.00040484997,0.0009597606,0.000078225064,0.00032955056,0.0001622504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039883025,0.00012854669,0.00032550664,0.00012817369,0.0002310082,0.000043751075,0.0000675548,0.000036660414,0.000034961977],"category_scores_gemma":[0.00025978516,0.00010269411,0.00005628593,0.0001468179,0.000044262593,0.00027773035,0.000018039467,0.00025575625,7.687098e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025694736,0.0018434988,0.2801888,0.00042796016,0.004137951,0.00012140826,0.005260507,0.66172105,0.017064253,0.00012431697,0.00028795705,0.02625283],"study_design_scores_gemma":[0.038953066,0.009616062,0.08762837,0.00085675536,0.0038226936,0.0001269581,0.007948472,0.8490065,0.001542113,0.000019403153,0.000033901197,0.00044575025],"about_ca_topic_score_codex":0.0005310583,"about_ca_topic_score_gemma":0.00049191,"teacher_disagreement_score":0.19256043,"about_ca_system_score_codex":0.0013544831,"about_ca_system_score_gemma":0.0030489534,"threshold_uncertainty_score":0.54087126},"labels":[],"label_agreement":null},{"id":"W4223492032","doi":"10.1080/13696998.2022.2063603","title":"Carbon footprint and associated costs of asthma exacerbation care among UK adults","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Carbon footprint; Exacerbation; Greenhouse gas; Asthma; Medicine; Asthma exacerbations; Environmental health; Population; Internal medicine","score_opus":0.016006508914593823,"score_gpt":0.2557213518250877,"score_spread":0.23971484291049389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223492032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975211,0.00017101763,0.0000018791259,0.0012194278,0.0002327366,0.00006920887,0.000009466431,0.0000021135843,0.0007730365],"genre_scores_gemma":[0.99898213,0.0007112311,0.000022923377,0.00020437059,0.000060742383,0.0000017428563,0.0000037670798,0.0000061132982,0.000007004206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990077,0.000055389275,0.00040284827,0.00008183009,0.00031275002,0.00013949252],"domain_scores_gemma":[0.999105,0.000077330995,0.00047953334,0.000060633876,0.000012342547,0.00026519469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008764224,0.000056772788,0.00018972448,0.000037903268,0.000058772206,0.000007081574,0.0001437408,0.00006419666,0.00082058605],"category_scores_gemma":[0.00019638766,0.00005408615,0.00003739799,0.000044664215,0.000069411915,0.00003343939,0.00018405872,0.0002667571,7.8396306e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025175913,0.00018254493,0.83271235,0.000057588168,0.00003502343,0.000044769313,0.008854291,0.001984137,0.000097778735,0.00006697012,0.00081747567,0.1548953],"study_design_scores_gemma":[0.0029708815,0.0012698106,0.9756331,0.00019422357,0.000024154318,0.00008820469,0.008338166,0.009131135,0.00018618513,0.0002453437,0.0017490241,0.00016976267],"about_ca_topic_score_codex":0.0007091348,"about_ca_topic_score_gemma":0.0014612052,"teacher_disagreement_score":0.15472554,"about_ca_system_score_codex":0.0007476121,"about_ca_system_score_gemma":0.000052616335,"threshold_uncertainty_score":0.8984842},"labels":[],"label_agreement":null},{"id":"W4240567294","doi":"10.3111/13696998.2014.909438","title":"Letter to the Editor","year":2014,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"Veterinary Practice and Education Studies","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Family medicine","score_opus":0.20580695784900213,"score_gpt":0.4714749754306188,"score_spread":0.2656680175816166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4240567294","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007543976,0.00011265244,0.00020032359,0.9312745,0.06544834,0.00014883939,0.0000054185034,0.00000550818,0.0020500466],"genre_scores_gemma":[0.0000465253,0.00050720613,0.000097476346,0.6207679,0.37612626,0.0000141782975,0.0000031325596,0.000019450543,0.0024178668],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997312,0.00057907705,0.0011302129,0.00013976,0.0004700455,0.00036888267],"domain_scores_gemma":[0.9950562,0.0029766231,0.0012329663,0.00031803185,0.00020327966,0.0002129152],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004010238,0.00016339791,0.0005372341,0.000117352305,0.00035149683,0.000024390138,0.0008538813,0.0009543746,0.002243133],"category_scores_gemma":[0.002039598,0.0000961942,0.00017428587,0.00004125198,0.00006131813,0.00010940424,0.00020024137,0.0070345555,0.0023251001],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020580052,0.000009846041,0.000038976195,0.000072566276,0.00010356271,0.000040021223,0.00086296274,0.0000019037785,5.3448638e-8,0.000013104357,0.997797,0.0010393955],"study_design_scores_gemma":[0.00025702655,0.0001172845,0.000043657434,0.00022814114,0.000059010665,0.00009204109,0.00043080898,0.0000081603,6.038183e-8,0.00007875275,0.9985841,0.00010095001],"about_ca_topic_score_codex":0.000019353096,"about_ca_topic_score_gemma":0.000012386944,"teacher_disagreement_score":0.31067792,"about_ca_system_score_codex":0.00019974356,"about_ca_system_score_gemma":0.0010245278,"threshold_uncertainty_score":0.99866897},"labels":[],"label_agreement":null},{"id":"W4242597024","doi":"10.3111/13696998.2011.650528","title":"Economic evaluation of a 100% whey-based partially hydrolyzed infant formula in the prevention of atopic dermatitis among Danish children","year":2011,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; PharmIdeas (Canada)","funders":"","keywords":"Medicine; Atopic dermatitis; Danish; Infant formula; Dermatology; Pediatrics","score_opus":0.026658612745991222,"score_gpt":0.29242777042454543,"score_spread":0.2657691576785542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242597024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978494,0.00027573414,0.00013549098,0.0007390095,0.00013083243,0.00026936704,0.0000047538097,0.0000021319486,0.00059326686],"genre_scores_gemma":[0.99925756,0.00017030611,0.00015980091,0.00031474428,0.00007251864,0.0000068559307,0.000009918769,0.000006342853,0.000001948332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982733,0.00021052927,0.001035645,0.00008016355,0.00028727297,0.0001130535],"domain_scores_gemma":[0.9987463,0.00009666643,0.00079627,0.00017271854,0.000076842945,0.000111196685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023812794,0.00008256067,0.00042267266,0.00013911311,0.000016944849,0.0000047937006,0.00023163857,0.0001498334,0.0005437969],"category_scores_gemma":[0.00035481257,0.000060935403,0.00019601891,0.00003528621,0.00014999784,0.00015686285,0.000018951998,0.0002066876,0.000002905117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022468065,0.00062517973,0.9867936,0.00008661747,0.00025556015,0.000024112936,0.0008708572,0.00041008112,0.000007898216,0.0004044768,0.0008332855,0.009463649],"study_design_scores_gemma":[0.0054324204,0.00020592139,0.9698118,0.0002946146,0.00038423008,0.00023632852,0.00010167033,0.019867217,0.0010003048,0.0025561973,0.00005116746,0.000058118098],"about_ca_topic_score_codex":0.00006800749,"about_ca_topic_score_gemma":0.00033820828,"teacher_disagreement_score":0.019457137,"about_ca_system_score_codex":0.0000654814,"about_ca_system_score_gemma":0.0010548028,"threshold_uncertainty_score":0.59541947},"labels":[],"label_agreement":null},{"id":"W4280552376","doi":"10.1080/13696998.2022.2078574","title":"Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal chondral defects of the knee – an Australian perspective","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; WOMAC; Surgery; Quality-adjusted life year; Osteoarthritis; Cost effectiveness; Quality of life (healthcare); Arthroplasty; Arthrofibrosis; Physical therapy; Range of motion","score_opus":0.02512278779591039,"score_gpt":0.3073446473954924,"score_spread":0.282221859599582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280552376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783444,0.00033017228,0.00014469739,0.00038154112,0.00031306554,0.0008824108,0.00010612288,0.0000013242097,0.000006239628],"genre_scores_gemma":[0.9996042,0.00015902404,0.00007484108,0.000030729912,0.00005472835,0.000042198346,0.000013945107,0.000009436099,0.000010890444],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888,0.0001156207,0.0005193085,0.00012459351,0.00024286367,0.00011756162],"domain_scores_gemma":[0.9985215,0.00027093024,0.0008179357,0.00016096758,0.00015016759,0.000078506084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004661723,0.000119370314,0.00072941603,0.00026208776,0.00004663538,0.0000026629903,0.00009771504,0.00008888088,0.00005428422],"category_scores_gemma":[0.000055471537,0.00006645292,0.00036435458,0.00026695596,0.00016358137,0.000055259683,0.000015775126,0.00017308301,4.5472643e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08920221,0.024561213,0.52403885,0.0009160974,0.03180507,0.00023789813,0.042917743,0.049234603,0.10574649,0.0077872877,0.00019607792,0.123356454],"study_design_scores_gemma":[0.06845097,0.15908845,0.1842285,0.00088276365,0.017151862,0.0015619982,0.05265356,0.0050807297,0.50837684,0.0011885515,0.00095980405,0.0003759774],"about_ca_topic_score_codex":0.0004155777,"about_ca_topic_score_gemma":0.0011575993,"teacher_disagreement_score":0.40263036,"about_ca_system_score_codex":0.000452413,"about_ca_system_score_gemma":0.0004422167,"threshold_uncertainty_score":0.27098715},"labels":[],"label_agreement":null},{"id":"W4311206227","doi":"10.1080/13696998.2022.2157596","title":"Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries","year":2022,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Socioeconomic status; Schizophrenia (object-oriented programming); Psychiatry; Demography; Environmental health; Gerontology; Population","score_opus":0.020873750268871782,"score_gpt":0.34054225721086384,"score_spread":0.31966850694199206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311206227","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009437237,0.9879883,4.4754142e-7,0.0010666588,0.00021426844,0.00047935985,0.00075914233,0.000003821821,0.000050750517],"genre_scores_gemma":[0.00025706078,0.9989365,0.00019962528,0.000080618454,0.00021288393,0.000010092837,0.00019884041,0.000036527956,0.000067882545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963884,0.00026082795,0.0022191654,0.00023389746,0.00062106346,0.00027666995],"domain_scores_gemma":[0.9948269,0.00089215353,0.0032215419,0.0002833756,0.00033905514,0.00043698147],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020245512,0.0003256549,0.0042593824,0.00027216095,0.000046095196,0.000016975893,0.00044008094,0.00048529936,0.002490999],"category_scores_gemma":[0.0017536808,0.00024084489,0.0009688463,0.00017488432,0.00041266368,0.00009832204,0.00021460919,0.0011761269,0.0000059037075],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002357559,0.00040408107,0.00011725845,0.13652508,0.007969136,0.00038288144,0.00036316735,0.0000016786458,3.9260905e-7,0.00035411614,0.0055739298,0.8459507],"study_design_scores_gemma":[0.008543246,0.0019149878,0.000109332796,0.23408881,0.0037092608,0.001152621,0.00017411546,0.0000373329,0.000007802611,0.00013200837,0.74982506,0.0003054423],"about_ca_topic_score_codex":0.000018995775,"about_ca_topic_score_gemma":0.000015792886,"teacher_disagreement_score":0.8456453,"about_ca_system_score_codex":0.00068798906,"about_ca_system_score_gemma":0.0040841554,"threshold_uncertainty_score":0.99842083},"labels":[],"label_agreement":null},{"id":"W4311367134","doi":"10.1080/13696998.2022.2156152","title":"The cost-effectiveness of a nursing home-based transitional care unit for increasing the potential for independent living in the community among hospitalized older adults","year":2022,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Geriatric Care and Nursing Homes","field":"Health Professions","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Bruyère","funders":"","keywords":"Medicine; Transitional care; Nursing homes; Independent living; Unit (ring theory); Nursing; Skilled Nursing Facility; Gerontology; Intensive care medicine; Health care","score_opus":0.035483687080570106,"score_gpt":0.37385944076368816,"score_spread":0.33837575368311806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311367134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849535,0.00040075887,0.0033137861,0.0045401314,0.0014872445,0.0016489741,0.000080074744,0.000003827196,0.000029828449],"genre_scores_gemma":[0.99905336,0.000051393792,0.000071608505,0.00024526633,0.00028316435,0.00024908228,0.00002739113,0.000017068902,0.0000016360704],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99461174,0.0038633512,0.000764223,0.00008682055,0.00039333478,0.00028054704],"domain_scores_gemma":[0.98470217,0.014139214,0.0006370938,0.00019015708,0.00024970755,0.00008166774],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0145717915,0.00010665491,0.00033880767,0.00009863331,0.002001623,0.000024442681,0.0006850713,0.00012852305,0.00004120545],"category_scores_gemma":[0.00085024274,0.00006290605,0.00027265874,0.000113410286,0.00018843709,0.00007051296,0.000052344585,0.0014267884,9.989084e-8],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056823876,0.0051748585,0.15041292,0.0043101017,0.000989538,0.000040032304,0.50812435,0.025841549,0.000049961745,0.0066302875,0.004577831,0.2370247],"study_design_scores_gemma":[0.010149787,0.00065023784,0.6179296,0.002302727,0.00018320313,0.000045084184,0.3592398,0.006815744,0.000007752672,0.0019261615,0.00060936913,0.00014057667],"about_ca_topic_score_codex":0.00043372094,"about_ca_topic_score_gemma":0.0003232671,"teacher_disagreement_score":0.46751666,"about_ca_system_score_codex":0.00048677684,"about_ca_system_score_gemma":0.0011083509,"threshold_uncertainty_score":0.9992976},"labels":[],"label_agreement":null},{"id":"W4316927784","doi":"10.1080/13696998.2023.2169496","title":"Adopting a portfolio of ultrasonic and advanced bipolar electrosurgery devices from a single manufacturer compared to currently used ultrasonic and advanced bipolar devices: a probabilistic budget impact analysis from a Spanish hospital perspective","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Thyroid and Parathyroid Surgery","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Electrosurgery; Portfolio; Energy budget; Surgery; Operations management; Engineering; Business","score_opus":0.01377082045706182,"score_gpt":0.282899033202611,"score_spread":0.2691282127455492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316927784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770252,0.020639947,0.0002520998,0.001050068,0.00029805853,0.0003631133,0.00032244893,0.000040636973,0.000008441245],"genre_scores_gemma":[0.9926234,0.005031787,0.0015272597,0.00028086707,0.0003556486,0.000008661671,0.00011550422,0.00005077243,0.000006091981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657536,0.00014048035,0.0014615442,0.0006023935,0.0006028659,0.0006173668],"domain_scores_gemma":[0.99519163,0.0018728619,0.0012348687,0.00032965306,0.0002780305,0.0010929629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010834581,0.00044394814,0.0020489134,0.00078638515,0.00009612417,0.00010003623,0.00026949687,0.00026734092,0.00015079661],"category_scores_gemma":[0.0018424139,0.0003711943,0.0005967396,0.00084551575,0.00018773037,0.00039019695,0.00008251573,0.0007627561,0.0000062923223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003908879,0.0016829072,0.91272247,0.00025377612,0.011274761,0.0005620821,0.010676455,0.004097004,0.0232417,0.00005489454,0.0010527408,0.030472327],"study_design_scores_gemma":[0.00807043,0.0025816576,0.9548728,0.0013634033,0.0039969366,0.0002728984,0.009930967,0.0071361726,0.0027093957,0.000418373,0.0075630196,0.00108398],"about_ca_topic_score_codex":0.00044899693,"about_ca_topic_score_gemma":0.0006205741,"teacher_disagreement_score":0.042150293,"about_ca_system_score_codex":0.0004145506,"about_ca_system_score_gemma":0.0008386197,"threshold_uncertainty_score":0.999874},"labels":[],"label_agreement":null},{"id":"W4318263697","doi":"10.1080/13696998.2023.2173466","title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Surgery","score_opus":0.030366608140798463,"score_gpt":0.2906257714463823,"score_spread":0.26025916330558385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318263697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871004,0.00022548213,0.00001086294,0.00023281785,0.0002670663,0.00046232692,0.000030414716,0.000002970873,0.000057999398],"genre_scores_gemma":[0.99915165,0.0005444898,0.0000464382,0.00009889619,0.00005528168,0.000013410004,0.000032372332,0.000020273108,0.00003721939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804664,0.00018365684,0.00073720707,0.00017104551,0.00061574415,0.00024569687],"domain_scores_gemma":[0.99819905,0.00085600984,0.00028878817,0.00013015547,0.00019958356,0.00032640496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011971653,0.00012289699,0.0006474803,0.00029178074,0.000020383963,0.000007029145,0.00016837177,0.00011058399,0.00024245144],"category_scores_gemma":[0.0004314483,0.00010588551,0.00006162716,0.00023574493,0.0001271953,0.000089108995,0.000048881455,0.0005646777,0.00000140117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00504278,0.00020737895,0.9744178,0.00030203044,0.00008682426,0.0003066655,0.00037044933,0.0005676012,0.0008559856,0.0000051906704,0.00012243203,0.017714867],"study_design_scores_gemma":[0.029521413,0.0006186555,0.9600152,0.0007186728,0.0000127361245,0.000034536482,0.0009778053,0.0049945777,0.0014318621,0.000012654222,0.0015622367,0.00009969265],"about_ca_topic_score_codex":0.039172087,"about_ca_topic_score_gemma":0.3485931,"teacher_disagreement_score":0.309421,"about_ca_system_score_codex":0.0010997787,"about_ca_system_score_gemma":0.003066805,"threshold_uncertainty_score":0.96722615},"labels":[],"label_agreement":null},{"id":"W4327684313","doi":"10.1080/13696998.2023.2192588","title":"Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALS","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Cytokinetics","keywords":"Medicine; Placebo; Amyotrophic lateral sclerosis; Post-hoc analysis; Quality of life (healthcare); Confidence interval; Quality-adjusted life year; Post hoc; Physical therapy; Randomized controlled trial; Clinical trial; Internal medicine; Cost effectiveness; Disease; Alternative medicine","score_opus":0.101716665152335,"score_gpt":0.34966019826966394,"score_spread":0.24794353311732892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327684313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980442,0.00020452926,0.000035522946,0.018523343,0.00018070143,0.00056273426,0.000021075424,0.000020124653,0.000009957209],"genre_scores_gemma":[0.99103296,0.006229967,0.00063225813,0.0016471841,0.0002557295,0.00002185009,0.000012723723,0.000040707495,0.00012664411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725854,0.00016267465,0.001160148,0.00024635356,0.0006458042,0.000526479],"domain_scores_gemma":[0.9975193,0.0009073956,0.00044169577,0.00017182225,0.00015023841,0.0008095579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031391154,0.00016604066,0.0008727681,0.0003288524,0.00006882108,0.00005718736,0.00021474296,0.00018996475,0.00011764978],"category_scores_gemma":[0.002301287,0.00011545826,0.00010386567,0.00023691882,0.00017851213,0.00026402494,0.00011514518,0.0005770068,0.0000057828224],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02084573,0.0007439229,0.8901842,0.0015481343,0.0006966969,0.00009201716,0.0027237209,0.00023626524,0.000052725907,0.0002828646,0.0062073637,0.07638631],"study_design_scores_gemma":[0.011339588,0.0021417558,0.9821706,0.0017946721,0.000024803432,0.000020448859,0.000248836,0.001277114,0.000004615648,0.00008077198,0.0007582728,0.00013851482],"about_ca_topic_score_codex":0.0002194912,"about_ca_topic_score_gemma":0.00038641292,"teacher_disagreement_score":0.09198636,"about_ca_system_score_codex":0.0003246524,"about_ca_system_score_gemma":0.0011496006,"threshold_uncertainty_score":0.4708251},"labels":[],"label_agreement":null},{"id":"W4328049416","doi":"10.1080/13696998.2023.2193112","title":"A practical guide for clinical and key opinion leader validation of health economic models","year":2023,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Key (lock); Opinion leadership; Expert opinion; Actuarial science; Family medicine; Management science; Intensive care medicine; Public relations; Computer science","score_opus":0.6558185005833402,"score_gpt":0.5904005839349129,"score_spread":0.06541791664842733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328049416","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016424428,0.004860432,0.024684014,0.1387996,0.8271555,0.00097366545,0.0016290104,0.000030666117,0.0002246846],"genre_scores_gemma":[0.00042801906,0.10767524,0.01981229,0.00472319,0.86601293,0.00008641188,0.0005299959,0.0003078437,0.00042407404],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97712666,0.0007251435,0.020301381,0.00083832676,0.0003893581,0.00061912736],"domain_scores_gemma":[0.95758486,0.018793125,0.021955626,0.0005893043,0.00034489555,0.0007321768],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.11747572,0.0004238779,0.004537862,0.0007457114,0.00013848527,0.00014597592,0.00079501414,0.001955217,0.00014412294],"category_scores_gemma":[0.057607368,0.00050813303,0.0007300128,0.00007778219,0.0003621782,0.0010320486,0.0001988172,0.0014695791,0.0001944273],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008964262,0.00011767785,0.00019031651,0.0010636958,0.00036502056,0.0000010280322,0.00025552567,0.00045646555,8.343022e-9,0.030395031,0.9664809,0.00058468577],"study_design_scores_gemma":[0.0030768192,0.0005639156,0.000058093483,0.0006449999,0.000039196457,0.000019192285,0.00040088143,0.023668086,3.7399334e-7,0.026238335,0.9449009,0.00038923993],"about_ca_topic_score_codex":0.0004500723,"about_ca_topic_score_gemma":0.00009728342,"teacher_disagreement_score":0.1340764,"about_ca_system_score_codex":0.0011841167,"about_ca_system_score_gemma":0.0075113527,"threshold_uncertainty_score":0.999737},"labels":[],"label_agreement":null},{"id":"W4360989335","doi":"10.1080/13696998.2023.2195753","title":"A systematic review of SF-6D health state valuation studies","year":2023,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Fonds de Recherche du Québec - Santé","keywords":"Checklist; Medicine; Valuation (finance); Preference; Dimension (graph theory); Health economics; Quality-adjusted life year; Population; Quality of life (healthcare); Scopus; EQ-5D; Systematic review; MEDLINE; Actuarial science; Health related quality of life; Statistics; Psychology; Public health; Environmental health; Cost effectiveness; Economics","score_opus":0.7462706308130562,"score_gpt":0.5826734476324421,"score_spread":0.16359718318061411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360989335","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007164448,0.9726024,0.00058624696,0.021573016,0.002346211,0.002399852,0.00039459975,0.00002275313,0.0000677333],"genre_scores_gemma":[4.6012357e-7,0.98996,0.0006408194,0.008120861,0.00072092237,0.00013166884,0.000045903314,0.000114406386,0.00026494137],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9599055,0.002329432,0.036069974,0.00057770294,0.0005477993,0.0005695715],"domain_scores_gemma":[0.93944496,0.0065337527,0.052113827,0.0008553158,0.00038278537,0.000669356],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.15101285,0.0005608051,0.018229462,0.0011800303,0.00010951996,0.000056977773,0.0013978154,0.00045935024,0.00021057809],"category_scores_gemma":[0.057230655,0.0005262571,0.0017356209,0.0004575428,0.00017089404,0.00040705738,0.00020545605,0.00097362074,0.0011561156],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000021384205,0.00006298501,0.0000018979276,0.9576426,0.0019518826,0.0000061820497,0.0004070885,0.0000095727555,1.2891674e-10,0.0068550743,0.025462823,0.007597727],"study_design_scores_gemma":[0.00037367895,0.00016432692,0.0000010087355,0.7289743,0.0004370963,0.00016017299,0.0003013237,0.00016383431,6.5259242e-9,0.0052015875,0.2639104,0.00031230235],"about_ca_topic_score_codex":0.00007337889,"about_ca_topic_score_gemma":0.00004730741,"teacher_disagreement_score":0.23844758,"about_ca_system_score_codex":0.002755644,"about_ca_system_score_gemma":0.00497201,"threshold_uncertainty_score":0.9997189},"labels":[],"label_agreement":null},{"id":"W4383481487","doi":"10.1080/13696998.2023.2234235","title":"Cost-effectiveness of tezepelumab in Canada for severe asthma","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); University of Alberta; AstraZeneca (Canada)","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Asthma; Cost–utility analysis; Exacerbation; Quality-adjusted life year; Cost-effectiveness analysis; Cost effectiveness; Incremental cost-effectiveness ratio; Cohort; Cost–benefit analysis; Emergency medicine; Internal medicine","score_opus":0.03029584279058423,"score_gpt":0.3078310479287403,"score_spread":0.27753520513815605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383481487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977911,0.0001822724,0.00008659458,0.0011800111,0.0004085393,0.00022648391,0.000027367043,0.0000027273627,0.000094905474],"genre_scores_gemma":[0.99912924,0.000214476,0.000048765884,0.00035038192,0.00021337456,0.000003299425,0.000005608572,0.000012035796,0.000022834389],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989712,0.000048203365,0.0005097588,0.0000789807,0.00023487053,0.00015697905],"domain_scores_gemma":[0.9987769,0.00052910746,0.0002143034,0.00008141983,0.000085699015,0.00031256746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001053656,0.000071387534,0.00044380935,0.00012398273,0.000013282428,0.0000029704472,0.00012786506,0.00008065999,0.000100108555],"category_scores_gemma":[0.00070874434,0.000056181965,0.00012258485,0.00009396198,0.00004135986,0.000044340188,0.000025064546,0.00018579832,0.000002173045],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076686344,0.00080458703,0.30646572,0.0035823896,0.0006258361,0.0024831954,0.00036604222,0.009544369,0.00026136843,0.0010290878,0.03138043,0.6357883],"study_design_scores_gemma":[0.022822926,0.0015913199,0.8289033,0.0024798894,0.00012271713,0.0008506851,0.0034862487,0.013968529,0.0014460459,0.00077997276,0.12321604,0.00033232674],"about_ca_topic_score_codex":0.009753057,"about_ca_topic_score_gemma":0.056564163,"teacher_disagreement_score":0.635456,"about_ca_system_score_codex":0.00040411527,"about_ca_system_score_gemma":0.006214436,"threshold_uncertainty_score":0.9994194},"labels":[],"label_agreement":null},{"id":"W4383872109","doi":"10.1080/13696998.2023.2234776","title":"Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Portugal","keywords":"Medicine; Bosutinib; Myeloid leukemia; Chronic care; Health care; Chronic disease; Internal medicine; Oncology; Intensive care medicine; Imatinib; Dasatinib","score_opus":0.029984387243782135,"score_gpt":0.3263907657694533,"score_spread":0.2964063785256712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383872109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918318,0.0016463723,0.00007121636,0.005133525,0.00042112928,0.0005704732,0.00002526428,0.00004859377,0.0002516372],"genre_scores_gemma":[0.9908737,0.006049945,0.00029315983,0.0009886838,0.001151399,0.00001586435,0.00028599842,0.00009495367,0.00024628532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99656755,0.0001305093,0.0014370484,0.00038191667,0.00081003486,0.0006729154],"domain_scores_gemma":[0.99752,0.0002875102,0.0009109137,0.00038170564,0.00013830967,0.0007615058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012755969,0.00029897658,0.0009715086,0.0005132447,0.000107416665,0.0000343876,0.0003478915,0.0002912339,0.0005536515],"category_scores_gemma":[0.00067323784,0.00022261529,0.00014832924,0.000536149,0.00013871117,0.00021777274,0.00010782412,0.0009164658,0.00004829074],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00422347,0.0008231016,0.042948615,0.0012541534,0.0004977444,0.0009227388,0.00368923,0.0028167095,0.0000084003605,0.000050726074,0.01752467,0.92524046],"study_design_scores_gemma":[0.25987184,0.03268094,0.23992524,0.013288076,0.0005260323,0.0016781937,0.0039374293,0.047028486,0.00038889624,0.00005270824,0.39930603,0.0013161221],"about_ca_topic_score_codex":0.00009811723,"about_ca_topic_score_gemma":0.001447077,"teacher_disagreement_score":0.9239243,"about_ca_system_score_codex":0.019435382,"about_ca_system_score_gemma":0.01881802,"threshold_uncertainty_score":0.98674434},"labels":[],"label_agreement":null},{"id":"W4384664050","doi":"10.1080/13696998.2023.2237336","title":"Early access for innovative oncology medicines: a different story in each nation","year":2023,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada)","funders":"AbbVie Canada","keywords":"Medicine; Internal medicine; Oncology; Family medicine","score_opus":0.7144830394150865,"score_gpt":0.5836889240515664,"score_spread":0.13079411536352015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384664050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020584692,0.94615805,0.0022261136,0.040210124,0.006457121,0.0020254208,0.000395592,0.000026544263,0.00044259249],"genre_scores_gemma":[0.0000633353,0.99187475,0.0002781769,0.003886233,0.0032037876,0.00028736703,0.000095177806,0.00011713047,0.0001940402],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9839024,0.0008416469,0.013821012,0.0006190493,0.0002527147,0.00056318723],"domain_scores_gemma":[0.9738437,0.009369655,0.015660841,0.00039373554,0.0002527295,0.000479336],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05289139,0.0004757846,0.0070512462,0.0025191852,0.000096701944,0.00010784882,0.0016132309,0.0013102596,0.00024121178],"category_scores_gemma":[0.024388157,0.00047295165,0.00065912365,0.00053913106,0.00016366689,0.0006213717,0.00020009509,0.0017750976,0.00025280792],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013178625,0.0011685416,0.0010115174,0.052767944,0.0025776287,0.00007016551,0.004434579,0.00009125303,9.716645e-9,0.11486665,0.16185878,0.6610211],"study_design_scores_gemma":[0.0019425818,0.0003495712,0.0002717481,0.0073911967,0.000072176765,0.000050942912,0.00036517924,0.00068858004,1.86749e-8,0.008498436,0.979977,0.00039258346],"about_ca_topic_score_codex":0.00013698924,"about_ca_topic_score_gemma":0.00036924795,"teacher_disagreement_score":0.8181182,"about_ca_system_score_codex":0.0048320075,"about_ca_system_score_gemma":0.0038633798,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W4385341021","doi":"10.1080/13696998.2023.2242197","title":"Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"Takeda Pharmaceutical Company","keywords":"Axitinib; Cabozantinib; Everolimus; Nivolumab; Medicine; Renal cell carcinoma; Oncology; Internal medicine; Urology; Second line; Tyrosine-kinase inhibitor; Sunitinib; Immunotherapy; First line; Cancer","score_opus":0.04274972990295816,"score_gpt":0.3051754524786486,"score_spread":0.2624257225756904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385341021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982787,0.00044093688,0.00003644805,0.00061947334,0.00007972916,0.00039593125,0.000019927378,0.000006462326,0.00012241409],"genre_scores_gemma":[0.998858,0.0006830212,0.00022986607,0.00007151546,0.000060968454,0.000014070497,0.00004302743,0.000022832002,0.000016748558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767774,0.00015690525,0.0011116284,0.0002703357,0.00044129384,0.00034207402],"domain_scores_gemma":[0.9981797,0.0004888364,0.0005536587,0.00022278648,0.00012696322,0.00042806639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017482366,0.00020638756,0.0014089415,0.0011497624,0.000018317385,0.000010928363,0.00016342613,0.00015393426,0.00006317261],"category_scores_gemma":[0.00015723659,0.00016288218,0.00019120952,0.000850311,0.00015685915,0.00009997396,0.00006185032,0.00048546016,0.0000021311353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049422206,0.0006786462,0.9588321,0.00027470017,0.00066244777,0.001755833,0.0008101003,0.024408445,0.0008083244,0.00003326584,0.000024130486,0.0067697754],"study_design_scores_gemma":[0.016300833,0.001528986,0.95190936,0.0003780338,0.00062175374,0.00022810935,0.0006690733,0.024378851,0.0037149508,0.000018480918,0.000110330555,0.00014123457],"about_ca_topic_score_codex":0.0002992681,"about_ca_topic_score_gemma":0.001097745,"teacher_disagreement_score":0.011358612,"about_ca_system_score_codex":0.00041844137,"about_ca_system_score_gemma":0.00061400107,"threshold_uncertainty_score":0.66421425},"labels":[],"label_agreement":null},{"id":"W4387542065","doi":"10.1080/13696998.2023.2269748","title":"A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; COPD; Pulmonary disease; Smoking cessation; Prioritization; Value for money; Multidisciplinary approach; Cost-effectiveness analysis; Cost–utility analysis; Disease; Intensive care medicine; Cost effectiveness; Physical therapy; Family medicine; Internal medicine","score_opus":0.025073270264530455,"score_gpt":0.3208668528375725,"score_spread":0.29579358257304206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387542065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99841297,0.00026475367,0.000028968298,0.00035425992,0.00022849542,0.00037051743,0.0001273723,0.000009216649,0.00020346126],"genre_scores_gemma":[0.9988901,0.0005330111,0.00001039934,0.000043051827,0.00022768485,0.000022717988,0.00023980055,0.000020019714,0.000013196965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721754,0.00018371671,0.0008385585,0.00026517216,0.0012082004,0.00028678778],"domain_scores_gemma":[0.99773794,0.00052781816,0.00057056104,0.00016481316,0.00047226975,0.00052659074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016401892,0.00015859236,0.00066341227,0.0014271825,0.00004477325,0.000020154259,0.00028326493,0.00015151205,0.00029231538],"category_scores_gemma":[0.0005009275,0.00014421283,0.00032375517,0.0011205582,0.00020768694,0.00038608807,0.00013482594,0.0004615351,0.0000038792887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006566353,0.00033557805,0.9757235,0.0005994365,0.0008742872,0.00018868117,0.00015056522,0.01054694,0.0000067447313,0.00010179388,0.0000117357595,0.010804067],"study_design_scores_gemma":[0.0023321018,0.000055747776,0.87043875,0.00038541143,0.00038903687,0.000007636405,0.00025088587,0.12534343,0.000015115931,0.0006096755,0.00007719348,0.00009501083],"about_ca_topic_score_codex":0.0001302718,"about_ca_topic_score_gemma":0.00016500168,"teacher_disagreement_score":0.11479649,"about_ca_system_score_codex":0.0016892566,"about_ca_system_score_gemma":0.0014318429,"threshold_uncertainty_score":0.5880828},"labels":[],"label_agreement":null},{"id":"W4388902364","doi":"10.1080/13696998.2023.2286778","title":"Real-world clinical management of individuals with Rett syndrome: a physician survey","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Genetics and Neurodevelopmental Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"ACADIA Pharmaceuticals","keywords":"Medicine; Rett syndrome; Family medicine; Pediatrics; Physical therapy","score_opus":0.028675360006546857,"score_gpt":0.3101046103406345,"score_spread":0.28142925033408767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388902364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829966,0.000065062384,0.000034961715,0.0005354506,0.00023327424,0.000067014866,0.00001634735,0.0000023354592,0.0007459023],"genre_scores_gemma":[0.9887118,0.010051787,0.0005358847,0.00037488205,0.000034607066,0.0000016490479,0.000039353927,0.000018738554,0.00023133706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871737,0.0000808218,0.0006419538,0.00016250055,0.00023748833,0.00015984495],"domain_scores_gemma":[0.99923205,0.000040797648,0.00037460268,0.00016445327,0.000049237366,0.00013883888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016558232,0.00009776006,0.00028130377,0.000079405356,0.000021216127,0.000010398737,0.00034900926,0.00009547437,0.000019831485],"category_scores_gemma":[0.00004501828,0.000081105434,0.0001028421,0.00014048211,0.00010944369,0.0000031320567,0.00015711473,0.00014951499,0.0000071006584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014196647,0.0017484522,0.7618081,0.00049546943,0.005713775,0.00096497184,0.00017596899,0.0016506145,0.0015819261,0.0009955429,0.071626656,0.15181886],"study_design_scores_gemma":[0.0014358176,0.00061868306,0.98288506,0.000092141956,0.000035540274,0.000042201893,0.00009455756,0.00005474037,0.00059128006,0.00012227366,0.013897138,0.00013055037],"about_ca_topic_score_codex":0.000008473944,"about_ca_topic_score_gemma":0.00007798669,"teacher_disagreement_score":0.22107697,"about_ca_system_score_codex":0.000009551492,"about_ca_system_score_gemma":0.00017680887,"threshold_uncertainty_score":0.33073837},"labels":[],"label_agreement":null},{"id":"W4389627613","doi":"10.1080/13696998.2023.2293379","title":"Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Cegep de Saint Jerome; Université de Montréal","funders":"Canadian Institutes of Health Research; Sanofi Genzyme; Novartis Pharma; Multiple Sclerosis International Federation; Sanofi; World Health Organization; Bayer HealthCare; Università di Catania; Multiple Sclerosis Society of Canada; Biogen; Celgene; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Atara Biotherapeutics; Eisai; Bristol-Myers Squibb","keywords":"Fingolimod; Medicine; Natalizumab; Relapsing remitting; Multiple sclerosis; Cost effectiveness; Physical therapy; Intensive care medicine; Internal medicine; Immunology","score_opus":0.14205289601937748,"score_gpt":0.3668817237976787,"score_spread":0.2248288277783012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389627613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978246,0.00054388825,0.00007061755,0.0007402762,0.00010990583,0.00064590847,0.000009290303,0.0000071159766,0.000048395457],"genre_scores_gemma":[0.99719644,0.002479883,0.0001440825,0.00006477827,0.00006859579,0.000024924628,0.000005595496,0.000014943511,7.872466e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973646,0.00093902054,0.00071973784,0.00021925235,0.00045274335,0.00030468145],"domain_scores_gemma":[0.98850614,0.010681283,0.000323299,0.00014151385,0.00017174051,0.00017602963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009120599,0.00016750862,0.0009198403,0.00065950194,0.000085482694,0.000035086145,0.00021415603,0.00015679662,0.000008388155],"category_scores_gemma":[0.00725156,0.00012061654,0.00008381814,0.00058895844,0.00036207464,0.00018057103,0.0002086542,0.0008489714,7.8439564e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003868776,0.00051969476,0.95245135,0.0022198232,0.00054961833,0.00019420986,0.0085645765,0.0039045704,0.005010687,0.00030095995,0.00020376801,0.02221199],"study_design_scores_gemma":[0.010465415,0.00030058174,0.9318912,0.005188604,0.000030628566,0.0001486615,0.0023882904,0.04883515,0.00047093275,0.00008896449,0.00008632903,0.000105259045],"about_ca_topic_score_codex":0.00047133828,"about_ca_topic_score_gemma":0.00020135075,"teacher_disagreement_score":0.04493058,"about_ca_system_score_codex":0.0002598396,"about_ca_system_score_gemma":0.00022510764,"threshold_uncertainty_score":0.8681319},"labels":[],"label_agreement":null},{"id":"W4391401198","doi":"10.1080/13696998.2024.2311507","title":"Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Oncology; Internal medicine; Adverse effect; Cancer; Immunotherapy","score_opus":0.051633340835480455,"score_gpt":0.3702759509359163,"score_spread":0.3186426101004359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391401198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925631,0.0022334515,0.00045704196,0.0025852825,0.0009415882,0.0007759541,0.000013352449,0.0000061845403,0.00042403073],"genre_scores_gemma":[0.9978606,0.0011161317,0.00017837985,0.00033438648,0.00040989986,0.00004415028,0.000004140736,0.000023296841,0.00002898293],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984382,0.00013190176,0.0007271139,0.000151026,0.0003237383,0.00022806333],"domain_scores_gemma":[0.99790484,0.0014401153,0.0002023987,0.00015887545,0.000110913265,0.00018284409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030569937,0.00013487792,0.00059467816,0.00017664513,0.000017355218,0.000023525985,0.00031309074,0.00018321919,0.00020722825],"category_scores_gemma":[0.000918406,0.0000853654,0.00026980063,0.00012885641,0.00013325292,0.000048066468,0.000029873956,0.00049881666,0.000002992801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061050434,0.0053886385,0.23791173,0.021359853,0.0062747663,0.0041050734,0.017808331,0.010807719,0.0085442485,0.012630817,0.084015206,0.5301032],"study_design_scores_gemma":[0.09450498,0.04276961,0.43870306,0.031021867,0.0050669713,0.026083887,0.005261925,0.10380304,0.08873441,0.023856623,0.1380453,0.0021483377],"about_ca_topic_score_codex":0.000020984147,"about_ca_topic_score_gemma":0.000048255424,"teacher_disagreement_score":0.5279549,"about_ca_system_score_codex":0.00037258992,"about_ca_system_score_gemma":0.0010936089,"threshold_uncertainty_score":0.34811},"labels":[],"label_agreement":null},{"id":"W4391749439","doi":"10.1080/13696998.2024.2314429","title":"Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Retrospective cohort study; Cohort; Health care; Emergency medicine; Cohort study; Environmental health; Medical costs; Economic impact analysis; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.017877827480009743,"score_gpt":0.3360064667503775,"score_spread":0.3181286392703677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391749439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384767,0.0015223863,0.000011023781,0.0027897756,0.00015743161,0.00064635195,0.000015284231,0.0000075656367,0.0010025311],"genre_scores_gemma":[0.9977495,0.0017586959,0.00002682613,0.00023314814,0.00018722743,0.000017952907,0.000002779929,0.000013872171,0.000009964409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982662,0.000098171244,0.0009767471,0.00017988101,0.00032921418,0.00014973797],"domain_scores_gemma":[0.99900025,0.00028913235,0.00026757014,0.0001837659,0.0001280618,0.00013119816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023724542,0.000113344955,0.0004896769,0.00028630235,0.000047348556,0.000042253352,0.00022083298,0.00011504685,0.00013175378],"category_scores_gemma":[0.0006048641,0.000078775214,0.00009101374,0.00013361036,0.00031454026,0.00021466648,0.00008581527,0.0007256485,0.000007612688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116354,0.00013026317,0.98933154,0.000092000504,0.0005702846,0.00005947686,0.0056196265,0.00013908996,0.000003255797,0.0010839893,0.00040957765,0.0024445276],"study_design_scores_gemma":[0.0020806822,0.00061802287,0.9830981,0.00039353754,0.00010178327,0.00009244176,0.0025211673,0.009487286,0.0000035911414,0.0005060098,0.0010315941,0.000065819346],"about_ca_topic_score_codex":0.00040687196,"about_ca_topic_score_gemma":0.00033405755,"teacher_disagreement_score":0.009348196,"about_ca_system_score_codex":0.00035658263,"about_ca_system_score_gemma":0.0004948762,"threshold_uncertainty_score":0.321236},"labels":[],"label_agreement":null},{"id":"W4393037974","doi":"10.1080/13696998.2024.2333683","title":"Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Medicine; Ulcerative colitis; Internal medicine; Intensive care medicine; Disease","score_opus":0.027120433038650665,"score_gpt":0.31007530068372613,"score_spread":0.2829548676450755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393037974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99658936,0.0008918233,0.00086519006,0.0012155982,0.000067340756,0.00022411555,0.00011947881,6.2210216e-7,0.000026463771],"genre_scores_gemma":[0.9964634,0.0029333537,0.00027904022,0.00019952918,0.000071201925,0.000015560398,0.00000915258,0.000008661542,0.000020063888],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9990808,0.00010221775,0.0005340595,0.00012852153,0.000049009897,0.00010541053],"domain_scores_gemma":[0.9991595,0.00029325506,0.00025129496,0.00013879963,0.00008628271,0.00007083107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007902962,0.000099020705,0.00032504436,0.000109016226,0.00002810082,0.000033401626,0.00016375727,0.00010439875,0.000023850622],"category_scores_gemma":[0.00011639797,0.000057393303,0.00021669541,0.000055102893,0.00016422458,0.000009090378,0.000032601536,0.0000638408,9.712919e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04232008,0.0030349924,0.09476753,0.0011764041,0.06445185,0.0002513061,0.043740693,0.34509915,0.049041394,0.03127318,0.0009952371,0.3238482],"study_design_scores_gemma":[0.010898635,0.005860936,0.5114329,0.00045074782,0.0041899206,0.00020169889,0.021132419,0.38138413,0.04583684,0.0027395631,0.014927152,0.0009450979],"about_ca_topic_score_codex":0.000017226546,"about_ca_topic_score_gemma":0.00051290693,"teacher_disagreement_score":0.41666532,"about_ca_system_score_codex":0.000048124286,"about_ca_system_score_gemma":0.00038452676,"threshold_uncertainty_score":0.23404309},"labels":[],"label_agreement":null},{"id":"W4394612987","doi":"10.1080/13696998.2024.2340932","title":"Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Vancouver Coastal Health","funders":"","keywords":"Medicine; Triptans; Phonophobia; Migraine; Photophobia; Nausea; Acute migraine; Calcitonin gene-related peptide; Vomiting; Migraine treatment; Anesthesia; Physical therapy; Pediatrics; Intensive care medicine; Internal medicine; Surgery; Alternative medicine; Placebo","score_opus":0.09629634190561051,"score_gpt":0.4055890361913808,"score_spread":0.30929269428577033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394612987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97952074,0.0061203996,0.00023357097,0.0127303945,0.00015090173,0.0010010314,0.00011721048,0.0000021460405,0.00012359912],"genre_scores_gemma":[0.99585325,0.0033790967,0.00013477268,0.0002458925,0.00027004062,0.000044956854,0.000010952752,0.000010536377,0.000050482347],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878836,0.000076478645,0.00065288576,0.00010886812,0.00021263631,0.00016075096],"domain_scores_gemma":[0.99800986,0.0014068141,0.00016924288,0.00014530942,0.00015249339,0.0001162818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013259852,0.00012343201,0.0007309232,0.00011514002,0.00003227333,0.000008377226,0.00018080723,0.00006671031,0.000048426475],"category_scores_gemma":[0.00024345105,0.000058587986,0.00034654455,0.000100427795,0.00014301558,0.000026716163,0.000028300095,0.00016882652,0.0000017544007],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03871542,0.007991671,0.106407136,0.010264517,0.029369658,0.0027171073,0.43541706,0.0027334823,0.0028059343,0.010378822,0.087254964,0.26594424],"study_design_scores_gemma":[0.04141868,0.042520232,0.16095564,0.0088357795,0.010548514,0.002367135,0.16563691,0.010323661,0.015814137,0.0019483295,0.53883183,0.0007991372],"about_ca_topic_score_codex":0.00026922402,"about_ca_topic_score_gemma":0.0009859498,"teacher_disagreement_score":0.4515769,"about_ca_system_score_codex":0.00018090257,"about_ca_system_score_gemma":0.00047781956,"threshold_uncertainty_score":0.23891488},"labels":[],"label_agreement":null},{"id":"W4394727331","doi":"10.1080/13696998.2024.2342749","title":"Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Attention deficit hyperactivity disorder; Medicine; Adverse effect; Psychiatry; Perspective (graphical); Attention deficit; Pediatrics; Internal medicine","score_opus":0.02027486281548536,"score_gpt":0.30703266958094594,"score_spread":0.2867578067654606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394727331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98833054,0.00030885037,0.001549725,0.008680192,0.00054517586,0.00039101177,0.000040829247,0.00003765693,0.000115999406],"genre_scores_gemma":[0.997402,0.0009942409,0.00034458714,0.00016067369,0.00031262345,0.000025575477,0.00003299539,0.000056395653,0.0006709144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982853,0.000059415343,0.00065337424,0.00026380146,0.0004445261,0.0002936116],"domain_scores_gemma":[0.9983276,0.0004787965,0.00035988458,0.00016190384,0.00033010455,0.00034169637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005369741,0.00023100831,0.00062282395,0.00021363299,0.00010224723,0.000026208829,0.000116008116,0.00021660863,0.00027882654],"category_scores_gemma":[0.0011486384,0.00016912656,0.00043281706,0.00012704304,0.000069957,0.00040383142,0.000026009022,0.00042064156,0.000028197017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002641228,0.0053162863,0.93297803,0.000513286,0.005759621,0.000756966,0.00024273181,0.0010332738,0.00056992716,0.0009035523,0.00020126524,0.049083814],"study_design_scores_gemma":[0.046064034,0.005132883,0.8698865,0.005572152,0.0034693305,0.004419518,0.005874471,0.051219147,0.00009715438,0.00024237545,0.0069451868,0.0010772474],"about_ca_topic_score_codex":0.000032512835,"about_ca_topic_score_gemma":0.00019431672,"teacher_disagreement_score":0.06309155,"about_ca_system_score_codex":0.0009527455,"about_ca_system_score_gemma":0.00057873654,"threshold_uncertainty_score":0.68967813},"labels":[],"label_agreement":null},{"id":"W4395043933","doi":"10.1080/13696998.2024.2345507","title":"Economic and healthcare resource utilization assessments of PET imaging in Coronary Artery Disease diagnosis: a systematic review and discussion of opportunities for future economic evaluations","year":2024,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Cardiac Imaging and Diagnostics","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"GE Healthcare","keywords":"Medicine; Coronary artery disease; Health care; Resource (disambiguation); Disease; Economic evaluation; Appropriate Use Criteria; Intensive care medicine; Cardiology; Pathology; Internal medicine; Economic growth","score_opus":0.09200519105737925,"score_gpt":0.4260465318408872,"score_spread":0.33404134078350795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395043933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005592662,0.9877917,0.00002062055,0.009205347,0.0004567553,0.0014335577,0.000515897,0.000004365839,0.000012472245],"genre_scores_gemma":[0.00079545064,0.9980805,0.00007849219,0.0003780374,0.0003111874,0.00013026551,0.00016208322,0.000042966036,0.000021001142],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99675167,0.00025431614,0.002417058,0.0002395226,0.00017667587,0.00016077908],"domain_scores_gemma":[0.99685,0.000791862,0.001602874,0.00024634387,0.00007212977,0.00043676383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026093817,0.00026885045,0.0030858833,0.0004127657,0.000026148617,0.00002950039,0.00013652476,0.000115782976,0.00001908887],"category_scores_gemma":[0.0006887293,0.0001798158,0.0004726774,0.00003673281,0.0001235487,0.00013427055,0.00008993071,0.0003611464,7.7464296e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030647363,0.00006708188,0.00088301976,0.8586447,0.0003589943,0.00008648408,0.00006887152,0.000004207078,2.7160854e-9,0.00026889954,0.0025735844,0.1370135],"study_design_scores_gemma":[0.0012112542,0.00019807681,0.0003903132,0.924933,0.020542657,0.0019555888,0.0011869249,0.0017984809,4.763968e-8,0.00026743728,0.047271512,0.00024471324],"about_ca_topic_score_codex":0.000004907764,"about_ca_topic_score_gemma":0.000011243966,"teacher_disagreement_score":0.13676877,"about_ca_system_score_codex":0.00044466145,"about_ca_system_score_gemma":0.0029079686,"threshold_uncertainty_score":0.73326755},"labels":[],"label_agreement":null},{"id":"W4400319636","doi":"10.1080/13696998.2024.2367919","title":"The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Insulet Corporation; Gilead Sciences; Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Roche Diabetes Care; Amgen","keywords":"Medicine; Observational study; Liraglutide; Type 2 diabetes; Dulaglutide; Exenatide; Health care; Diabetes mellitus; Glucagon-like peptide 1 receptor; Real world evidence; Intensive care medicine; Internal medicine; Family medicine; Agonist; Endocrinology","score_opus":0.03135285047652705,"score_gpt":0.3399828926197037,"score_spread":0.3086300421431767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400319636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938399,0.0016506392,3.049101e-7,0.0037880922,0.000073152616,0.0005838022,0.000003377182,0.0000019490121,0.000058778056],"genre_scores_gemma":[0.99192595,0.007559306,0.0001875637,0.00023887256,0.000023914401,0.000008517366,0.000002407046,0.000009557333,0.00004392923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833065,0.00014741199,0.001016539,0.00016001544,0.00020756802,0.00013780563],"domain_scores_gemma":[0.9975986,0.0017497705,0.0003887884,0.00009611801,0.000059856844,0.00010688989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016346098,0.00010973311,0.0005970894,0.00021898995,0.000018724071,0.000023839071,0.00004950341,0.000042012154,0.0000014263348],"category_scores_gemma":[0.00056600367,0.0000647902,0.0000279046,0.00015886573,0.00014109944,0.0001962626,0.000053086576,0.00020251403,8.978106e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000345298,0.0011686796,0.9725254,0.00004697853,0.00035834056,0.000037588696,0.00073147495,0.000017686012,1.3126899e-7,0.0003795304,0.00003975349,0.02434913],"study_design_scores_gemma":[0.0062932414,0.0044928333,0.98615766,0.00048916956,0.00010415764,0.000002508034,0.00073109486,0.0005035484,7.4169986e-7,0.00006898025,0.0011098933,0.000046176883],"about_ca_topic_score_codex":0.00035836085,"about_ca_topic_score_gemma":0.0022640422,"teacher_disagreement_score":0.024302954,"about_ca_system_score_codex":0.00025036975,"about_ca_system_score_gemma":0.00023727736,"threshold_uncertainty_score":0.26420677},"labels":[],"label_agreement":null},{"id":"W4400366419","doi":"10.1080/13696998.2024.2374645","title":"The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Crohn's disease; Retrospective cohort study; Disease; Pediatrics; Database; Internal medicine","score_opus":0.006707122821189735,"score_gpt":0.248372093474541,"score_spread":0.24166497065335127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400366419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986923,0.00034084637,0.000015882793,0.00008092109,0.00006844284,0.0004804285,0.00030425764,0.000004891489,0.000012050227],"genre_scores_gemma":[0.9978492,0.0018031995,0.000023151148,0.0000106711905,0.00017302338,0.000027632263,0.00006385394,0.000024834715,0.000024423776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988657,0.000068510206,0.0004477593,0.0002966552,0.00011150489,0.00020981899],"domain_scores_gemma":[0.9988562,0.000060880717,0.00029015052,0.00028933186,0.00007005046,0.00043339847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002595685,0.00025580727,0.0003330588,0.000062673986,0.0000887188,0.00006280689,0.00016832621,0.000081606,0.000034759254],"category_scores_gemma":[0.00004557863,0.000121658486,0.00016923941,0.00003094148,0.00025762207,0.000021514372,0.000053164025,0.00010058151,0.0000014433901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068165753,0.0005696054,0.9874402,0.000011998163,0.0016747284,0.0005608919,0.00007102572,0.0014235603,0.000006753172,0.000013751702,0.00005066232,0.0013602056],"study_design_scores_gemma":[0.005218704,0.009674696,0.9818674,0.000060988103,0.00037256404,0.00002720149,0.00006610716,0.0023292957,0.000039476636,0.000011747914,0.00017839835,0.0001534609],"about_ca_topic_score_codex":0.00015476007,"about_ca_topic_score_gemma":0.0015542681,"teacher_disagreement_score":0.009105091,"about_ca_system_score_codex":0.00073912996,"about_ca_system_score_gemma":0.0013065661,"threshold_uncertainty_score":0.49610892},"labels":[],"label_agreement":null},{"id":"W4400741621","doi":"10.1080/13696998.2024.2379212","title":"Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Fresenius Kabi","keywords":"Biosimilar; Medicine; Tocilizumab; Adalimumab; Intensive care medicine; Rheumatoid arthritis; Internal medicine","score_opus":0.08273379655443044,"score_gpt":0.3413688276508669,"score_spread":0.2586350310964365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400741621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.576734,0.030087398,0.16451527,0.21623172,0.0039517945,0.001989465,0.00036080403,0.0001005452,0.006029012],"genre_scores_gemma":[0.9835742,0.0064432505,0.0030479394,0.006115079,0.00041378918,0.000011939665,0.0000043266245,0.00004846123,0.000341006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890625,0.00019876109,0.00044344008,0.00018624529,0.000058739133,0.00020654668],"domain_scores_gemma":[0.99869597,0.00074845325,0.00018131349,0.00011192609,0.00012923579,0.00013309461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017856992,0.00013569248,0.0003061437,0.00006991759,0.0001262749,0.00010674278,0.00035542503,0.00016084457,0.000310239],"category_scores_gemma":[0.00037738818,0.00006484593,0.00012002486,0.000060985312,0.00036406206,0.00013887863,0.000121438155,0.00059331034,0.0000021311118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012559231,0.0009578685,0.00019301777,0.00052848435,0.006692414,0.00091387983,0.009607535,0.002662713,0.00038516396,0.06441485,0.07388407,0.8272008],"study_design_scores_gemma":[0.0057895766,0.0051114694,0.00006828432,0.0010458325,0.00088209915,0.0047173197,0.009522727,0.08102007,0.0020224152,0.011519849,0.87764096,0.000659413],"about_ca_topic_score_codex":0.00002701142,"about_ca_topic_score_gemma":0.000019938032,"teacher_disagreement_score":0.82654136,"about_ca_system_score_codex":0.000089942994,"about_ca_system_score_gemma":0.00046125692,"threshold_uncertainty_score":0.33968994},"labels":[],"label_agreement":null},{"id":"W4402221900","doi":"10.1080/13696998.2024.2400856","title":"Societal costs and quality of life associated with arginase 1 deficiency in a European setting – a multinational, cross-sectional survey","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Metabolism and Genetic Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inversago Pharma (Canada)","funders":"Immedica Pharma; Universitätsklinikum Heidelberg; Queen Mary University of London","keywords":"Medicine; Cross-sectional study; Multinational corporation; Quality of life (healthcare); Disease; Environmental health; Arginase; Cognitive impairment; Health care; Gerontology; Economic growth; Internal medicine; Pathology; Nursing","score_opus":0.026291049317596186,"score_gpt":0.3155181711262586,"score_spread":0.2892271218086624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402221900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965169,0.0024282583,0.00039496965,0.00015272346,0.00013745311,0.00003289484,0.00004644699,0.0000013136504,0.00028907767],"genre_scores_gemma":[0.99907964,0.0005206541,0.000117753676,0.00014297814,0.000072226,4.890755e-7,0.000034262423,0.000008419865,0.000023590605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988674,0.00020327495,0.0005093432,0.00013521765,0.0001846505,0.00010012726],"domain_scores_gemma":[0.9993891,0.00014470842,0.00022379396,0.000052717663,0.000093237795,0.000096440475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004516063,0.00006853174,0.00016053025,0.000044982626,0.0000220757,0.00003494462,0.00012317717,0.000086358814,0.000027314101],"category_scores_gemma":[0.001644268,0.000057098405,0.00005815804,0.000049336828,0.00014305933,0.000007512219,0.000048585687,0.00015361632,6.7198494e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012677704,0.000147307,0.9938647,0.00004565687,0.000097891614,0.0000060675943,0.000083243736,0.00054277823,0.0004810815,0.00021330557,0.00018652208,0.004204654],"study_design_scores_gemma":[0.001141761,0.00008491658,0.99673176,0.000034373665,0.000004522113,0.000015937598,0.000060011505,0.001211316,0.000056232362,0.000029652905,0.0005600792,0.000069438734],"about_ca_topic_score_codex":0.000021489412,"about_ca_topic_score_gemma":0.00017904739,"teacher_disagreement_score":0.0041352157,"about_ca_system_score_codex":0.000011598449,"about_ca_system_score_gemma":0.00044481264,"threshold_uncertainty_score":0.23284054},"labels":[],"label_agreement":null},{"id":"W4402407314","doi":"10.1080/13696998.2024.2399438","title":"Clinical and economic impact of first-line or drug-naïve catheter ablation and delayed second-line catheter ablation for atrial fibrillation using a patient-level simulation model","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Atrial fibrillation; Ablation; Catheter ablation; Catheter; Cardiology; Internal medicine; Drug; Surgery; Anesthesia; Pharmacology","score_opus":0.12685746263441255,"score_gpt":0.41165732898621876,"score_spread":0.2847998663518062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402407314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95264345,0.00037913644,0.04472903,0.0011040341,0.0005729195,0.00047337046,0.00007700528,0.000010967497,0.000010107094],"genre_scores_gemma":[0.9917471,0.0008533889,0.004449193,0.000054291002,0.002752003,4.0953452e-7,0.000042891264,0.000031159987,0.0000695596],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99774015,0.000047811453,0.0016453528,0.0002295171,0.00018394939,0.00015324069],"domain_scores_gemma":[0.99791896,0.0008941409,0.0007290554,0.00011502378,0.00012268146,0.00022011549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001405219,0.00017901091,0.00063777866,0.00028539816,0.00005855968,0.000058955677,0.000051799685,0.00024440032,0.00014119869],"category_scores_gemma":[0.000513706,0.00013362865,0.0005342696,0.00005457671,0.00008280917,0.00046541257,0.000046597317,0.00017947066,0.0000013528623],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003426297,0.000016058082,0.041973755,0.00022587353,0.00083342975,0.0000039490465,0.00062892115,0.89674366,0.000020262813,0.0001742553,0.00014338268,0.055810153],"study_design_scores_gemma":[0.0038919619,0.0011336289,0.0054673296,0.0001611276,0.00047102282,0.00004860086,0.00003476645,0.98678106,0.000014663032,0.0010819697,0.000784751,0.0001291257],"about_ca_topic_score_codex":0.00003520704,"about_ca_topic_score_gemma":0.00008695396,"teacher_disagreement_score":0.09003739,"about_ca_system_score_codex":0.00025090532,"about_ca_system_score_gemma":0.00048851076,"threshold_uncertainty_score":0.5449218},"labels":[],"label_agreement":null},{"id":"W4402836199","doi":"10.1080/13696998.2024.2407631","title":"Epidemiology and burden of chronic insomnia disorder in Europe: an analysis of the 2020 National Health and Wellness Survey","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Sleep and related disorders","field":"Psychology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Epidemiology; Insomnia; Chronic insomnia; Psychiatry; Environmental health; Gerontology; Family medicine; Internal medicine; Sleep disorder","score_opus":0.026938506276656244,"score_gpt":0.3539406247598802,"score_spread":0.32700211848322397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402836199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96252954,0.025801215,0.000112358895,0.010793386,0.0005567275,0.00004677753,0.000021597809,0.0000015233921,0.00013685944],"genre_scores_gemma":[0.9869147,0.012545084,0.000010689573,0.00040387354,0.000086474094,5.9018345e-7,0.00000771764,0.000007643987,0.000023247043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980058,0.0007408674,0.00086946914,0.000141378,0.000113733724,0.00012875207],"domain_scores_gemma":[0.99833155,0.0010217329,0.0003723646,0.00009226557,0.000051520543,0.0001305468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004634358,0.00007157369,0.000489049,0.00024736364,0.000020036236,0.000003997335,0.00019905757,0.00016623746,0.00028019262],"category_scores_gemma":[0.0009171428,0.000047325582,0.00007191895,0.00040562937,0.0002709997,0.00005169036,0.000048755668,0.00041599642,0.0000010987684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029165545,0.00051605323,0.7942999,0.00014326103,0.0052550384,0.000018113205,0.005998517,0.014840839,0.0000020257064,0.019928345,0.002941517,0.15576471],"study_design_scores_gemma":[0.0023150244,0.00047589774,0.87845695,0.00014465777,0.00026911913,0.00010588345,0.0014229286,0.10564387,5.950226e-7,0.0017929756,0.009246979,0.00012510273],"about_ca_topic_score_codex":0.0009146728,"about_ca_topic_score_gemma":0.0015798995,"teacher_disagreement_score":0.1556396,"about_ca_system_score_codex":0.00004684357,"about_ca_system_score_gemma":0.0005712227,"threshold_uncertainty_score":0.30679128},"labels":[],"label_agreement":null},{"id":"W4403231560","doi":"10.1080/13696998.2024.2413284","title":"Out of focus but still relevant? Influenza-related resource utilization and vaccination coverage gaps in adults below 60 years of age with underlying conditions: an analysis of 2016–2024 real-world data in Germany","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Medicine; Real world data; Vaccination; Focus (optics); Environmental health; Demography; Virology; Data science","score_opus":0.08751726145509976,"score_gpt":0.4022338561713753,"score_spread":0.31471659471627556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403231560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698395,0.0018188352,0.00008789462,0.00041555046,0.00005295277,0.00020139813,0.00018759604,0.0000050988815,0.00024671148],"genre_scores_gemma":[0.989442,0.010182438,0.00015496538,0.00006559518,0.00002902728,0.0000019981183,0.00006597617,0.000017013857,0.000040976898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975847,0.00014311967,0.0013731241,0.0002246958,0.0005075471,0.00016681344],"domain_scores_gemma":[0.99812245,0.00067102915,0.00059559784,0.00030034265,0.00016399201,0.00014659076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023833152,0.0001159208,0.000785117,0.0017623623,0.000014504989,0.000016576609,0.00022296772,0.00012065293,0.00008271358],"category_scores_gemma":[0.001235422,0.00009974086,0.000068695605,0.0007477428,0.00019896889,0.0003902529,0.00012267867,0.0005161636,7.366454e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016200555,0.0032010332,0.5777636,0.008331896,0.017678188,0.006125339,0.043336943,0.030696383,0.0021881347,0.0070927413,0.001994,0.28539118],"study_design_scores_gemma":[0.0048594167,0.00072899373,0.8597535,0.0037501252,0.0007713149,0.000024177029,0.0014194992,0.12690498,0.00007756035,0.00055991433,0.0010135161,0.00013700323],"about_ca_topic_score_codex":0.00066865486,"about_ca_topic_score_gemma":0.007364728,"teacher_disagreement_score":0.28525418,"about_ca_system_score_codex":0.00023805346,"about_ca_system_score_gemma":0.00049887184,"threshold_uncertainty_score":0.4109691},"labels":[],"label_agreement":null},{"id":"W4403787695","doi":"10.1080/13696998.2024.2422227","title":"Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Ibrutinib; Mantle cell lymphoma; Medicine; Oncology; Internal medicine; Refractory (planetary science); Lymphoma; Chronic lymphocytic leukemia; Leukemia; Metallurgy","score_opus":0.0384226166842584,"score_gpt":0.3214999179717034,"score_spread":0.283077301287445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403787695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869236,0.0051386165,0.000010960655,0.0023254068,0.0018398362,0.00012549985,0.0000105781,0.000015879208,0.0036096438],"genre_scores_gemma":[0.99654865,0.0024213656,0.00034489218,0.00017715398,0.00037894788,0.0000032771366,0.000009322267,0.000027701408,0.000088690664],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977288,0.000066857705,0.0012919236,0.00020426133,0.00045278625,0.00025532607],"domain_scores_gemma":[0.99815875,0.00079141965,0.00042974149,0.00018789188,0.00005066417,0.00038150998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009383192,0.00018772233,0.00092102785,0.00034155304,0.000022642025,0.000027845352,0.00022184582,0.00031850062,0.00053816475],"category_scores_gemma":[0.0001738117,0.00014628477,0.00029407637,0.00015957053,0.000097337645,0.00009761645,0.000067026725,0.00043155483,0.00006466568],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010167628,0.020521527,0.16226473,0.0022594703,0.0029822493,0.007236383,0.009815274,0.00053294725,0.00043520477,0.0048803426,0.032611385,0.7462929],"study_design_scores_gemma":[0.20344037,0.01722749,0.36713105,0.012176966,0.0033597508,0.0028940428,0.011451735,0.028168164,0.03881934,0.0019837106,0.3116824,0.0016649609],"about_ca_topic_score_codex":0.00008038613,"about_ca_topic_score_gemma":0.000053049658,"teacher_disagreement_score":0.7446279,"about_ca_system_score_codex":0.00060655305,"about_ca_system_score_gemma":0.0011855281,"threshold_uncertainty_score":0.596532},"labels":[],"label_agreement":null},{"id":"W4404297940","doi":"10.1080/13696998.2024.2419721","title":"Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Medicine; Health care; Bipolar disorder; Resource (disambiguation); Bipolar I disorder; Resource use; Psychiatry; Mania; Environmental science; Environmental resource management; Mood; Economics","score_opus":0.057437312655586804,"score_gpt":0.31017611298156134,"score_spread":0.2527388003259745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404297940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9091492,0.06462941,0.0009223594,0.024461588,0.00034842538,0.00034969693,0.00009594836,0.000015170759,0.00002813974],"genre_scores_gemma":[0.9769254,0.022291826,0.00032964392,0.0001859527,0.00012397426,0.0000051252064,0.000073740106,0.000028910648,0.000035438883],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991023,0.000027340795,0.00041160535,0.00011784782,0.00020845997,0.00013242323],"domain_scores_gemma":[0.9988794,0.0004972447,0.00017405523,0.000086310596,0.000112259906,0.00025075136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004107306,0.00010039198,0.00033245047,0.000107792584,0.000039162398,0.000024347546,0.000050262828,0.00014334382,0.000024302159],"category_scores_gemma":[0.0005067228,0.000071353206,0.00008591459,0.000081260165,0.00008037812,0.00009660301,0.000017322149,0.00020972153,4.361796e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007086508,0.0015698685,0.3881169,0.0017899029,0.004930622,0.00015872609,0.0017765912,0.00019289783,0.000011619208,0.008687991,0.00526638,0.580412],"study_design_scores_gemma":[0.017865561,0.0067720157,0.08237375,0.0028813013,0.0013011633,0.0004050972,0.0004911272,0.016658416,0.00009462484,0.00011986039,0.8708001,0.00023698252],"about_ca_topic_score_codex":0.000108942804,"about_ca_topic_score_gemma":0.0031813872,"teacher_disagreement_score":0.8655337,"about_ca_system_score_codex":0.00024326431,"about_ca_system_score_gemma":0.0004750409,"threshold_uncertainty_score":0.29096994},"labels":[],"label_agreement":null},{"id":"W4404611184","doi":"10.1080/13696998.2024.2431413","title":"A US payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cardiac Imaging and Diagnostics","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"GE Healthcare","keywords":"Medicine; Coronary artery disease; Cardiology; Internal medicine","score_opus":0.016928077055500534,"score_gpt":0.32028627512266167,"score_spread":0.30335819806716113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404611184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832105,0.0025058198,0.0001464679,0.0131886015,0.00043805744,0.00015061446,0.00016102564,0.0000064843807,0.00019239757],"genre_scores_gemma":[0.9964023,0.0013373309,0.000114431314,0.0016993961,0.000394057,0.0000061495466,0.00002155538,0.000017186765,0.000007560204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978695,0.000104725965,0.0010858034,0.00017300545,0.00054439885,0.0002225522],"domain_scores_gemma":[0.9970058,0.0017187654,0.00025059667,0.00032977338,0.000100936755,0.00059412094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015792341,0.00016311456,0.0010227007,0.00072620093,0.000015732043,0.000034901517,0.00028139967,0.000056174933,0.00043728683],"category_scores_gemma":[0.0015442497,0.00010695242,0.0009118799,0.00055059826,0.00012208219,0.0000887614,0.00006052955,0.0004676272,0.000010455496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007381898,0.0007474069,0.95101,0.00016845384,0.003063664,0.0035140887,0.0008667255,0.0087743625,0.000013797025,0.00010567882,0.025166653,0.0058309715],"study_design_scores_gemma":[0.0014150274,0.0003316672,0.96601796,0.0006741241,0.0034662057,0.0005760436,0.00037352528,0.023680983,0.000055836746,0.00017097282,0.0031076076,0.00013005777],"about_ca_topic_score_codex":0.000098213335,"about_ca_topic_score_gemma":0.00006537509,"teacher_disagreement_score":0.022059046,"about_ca_system_score_codex":0.00019770904,"about_ca_system_score_gemma":0.0008519973,"threshold_uncertainty_score":0.47879842},"labels":[],"label_agreement":null},{"id":"W4405289127","doi":"10.1080/13696998.2024.2441072","title":"Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; McGill University; Jewish General Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre; Medtronic (Canada); University of British Columbia; NOSM University; Western University; St. Michael's Hospital","funders":"","keywords":"Medicine; Denervation; Resistant hypertension; Internal medicine; Intensive care medicine; Blood pressure; Cardiology","score_opus":0.05458691882545098,"score_gpt":0.30531858271235324,"score_spread":0.25073166388690227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405289127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785056,0.012183249,0.0012271939,0.007137759,0.0006247134,0.00025352533,0.000016645503,0.0000032263172,0.000048057416],"genre_scores_gemma":[0.99618113,0.002146892,0.00027125838,0.0011469017,0.00021761066,0.000008581225,0.000007678492,0.000009040197,0.000010885494],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99867964,0.000054498632,0.0007494856,0.00011846252,0.00027507616,0.00012286783],"domain_scores_gemma":[0.99826765,0.0010698388,0.00019159407,0.00009010673,0.00023812991,0.00014266498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014354602,0.00008827243,0.0011102015,0.0003763283,0.000017546,0.000007505667,0.000081696504,0.000093924595,0.000046026897],"category_scores_gemma":[0.0005529265,0.00006271416,0.00026502556,0.0002672252,0.000030788375,0.00006995195,0.0000157216,0.00022219098,2.3706829e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010100857,0.0010524808,0.17076501,0.00238625,0.07137209,0.0041324864,0.0008818212,0.027214753,0.007479335,0.0045583826,0.040353198,0.6597033],"study_design_scores_gemma":[0.02463261,0.0012306259,0.22136158,0.003012832,0.034531634,0.001091206,0.0008109115,0.6069956,0.0029609622,0.001114904,0.10179393,0.0004632337],"about_ca_topic_score_codex":0.05750564,"about_ca_topic_score_gemma":0.19399953,"teacher_disagreement_score":0.65924007,"about_ca_system_score_codex":0.00021680474,"about_ca_system_score_gemma":0.0024138927,"threshold_uncertainty_score":0.9487705},"labels":[],"label_agreement":null},{"id":"W4405379562","doi":"10.1080/13696998.2024.2442240","title":"Real-world healthcare resource utilization of Alzheimer’s disease in the early and advanced stages: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novo Nordisk","keywords":"Medicine; Retrospective cohort study; Disease; Health care; Cohort; Emergency medicine; Internal medicine","score_opus":0.03722525300815707,"score_gpt":0.3788974881855275,"score_spread":0.34167223517737044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405379562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886608,0.0015296515,0.000021376694,0.008608517,0.00007972871,0.000589416,0.000008081055,0.00000456195,0.0004978595],"genre_scores_gemma":[0.99650747,0.0029953094,0.000019157404,0.0002648092,0.00012856368,0.000010999304,0.0000038515773,0.000010500275,0.000059370777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983572,0.000178704,0.00055387197,0.00015334914,0.0006122536,0.0001446657],"domain_scores_gemma":[0.9991863,0.00017127031,0.00014172294,0.00011934972,0.00011322764,0.00026813315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028311796,0.000080295205,0.00032288927,0.00025073194,0.000027672777,0.000033251432,0.00011701687,0.000038058966,0.000092852555],"category_scores_gemma":[0.00032146025,0.000052966232,0.00006820908,0.00020231432,0.00010392903,0.00011318827,0.000043132135,0.0004707249,0.0000011810348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041708237,0.00031128508,0.98246753,0.00007918882,0.00017537431,0.00032254052,0.0010475494,0.000002506339,0.0000024374372,0.0006793991,0.00016649942,0.014328627],"study_design_scores_gemma":[0.0013751503,0.0011999222,0.99321496,0.0003800496,0.00018460467,0.000020438585,0.001633808,0.0006795377,0.00000975953,0.0003597027,0.000900947,0.00004110944],"about_ca_topic_score_codex":0.0001462362,"about_ca_topic_score_gemma":0.00016651746,"teacher_disagreement_score":0.014287517,"about_ca_system_score_codex":0.00011929261,"about_ca_system_score_gemma":0.00048860325,"threshold_uncertainty_score":0.21599002},"labels":[],"label_agreement":null},{"id":"W4405519798","doi":"10.1080/13696998.2024.2444157","title":"Systematic review of cost-effectiveness modelling studies for haemophilia","year":2024,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Haemophilia; Cost effectiveness; Intensive care medicine; Systematic review; MEDLINE; Medical physics; Surgery; Risk analysis (engineering)","score_opus":0.2853292764518334,"score_gpt":0.5007652775846267,"score_spread":0.21543600113279332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405519798","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008616414,0.9936445,0.00026719927,0.0010066014,0.0007744864,0.004218411,0.000035953446,0.0000061229325,0.00003815308],"genre_scores_gemma":[0.0000027375265,0.99851906,0.00024374564,0.000097096876,0.00064952415,0.00023121947,0.000018911313,0.000060116836,0.00017761001],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99571586,0.00027873425,0.0029282055,0.00023304469,0.00059554254,0.00024860154],"domain_scores_gemma":[0.99511534,0.0024061166,0.0013196043,0.00030693988,0.0004783696,0.0003736453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065321503,0.00035343284,0.008153572,0.0003660068,0.000029477542,0.0000149643465,0.00038561516,0.00040074583,0.000031222822],"category_scores_gemma":[0.0032010814,0.00018675567,0.0022246453,0.0001621608,0.00014425478,0.00005322942,0.00009833118,0.00084663974,0.000022363318],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026376782,0.00009300097,1.164105e-7,0.93751377,0.005820461,0.00014532857,0.000020231591,0.0000034870745,8.8885e-9,0.00020971397,0.000991591,0.055175904],"study_design_scores_gemma":[0.00056434557,0.00035514525,9.535168e-9,0.86977714,0.019737406,0.0011133621,0.00002770617,0.00056388596,7.349372e-7,0.00023969107,0.10750917,0.000111426445],"about_ca_topic_score_codex":6.8895696e-7,"about_ca_topic_score_gemma":2.8252867e-7,"teacher_disagreement_score":0.106517576,"about_ca_system_score_codex":0.0006452089,"about_ca_system_score_gemma":0.0023087028,"threshold_uncertainty_score":0.76156753},"labels":[],"label_agreement":null},{"id":"W4406230605","doi":"10.1080/13696998.2025.2451526","title":"Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England &amp; Wales: results of the FINE-CKD model","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Kidney disease; Type 2 diabetes; Diabetes mellitus; Internal medicine; Disease; Comorbidity; Intensive care medicine; Endocrinology","score_opus":0.01777631396868015,"score_gpt":0.28133102631907003,"score_spread":0.2635547123503899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406230605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958667,0.0016460848,0.00005385428,0.0015642194,0.00013027478,0.00053493585,0.0001748784,0.0000017182198,0.000027293845],"genre_scores_gemma":[0.9982495,0.0011789476,0.00008302455,0.00033021186,0.000069705886,0.000011703037,0.00004248702,0.0000098826895,0.000024577072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989875,0.000055468132,0.0005170031,0.00012312409,0.00017178089,0.00014511816],"domain_scores_gemma":[0.9984439,0.0005824359,0.0002906685,0.00018701183,0.0001772624,0.0003187013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068912114,0.00010833507,0.00046876224,0.00010064727,0.000018592786,0.0000054350007,0.00014418313,0.00008120432,0.000014574457],"category_scores_gemma":[0.0020391007,0.00006395786,0.000099634846,0.00009424864,0.00015913698,0.0000556606,0.000040928146,0.00016613347,1.1883047e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021385346,0.0019892983,0.94411755,0.0026451803,0.00074337184,0.0000024391752,0.00023730882,0.0026636652,0.00018284099,0.0002733465,0.0026277262,0.023131954],"study_design_scores_gemma":[0.13378195,0.00258728,0.7771872,0.009551913,0.0006910202,0.0000018551777,0.000023955143,0.05927511,0.0017679342,0.0034401382,0.0114090815,0.0002825006],"about_ca_topic_score_codex":0.0000073700244,"about_ca_topic_score_gemma":0.000033520944,"teacher_disagreement_score":0.16693027,"about_ca_system_score_codex":0.00012288049,"about_ca_system_score_gemma":0.0028572443,"threshold_uncertainty_score":0.5068629},"labels":[],"label_agreement":null},{"id":"W4406690128","doi":"10.1080/13696998.2025.2457872","title":"Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Health care; Major depressive disorder; Intensive care medicine; Psychiatry; Mood","score_opus":0.045006711778151035,"score_gpt":0.3490403308563574,"score_spread":0.30403361907820636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406690128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513288,0.011511379,0.00075335876,0.035331365,0.00041784186,0.00050475984,0.000013493521,0.000004672401,0.00013431463],"genre_scores_gemma":[0.99231404,0.00571682,0.00032790552,0.001390871,0.0001853484,0.00000954436,0.000011705774,0.000016710223,0.00002704077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989436,0.000054787473,0.0004981068,0.00013827904,0.00023155977,0.00013361353],"domain_scores_gemma":[0.99846554,0.0005967356,0.00044738155,0.00016333455,0.000180281,0.00014675065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004981972,0.000116517695,0.00037389275,0.00010610583,0.000106970794,0.000013364611,0.00013609008,0.0001589202,0.00002425316],"category_scores_gemma":[0.00063269323,0.000072949486,0.000112170055,0.00007094408,0.00013598638,0.00007062465,0.00005035566,0.00022933105,2.0167708e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04614835,0.0014151705,0.14553471,0.00059052027,0.003064648,0.00008772605,0.0021040482,0.00091506937,0.00019017463,0.0096543245,0.005539012,0.78475624],"study_design_scores_gemma":[0.2704394,0.013674956,0.2569074,0.010564234,0.003724042,0.0012387593,0.008589617,0.05534121,0.01100879,0.005411299,0.36218598,0.00091432733],"about_ca_topic_score_codex":0.00013618435,"about_ca_topic_score_gemma":0.00017113658,"teacher_disagreement_score":0.7838419,"about_ca_system_score_codex":0.00025859397,"about_ca_system_score_gemma":0.0005299305,"threshold_uncertainty_score":0.29747936},"labels":[],"label_agreement":null},{"id":"W4407741494","doi":"10.1080/13696998.2025.2470014","title":"The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Term (time); Gerontology; Actuarial science; Demography; Economics","score_opus":0.025189035262283416,"score_gpt":0.36745650372665334,"score_spread":0.34226746846436995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407741494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98871076,0.00006663468,0.0000015192205,0.010778411,0.000090081485,0.00024549442,0.000014864709,0.0000018014762,0.00009045976],"genre_scores_gemma":[0.99736077,0.0021634072,0.0000111152085,0.00038688025,0.000037101367,0.0000035462372,0.000022030432,0.0000051455154,0.000009985203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985907,0.00017484967,0.0006316396,0.000089118985,0.0003403782,0.00017329819],"domain_scores_gemma":[0.9978452,0.0014707209,0.00016389672,0.00022257425,0.000092303366,0.00020532624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014759998,0.000109065964,0.00040664096,0.0001493034,0.000056720008,0.000029166415,0.0002367269,0.00006425909,0.000023809624],"category_scores_gemma":[0.00087745447,0.00004796407,0.00015257204,0.00016445648,0.00037005,0.00004561115,0.00005636288,0.00049284584,3.3467515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026694587,0.00065987697,0.9803207,0.000019185554,0.00032083376,0.000025899957,0.000105061285,0.000021690304,1.2060067e-7,0.0002459171,0.00022930793,0.015381958],"study_design_scores_gemma":[0.004067431,0.0007636707,0.9941086,0.00013148646,0.000059645186,0.0000036744973,0.00006709282,0.0003072305,0.0000046259897,0.00041692067,0.000037096957,0.00003251826],"about_ca_topic_score_codex":0.0011973862,"about_ca_topic_score_gemma":0.01556151,"teacher_disagreement_score":0.015349439,"about_ca_system_score_codex":0.00033383325,"about_ca_system_score_gemma":0.0004036481,"threshold_uncertainty_score":0.8683688},"labels":[],"label_agreement":null},{"id":"W4408054087","doi":"10.1080/13696998.2025.2473810","title":"Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Respiratory viral infections research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; McMaster University; Hamilton Health Sciences; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Public Health Agency of Canada","keywords":"Medicine; Respiratory system; Cost effectiveness; Environmental health; Virology; Pediatrics; Intensive care medicine; Internal medicine; Risk analysis (engineering)","score_opus":0.02631463215619173,"score_gpt":0.3251406147955996,"score_spread":0.29882598263940785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408054087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99872935,0.0003822339,0.000044278844,0.0001285724,0.0003365139,0.0002444709,0.000011417825,9.4598727e-7,0.00012222765],"genre_scores_gemma":[0.9994661,0.0002977549,0.00007572363,0.00006794778,0.00006571107,0.000003749626,4.7140358e-7,0.000008147597,0.000014344681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984806,0.00014682839,0.0007735046,0.00011778989,0.00032351626,0.00015772694],"domain_scores_gemma":[0.99914134,0.00025522712,0.00017499106,0.00015587812,0.00005250705,0.00022004073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014060392,0.00009335342,0.0004953431,0.00040057392,0.000019812216,0.000005611893,0.00016670176,0.000097179705,0.000057617497],"category_scores_gemma":[0.00039306778,0.00008183557,0.000059015307,0.0001221743,0.0001266922,0.00009184782,0.00013504173,0.0004010711,5.898059e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028737735,0.00026956332,0.8118861,0.0004564327,0.00034806653,0.0003278223,0.00016175587,0.0016035003,0.14719442,0.00009081571,0.0001221632,0.034665633],"study_design_scores_gemma":[0.005875193,0.0015390276,0.6175559,0.0013623389,0.000051898067,0.000074177704,0.0013824924,0.00036976187,0.36385402,0.00003025133,0.007763822,0.0001411077],"about_ca_topic_score_codex":0.090355955,"about_ca_topic_score_gemma":0.019003341,"teacher_disagreement_score":0.2166596,"about_ca_system_score_codex":0.00180495,"about_ca_system_score_gemma":0.003154185,"threshold_uncertainty_score":0.9988973},"labels":[],"label_agreement":null},{"id":"W4408507154","doi":"10.1080/13696998.2025.2480479","title":"Bridging the gap in public healthcare services in developing countries: lessons from the family doctor contract services in China","year":2025,"lang":"en","type":"editorial","venue":"Journal of Medical Economics","topic":"Healthcare Systems and Reforms","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Bridging (networking); Medicine; China; Developing country; Health care; Family medicine; Nursing; Public relations; Economic growth; Political science; Law","score_opus":0.03394145539510101,"score_gpt":0.29999454107634044,"score_spread":0.2660530856812394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408507154","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30427378,0.027884327,0.000059682447,0.25906336,0.40656295,0.00061709963,0.0010417545,0.000011826451,0.00048519234],"genre_scores_gemma":[0.41603962,0.20456323,0.000076214834,0.0137050785,0.3651195,0.00006604647,0.00021897597,0.0001098165,0.00010153148],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99370074,0.00023798966,0.0043945736,0.0005509697,0.000338233,0.0007774765],"domain_scores_gemma":[0.99500394,0.0012255231,0.0028640917,0.000492474,0.00014161668,0.00027233502],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.010251086,0.0004248756,0.0019831886,0.0007042096,0.00016859734,0.00044461736,0.002313577,0.0015885916,0.000057705318],"category_scores_gemma":[0.0006891448,0.0002788245,0.0002587466,0.00044028592,0.00010447313,0.0005416049,0.00027595976,0.0038099012,0.000023039864],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007676615,0.00072234264,0.5169177,0.011890933,0.0015907062,0.0008568803,0.03945127,0.0009325736,2.172589e-7,0.15772323,0.17159474,0.09755176],"study_design_scores_gemma":[0.0017671203,0.000038983286,0.09338719,0.004003694,0.0000047299136,0.000008246781,0.0012417451,0.0024308101,1.0842042e-7,0.003911035,0.8928962,0.00031014442],"about_ca_topic_score_codex":0.13301621,"about_ca_topic_score_gemma":0.17296818,"teacher_disagreement_score":0.72130144,"about_ca_system_score_codex":0.002044537,"about_ca_system_score_gemma":0.0041587246,"threshold_uncertainty_score":0.9999664},"labels":[],"label_agreement":null},{"id":"W4408993723","doi":"10.1080/13696998.2025.2482372","title":"Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada – a matched, population-based observational study","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Observational study; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Vaccination; 2019-20 coronavirus outbreak; Population; Demography; Pediatrics; Gerontology; Family medicine; Internal medicine; Virology; Environmental health; Outbreak; Disease","score_opus":0.08074085739630515,"score_gpt":0.38380382450014033,"score_spread":0.3030629671038352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408993723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868047,0.000038228893,0.00003105973,0.0125033995,0.00016266228,0.00040325822,0.000010147301,0.0000033753493,0.000043128508],"genre_scores_gemma":[0.9840086,0.0000056430868,0.00011122853,0.015740084,0.000100882884,0.000011453981,0.000005914662,0.00000994718,0.000006224151],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799126,0.00013912385,0.0012264436,0.00016243522,0.00032162678,0.00015912193],"domain_scores_gemma":[0.9978312,0.0012942076,0.00049876986,0.000177099,0.000072614355,0.00012607306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027326646,0.0001113232,0.0005778481,0.00019972106,0.000082275255,0.0000389103,0.00025762673,0.00010949471,0.000073350806],"category_scores_gemma":[0.0006333696,0.0000805847,0.000074833566,0.00008579374,0.00019751563,0.00010997368,0.00006267877,0.0007251073,3.7405877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029128417,0.00013671123,0.99822664,0.000037526403,0.00023838188,0.000043449472,0.00034634647,0.00019124459,0.000013908778,0.00013734157,0.00009646166,0.0002407073],"study_design_scores_gemma":[0.005449799,0.00019833379,0.9867058,0.0002069002,0.000079527825,0.000033698696,0.0013100046,0.002356474,0.00002690821,0.00023523961,0.0033287369,0.00006860442],"about_ca_topic_score_codex":0.7566786,"about_ca_topic_score_gemma":0.8922901,"teacher_disagreement_score":0.13561152,"about_ca_system_score_codex":0.00095611083,"about_ca_system_score_gemma":0.020139692,"threshold_uncertainty_score":0.9854152},"labels":[],"label_agreement":null},{"id":"W4409981668","doi":"10.1080/13696998.2025.2499333","title":"Cost-effectiveness analysis of implementing 20-valent pneumococcal conjugate vaccine into the Romanian pediatric national immunization program","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Pneumococcal conjugate vaccine; Immunization program; Immunization; Pediatrics; Conjugate; Vaccination; Romanian; Pneumococcal vaccination; Streptococcus pneumoniae; Virology; Immunology; Antibody; Antibiotics","score_opus":0.024306054771491812,"score_gpt":0.3696598415264782,"score_spread":0.34535378675498635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409981668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910955,0.00019932697,0.0010383342,0.0064224154,0.0003552695,0.00040973132,0.000006698089,0.000011059908,0.0004617077],"genre_scores_gemma":[0.9982434,0.00081797334,0.00007953882,0.000480075,0.00030484077,0.000023760469,0.000019054334,0.000008390351,0.000022990867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982322,0.00015775839,0.0009742206,0.00011948163,0.00035042327,0.00016590998],"domain_scores_gemma":[0.99819624,0.0004376272,0.0005951626,0.00014167452,0.00048398116,0.0001453026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026981635,0.00011107128,0.0005160665,0.00066850963,0.00014286196,0.000025916908,0.00021247189,0.00012672659,0.0001263896],"category_scores_gemma":[0.0006660702,0.00007547241,0.0003431788,0.0007942283,0.000060471288,0.00009185639,0.000085048094,0.00040950198,0.0000018926403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030967468,0.0015164732,0.9166675,0.00037380165,0.006976131,0.00002798769,0.00056174013,0.00665012,0.002221278,0.004321001,0.00056663045,0.05980767],"study_design_scores_gemma":[0.0038236564,0.00057511864,0.91455466,0.00014821163,0.004333769,0.000081820835,0.0003414307,0.031543262,0.00047829575,0.00039251675,0.043594662,0.00013257461],"about_ca_topic_score_codex":0.000020112948,"about_ca_topic_score_gemma":0.00009421829,"teacher_disagreement_score":0.059675097,"about_ca_system_score_codex":0.0002480486,"about_ca_system_score_gemma":0.00092029537,"threshold_uncertainty_score":0.30776757},"labels":[],"label_agreement":null},{"id":"W4410031891","doi":"10.1080/13696998.2025.2498853","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre","funders":"Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Standard of care; Lymphoma; Oncology; Internal medicine; Pediatrics; Family medicine","score_opus":0.01783357241865267,"score_gpt":0.319916550429289,"score_spread":0.3020829780106363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410031891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970963,0.00015821986,0.00004299205,0.0006934057,0.00029635988,0.00092878606,0.00016726593,0.0000016156323,0.0006150792],"genre_scores_gemma":[0.99932945,0.00012259788,0.00004955372,0.00029380256,0.000050399336,0.000011557677,0.000015181348,0.000014358617,0.0001131052],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99766827,0.00027760738,0.00091056677,0.00017338057,0.00065921247,0.00031095627],"domain_scores_gemma":[0.9977395,0.00048364568,0.00039944172,0.0003556725,0.00048698927,0.0005347382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020589714,0.00013570723,0.0011905603,0.0009523096,0.000039818624,0.000010833235,0.000400472,0.00018251524,0.0005868387],"category_scores_gemma":[0.0007946139,0.00008540181,0.00029491386,0.00090206636,0.00011291606,0.000043488093,0.00007086544,0.000380615,5.555898e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59660846,0.0037559138,0.342668,0.0006361875,0.0044657383,0.00015593959,0.0024725734,0.0014303069,0.00025975783,0.0001122922,0.00081724854,0.04661759],"study_design_scores_gemma":[0.47702405,0.010454915,0.43833238,0.001748271,0.002115805,0.000009437954,0.0023450914,0.0018136033,0.003473247,0.000019773503,0.062354993,0.00030843503],"about_ca_topic_score_codex":0.006844186,"about_ca_topic_score_gemma":0.16051035,"teacher_disagreement_score":0.15366615,"about_ca_system_score_codex":0.002151214,"about_ca_system_score_gemma":0.0076337354,"threshold_uncertainty_score":0.99976933},"labels":[],"label_agreement":null},{"id":"W4410568479","doi":"10.1080/13696998.2025.2503660","title":"Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; McGill University Health Centre","funders":"Sanofi; AstraZeneca; Pfizer; Astellas Pharma; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Androgen deprivation therapy; Prostate cancer; Oncology; Internal medicine; Castration; Androgen; Cancer; Androgen receptor; Hormone","score_opus":0.03357280887964614,"score_gpt":0.33903134205413193,"score_spread":0.3054585331744858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410568479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936186,0.002369288,0.00034669775,0.0018161429,0.00027847296,0.0014111045,0.00015189317,0.0000010045652,0.0000067714354],"genre_scores_gemma":[0.9699394,0.029614566,0.00020589889,0.000034232155,0.00005007513,0.00011534216,0.000023267916,0.0000094058005,0.000007810354],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988298,0.00007696635,0.0005322349,0.0001332811,0.0002631428,0.00016457062],"domain_scores_gemma":[0.99780196,0.001254434,0.0004070412,0.000119359465,0.00030717373,0.00011001359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058452785,0.00012552379,0.00055141514,0.00010636668,0.000031369374,0.0000061499723,0.00008780873,0.000046886125,0.00001375727],"category_scores_gemma":[0.00012038645,0.000070335314,0.00008188406,0.00014420871,0.00012378675,0.00004459035,0.000009009992,0.00015935664,6.588789e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14457998,0.0022079884,0.11041428,0.0007534954,0.006957375,0.00016059614,0.0016685936,0.007930812,0.0032678307,0.0001815149,0.00019109466,0.7216864],"study_design_scores_gemma":[0.14742336,0.015783116,0.19230813,0.0032435746,0.0013117741,0.00006187429,0.002849898,0.0131899,0.6219479,0.00035291788,0.0012176579,0.00030991365],"about_ca_topic_score_codex":0.086947374,"about_ca_topic_score_gemma":0.15561828,"teacher_disagreement_score":0.72137654,"about_ca_system_score_codex":0.001550342,"about_ca_system_score_gemma":0.0068069617,"threshold_uncertainty_score":0.9988235},"labels":[],"label_agreement":null},{"id":"W4410888471","doi":"10.1080/13696998.2025.2513766","title":"Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Treatment of Major Depression","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Bausch Health; AbbVie Canada; H. Lundbeck A/S; National Natural Science Foundation of China; Eisai; Purdue University; Biogen; Canadian Institutes of Health Research; Sunovion; Novo Nordisk; Sanofi; Pfizer","keywords":"Medicine; Bipolar disorder; Major depressive disorder; Psychiatry; Bipolar I disorder; Mania; Mood","score_opus":0.007955991016454639,"score_gpt":0.2904175366401365,"score_spread":0.28246154562368186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410888471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99007314,0.0033186814,0.000099179284,0.005906148,0.00013159806,0.0002787128,0.0000065075224,0.0000033220397,0.0001827163],"genre_scores_gemma":[0.9900294,0.00950004,0.000096840384,0.0002642912,0.000038429822,0.000009295437,0.000017339442,0.000011640069,0.000032712043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985005,0.00029991413,0.0006590283,0.00014190626,0.00023767205,0.00016092883],"domain_scores_gemma":[0.997968,0.0014188593,0.00026887294,0.0001784066,0.00006051422,0.00010535568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015734433,0.00013369427,0.0005540507,0.0006375162,0.000025478785,0.000012461042,0.00020528394,0.0001305345,0.000032384152],"category_scores_gemma":[0.0005788374,0.000082897255,0.00007355715,0.00034605726,0.00014481063,0.000089874215,0.00007835266,0.00052202435,5.254813e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009910254,0.000655691,0.98110247,0.00028177915,0.00016387172,0.00013243081,0.0002716573,0.000537664,0.00005501425,0.0007230947,0.000127277,0.014958028],"study_design_scores_gemma":[0.013746629,0.00029133476,0.9740942,0.0015979643,0.00016128161,0.000058582416,0.00044400405,0.0024801537,0.00027166214,0.0014044832,0.0053706844,0.00007902461],"about_ca_topic_score_codex":0.0017936195,"about_ca_topic_score_gemma":0.0023138928,"teacher_disagreement_score":0.014879003,"about_ca_system_score_codex":0.0001229218,"about_ca_system_score_gemma":0.00024069381,"threshold_uncertainty_score":0.3380452},"labels":[],"label_agreement":null},{"id":"W4412387662","doi":"10.1080/13696998.2025.2530862","title":"Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Pembrolizumab; Stage (stratigraphy); Chemotherapy; Oncology; Lung cancer; Adjuvant chemotherapy; Adjuvant; Cancer; Internal medicine; Resection; Surgery; Immunotherapy","score_opus":0.024088500101018588,"score_gpt":0.3212812795561362,"score_spread":0.29719277945511763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412387662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974524,0.0011906842,0.00025321054,0.0004726223,0.00022869761,0.00030828922,0.00003010249,0.0000012524627,0.000062743464],"genre_scores_gemma":[0.9976982,0.001889417,0.00007120337,0.00026281615,0.000032464384,0.000010068341,0.0000072642088,0.000009074674,0.000019506211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987635,0.00007878854,0.0006796379,0.00014142487,0.00019864611,0.00013800457],"domain_scores_gemma":[0.9990056,0.0002513759,0.00041031913,0.00013513422,0.00006244024,0.00013513755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005699927,0.00012191256,0.00085631217,0.0003751096,0.000022686352,0.0000070543642,0.000091564434,0.00009415429,0.00010870405],"category_scores_gemma":[0.000022643591,0.0001002871,0.00022869433,0.00027342726,0.000048354963,0.00004675845,0.000007948622,0.00013743066,1.8277067e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020672059,0.0005322053,0.9079855,0.00040909066,0.004686347,0.00009956548,0.000717509,0.0057111327,0.0042975526,0.000008753331,0.000024586314,0.0548557],"study_design_scores_gemma":[0.030443257,0.0017227933,0.8639997,0.00074755895,0.001203327,0.000007356284,0.0005492263,0.08563504,0.01489507,0.0000061730693,0.00066287536,0.00012760461],"about_ca_topic_score_codex":0.49344268,"about_ca_topic_score_gemma":0.5400901,"teacher_disagreement_score":0.07992391,"about_ca_system_score_codex":0.0015916497,"about_ca_system_score_gemma":0.003906207,"threshold_uncertainty_score":0.69294435},"labels":[],"label_agreement":null},{"id":"W4412511548","doi":"10.1080/13696998.2025.2536430","title":"Evaluating the impact of population-based and cohort-based models in cost-effectiveness analysis: a case study of pneumococcal conjugate vaccines in infants in Germany","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Pneumonia and Respiratory Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Pneumococcal conjugate vaccine; Cohort; Population; Conjugate; Intensive care medicine; Pediatrics; Pneumococcal disease; Streptococcus pneumoniae; Internal medicine; Environmental health; Antibiotics","score_opus":0.0533297024258658,"score_gpt":0.4279798779205503,"score_spread":0.3746501754946845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412511548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987708,0.000068026,0.00009903785,0.00030018334,0.000057688056,0.000688327,0.0000046264618,0.0000017233453,0.000009587437],"genre_scores_gemma":[0.99983567,0.000025113633,0.000008638233,0.00008204005,0.000017468414,0.000023611621,0.000001410603,0.0000056482822,3.862512e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785405,0.00046720967,0.0012260845,0.00013316047,0.00018992304,0.00012958606],"domain_scores_gemma":[0.99797505,0.0011583915,0.00048672347,0.00016007131,0.0001176105,0.00010214575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038428383,0.000115150186,0.0008421301,0.0010503357,0.000025894042,0.000008655087,0.000091173424,0.00011841052,0.000014082691],"category_scores_gemma":[0.00070721225,0.00007599321,0.00016111099,0.00061551674,0.00004785228,0.00008340328,0.000024137411,0.00043238213,4.700285e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003083685,0.0005641446,0.6296956,0.000042092586,0.000247581,0.00015658438,0.00014924821,0.3677672,0.00017654334,0.000004736332,1.7430176e-7,0.00088768534],"study_design_scores_gemma":[0.00483089,0.0004804114,0.5680319,0.00022036627,0.00021935119,0.00005982851,0.00025886093,0.4258062,0.000012777938,0.000047428653,1.53691e-7,0.00003184921],"about_ca_topic_score_codex":0.0039436105,"about_ca_topic_score_gemma":0.0050834543,"teacher_disagreement_score":0.061663732,"about_ca_system_score_codex":0.00026706723,"about_ca_system_score_gemma":0.0009095005,"threshold_uncertainty_score":0.5961585},"labels":[],"label_agreement":null},{"id":"W4412782195","doi":"10.1080/13696998.2025.2542026","title":"A systematic review of health state utility values for influenza and influenza-like illness","year":2025,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Medicine; Influenza-like illness; Intensive care medicine; Respiratory illness; Virology; Family medicine; Internal medicine; Virus; Respiratory system","score_opus":0.40617152015994623,"score_gpt":0.5262277801090721,"score_spread":0.12005625994912589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412782195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033842432,0.9868279,0.0023226477,0.004444413,0.0014666194,0.0037267562,0.0010660888,0.000012749463,0.00009895583],"genre_scores_gemma":[0.0000016321537,0.96965855,0.0009590634,0.028795267,0.00025186734,0.00018154617,0.000023845476,0.00005815379,0.00007009172],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.96698487,0.0016863695,0.029853022,0.0006425561,0.0002805905,0.00055259286],"domain_scores_gemma":[0.9563345,0.0077341,0.034103774,0.0008696139,0.00031176207,0.0006462657],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.11018313,0.00057917536,0.015914729,0.0008823717,0.00016108375,0.000084699874,0.0012281688,0.0005895538,0.00013730349],"category_scores_gemma":[0.03829813,0.0005610426,0.001397862,0.00026238395,0.0002270934,0.00042647464,0.00021219482,0.0007817939,0.000038027352],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000083413515,0.00007692197,0.000026601432,0.9595238,0.0007497589,7.979083e-7,0.00025545195,0.0000021154783,9.778722e-11,0.0043344875,0.007892081,0.027129624],"study_design_scores_gemma":[0.0005549094,0.00010132206,0.0000041167777,0.48313355,0.00030067316,0.000046998128,0.00010671095,0.00013051447,6.346406e-9,0.003123864,0.5122244,0.0002729397],"about_ca_topic_score_codex":0.000095539544,"about_ca_topic_score_gemma":0.00002144758,"teacher_disagreement_score":0.5043323,"about_ca_system_score_codex":0.0010752523,"about_ca_system_score_gemma":0.0055920123,"threshold_uncertainty_score":0.9996841},"labels":[],"label_agreement":null},{"id":"W4413329953","doi":"10.1080/13696998.2025.2549630","title":"The potential impact of the next-generation COVID-19 mRNA-1283 vaccine in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Moderna","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; 2019-20 coronavirus outbreak; Internal medicine; Outbreak; Disease","score_opus":0.04340597853274404,"score_gpt":0.35164069687399546,"score_spread":0.30823471834125143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413329953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95801336,0.00079182757,0.00013080245,0.040039215,0.00071841734,0.00013575242,0.0000032514438,0.0000018252526,0.0001655684],"genre_scores_gemma":[0.96617705,0.0003136326,0.000013235823,0.03303882,0.000428677,0.0000018566724,3.832964e-7,0.000008173538,0.000018162096],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983529,0.00010864867,0.0007617626,0.00009758047,0.00046221743,0.0002169075],"domain_scores_gemma":[0.9988556,0.0003687164,0.00028638495,0.00023270371,0.000110601024,0.00014602792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016648605,0.00009267182,0.0003316083,0.00011766477,0.000084189145,0.000030350393,0.00048094912,0.00010312157,0.000055789293],"category_scores_gemma":[0.002308202,0.000048121226,0.00020634104,0.00018609477,0.0000680293,0.00006722151,0.000091626134,0.0006287298,0.0000011360505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005087419,0.00063439296,0.65747005,0.00033564403,0.0017315178,0.0007405806,0.00045439313,0.0046107676,0.020174546,0.0023556107,0.18400507,0.122399986],"study_design_scores_gemma":[0.033001088,0.0012495315,0.27040234,0.00067813776,0.00040975673,0.0017423016,0.0020887472,0.2611683,0.018613623,0.004215607,0.4059649,0.00046566888],"about_ca_topic_score_codex":0.20532699,"about_ca_topic_score_gemma":0.510136,"teacher_disagreement_score":0.38706774,"about_ca_system_score_codex":0.0019728383,"about_ca_system_score_gemma":0.029811526,"threshold_uncertainty_score":0.9756885},"labels":[],"label_agreement":null},{"id":"W4413447400","doi":"10.1080/13696998.2025.2550860","title":"Projected hospitalization cost impact of the selective cytopheretic device in pediatric acute kidney injury","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Acute Kidney Injury Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seastar Chemicals (Canada)","funders":"","keywords":"Medicine; Acute kidney injury; Emergency medicine; Intensive care medicine; Internal medicine","score_opus":0.01172844044481387,"score_gpt":0.36020866980754135,"score_spread":0.3484802293627275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413447400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98657954,0.00007946048,0.00013741208,0.010604475,0.00035482968,0.000512294,0.000065280794,0.0000052996015,0.0016614256],"genre_scores_gemma":[0.99644625,0.0017016382,0.00013519831,0.0012826264,0.00026181364,0.000009162095,0.000009927403,0.000016039397,0.00013734246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815434,0.00014111475,0.0008826353,0.00013880804,0.00043703674,0.00024606797],"domain_scores_gemma":[0.9983694,0.00014787604,0.00047959536,0.00021404681,0.00039212848,0.00039693512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011621153,0.00013150844,0.00051009684,0.00042844313,0.00003195835,0.00001638083,0.0004355037,0.00025238644,0.00019321825],"category_scores_gemma":[0.00441674,0.00008428876,0.00024256943,0.00092553685,0.00012538552,0.00013424674,0.00012183933,0.0009061521,0.000003811891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018207789,0.0006421204,0.8611833,0.0002480171,0.0008329334,0.000058472007,0.00041903357,0.000018989625,0.00038715746,0.00028487344,0.12780073,0.006303593],"study_design_scores_gemma":[0.009506943,0.0022727845,0.9709219,0.00083270733,0.0008043948,0.00037600606,0.00014923545,0.008096132,0.0030167303,0.0008138182,0.0029843247,0.00022507721],"about_ca_topic_score_codex":0.000047489888,"about_ca_topic_score_gemma":0.000007778772,"teacher_disagreement_score":0.1248164,"about_ca_system_score_codex":0.00086130557,"about_ca_system_score_gemma":0.009470109,"threshold_uncertainty_score":0.99614525},"labels":[],"label_agreement":null},{"id":"W4413582459","doi":"10.1080/13696998.2025.2551449","title":"Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Diabetes Management and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); EVERSANA (Canada)","funders":"Novo Nordisk Canada; Centre de Regulació Genòmica","keywords":"Medicine; Type 2 diabetes; Insulin; Diabetes mellitus; Internal medicine; Intensive care medicine; Endocrinology","score_opus":0.03849923940399257,"score_gpt":0.3348081547398108,"score_spread":0.2963089153358182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413582459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938232,0.0018708061,0.00004622495,0.0031689887,0.00042364598,0.00040898792,0.0000049785594,5.024679e-7,0.00025268408],"genre_scores_gemma":[0.9962743,0.0033745542,0.000047142028,0.00013211316,0.00006413439,0.00001003869,0.000002167329,0.0000045244606,0.000091017304],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99921364,0.000042541473,0.00040727126,0.000054038064,0.00016082001,0.00012171197],"domain_scores_gemma":[0.9982145,0.0013658749,0.00014431617,0.0000982586,0.000104438026,0.00007260269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011318583,0.00005390866,0.00039632525,0.000113315975,0.00001047741,0.0000032204953,0.00015362995,0.000044006763,0.000047686623],"category_scores_gemma":[0.0004297688,0.00003126485,0.00008280099,0.000102518854,0.00006365749,0.000019989979,0.000021277523,0.00009919991,2.1253659e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017513073,0.0010003629,0.34149584,0.0011048677,0.0013538288,0.000017408222,0.00008153607,0.0012902371,0.00008400395,0.0014430525,0.0020453972,0.6483322],"study_design_scores_gemma":[0.033864703,0.0062563675,0.6238001,0.002932819,0.00076932943,0.000003433661,0.0011201015,0.10780405,0.014929967,0.0024150012,0.20589322,0.00021089477],"about_ca_topic_score_codex":0.009790836,"about_ca_topic_score_gemma":0.03893787,"teacher_disagreement_score":0.6481213,"about_ca_system_score_codex":0.00042506034,"about_ca_system_score_gemma":0.0021919478,"threshold_uncertainty_score":0.99680305},"labels":[],"label_agreement":null},{"id":"W4413992600","doi":"10.1080/13696998.2025.2555144","title":"Real world evidence on health care resource utilization and economic burden of arrhythmias in patients with COPD","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"iRhythm Technologies","keywords":"Medicine; COPD; Real world evidence; Health care; Intensive care medicine; Resource (disambiguation); Internal medicine; Economic growth","score_opus":0.023086528648673867,"score_gpt":0.32753139108201673,"score_spread":0.30444486243334284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413992600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688537,0.0017788847,0.000012931202,0.00990848,0.00011121095,0.00029972044,0.00001432269,0.0000033205997,0.0009857845],"genre_scores_gemma":[0.99626404,0.0028771488,0.00012441246,0.00042817046,0.00018981402,0.0000024816034,0.000010920664,0.000014292295,0.000088745444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843967,0.00009640348,0.00073594955,0.0002002211,0.0003256927,0.00020204225],"domain_scores_gemma":[0.9986578,0.00029494843,0.00039004325,0.00019807961,0.00010827976,0.00035083623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006867854,0.00011534662,0.00052017975,0.00044405114,0.00003126149,0.000012721376,0.00015564926,0.00008354246,0.000106965934],"category_scores_gemma":[0.00029237205,0.00009635269,0.000058182577,0.00012444121,0.00018597914,0.000116184245,0.00007089798,0.00043435814,0.0000019479298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00839787,0.00029898534,0.6898547,0.0017423399,0.00022475753,0.00010395662,0.0012369127,0.0015675655,0.000001143442,0.0022985914,0.003236068,0.29103714],"study_design_scores_gemma":[0.00768416,0.0010538165,0.9746361,0.0045617674,0.0000507032,0.000021990712,0.0012561645,0.0031036634,0.000026566617,0.00013608862,0.0073543806,0.0001146135],"about_ca_topic_score_codex":0.00029295083,"about_ca_topic_score_gemma":0.0004350991,"teacher_disagreement_score":0.29092252,"about_ca_system_score_codex":0.0015933097,"about_ca_system_score_gemma":0.002783403,"threshold_uncertainty_score":0.49376377},"labels":[],"label_agreement":null},{"id":"W4414882805","doi":"10.1080/13696998.2025.2560759","title":"Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): demonstration of savings from a societal perspective in the UK","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"AbbVie","keywords":"Perspective (graphical); Health care; Disease; Healthcare system; MEDLINE; Health economics; Public health","score_opus":0.011813621235428545,"score_gpt":0.2903740562733734,"score_spread":0.27856043503794486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414882805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874884,0.002029823,0.00022966837,0.008937044,0.00025701406,0.0002269691,0.000030144096,0.0000032908174,0.00079763704],"genre_scores_gemma":[0.99683917,0.0013606563,0.0005596074,0.0010656925,0.00012871702,0.000011370821,0.000008336953,0.0000084775165,0.00001796047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985135,0.00009073481,0.0006815375,0.00019727384,0.00033715303,0.0001797582],"domain_scores_gemma":[0.99892914,0.0002526631,0.00033383924,0.00017363012,0.00007657732,0.00023417425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070832984,0.00014107491,0.0004751468,0.00018098089,0.00002815471,0.000016656226,0.00023415127,0.00011507464,0.00011483332],"category_scores_gemma":[0.00047602534,0.00010308274,0.00024021174,0.00014643745,0.00009425246,0.00011812695,0.000038575727,0.00041227322,0.0000020950142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006170154,0.0047086123,0.89905244,0.00016721473,0.0010779572,0.002181943,0.0047670933,0.00032164413,0.00045009173,0.02275518,0.0013627596,0.056984935],"study_design_scores_gemma":[0.011358949,0.0003509882,0.9511923,0.0009547034,0.00039587758,0.00004330318,0.007168628,0.003755865,0.00029420684,0.021939434,0.0023978017,0.00014790882],"about_ca_topic_score_codex":0.00019311563,"about_ca_topic_score_gemma":0.00031411767,"teacher_disagreement_score":0.056837026,"about_ca_system_score_codex":0.0004771019,"about_ca_system_score_gemma":0.001123771,"threshold_uncertainty_score":0.42035922},"labels":[],"label_agreement":null},{"id":"W4416697794","doi":"10.1080/13696998.2025.2587415","title":"Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"Bausch Health","keywords":"Rifaximin; Hepatic encephalopathy; Value (mathematics); Symptomatic treatment; Encephalopathy","score_opus":0.08623451281034923,"score_gpt":0.36309682990879755,"score_spread":0.27686231709844833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416697794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945237,0.0016673016,0.0027026131,0.0003990227,0.0001801161,0.0005025528,0.000012673707,0.0000015633733,0.000010448127],"genre_scores_gemma":[0.9950976,0.004434507,0.00028028796,0.000079447134,0.00008619781,0.000007721445,0.0000014382448,0.0000071549484,0.0000056873887],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9989629,0.00004699018,0.00060946157,0.000106853426,0.00017662016,0.000097205564],"domain_scores_gemma":[0.9988712,0.0005159019,0.00029199247,0.00011775882,0.00008290358,0.00012022521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040132774,0.000112284746,0.00048498367,0.00011908395,0.00006266773,0.000009810123,0.000054831802,0.00006094691,0.000006698495],"category_scores_gemma":[0.000026040909,0.000066355424,0.00016054875,0.00005067389,0.00006527344,0.000057782858,0.000006209999,0.000057317033,8.376144e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010767325,0.022795215,0.6863807,0.0019000265,0.027954115,0.00416593,0.064694226,0.00925479,0.001434939,0.001040418,0.00003316033,0.1695792],"study_design_scores_gemma":[0.1443914,0.05038754,0.23571208,0.0038660031,0.06942274,0.008178204,0.13462196,0.33799845,0.0131463995,0.0012540825,0.00034535577,0.000675791],"about_ca_topic_score_codex":0.0011397245,"about_ca_topic_score_gemma":0.0005111359,"teacher_disagreement_score":0.4506686,"about_ca_system_score_codex":0.0001837114,"about_ca_system_score_gemma":0.0005487829,"threshold_uncertainty_score":0.27058956},"labels":[],"label_agreement":null},{"id":"W4416836832","doi":"10.1080/13696998.2025.2587412","title":"Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicaid; Major depressive disorder; Economic impact analysis; Depression (economics); Economic analysis; Cohort study","score_opus":0.030970692370175607,"score_gpt":0.38633706116779126,"score_spread":0.35536636879761563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416836832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883866,0.0030030147,0.00026349755,0.0056936387,0.0015824204,0.0004438386,0.000047635418,0.000003546221,0.00057582423],"genre_scores_gemma":[0.99809295,0.0009798261,0.00008543233,0.00045002546,0.00030677204,0.000027476013,0.000008384362,0.000016961241,0.000032164528],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987116,0.000050113347,0.0006777905,0.00016538103,0.0001402449,0.00025489886],"domain_scores_gemma":[0.99799913,0.00082620047,0.0007499291,0.00019859745,0.000073378855,0.0001527684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005871831,0.00017217401,0.00048312434,0.00011300568,0.00018152576,0.000026837044,0.0004349299,0.00016338866,0.0008533734],"category_scores_gemma":[0.0000668824,0.00009533165,0.00022922657,0.000055969114,0.00020354294,0.00012741743,0.000041621468,0.00025750374,0.0000032634498],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13390994,0.0032632616,0.30642164,0.00035387458,0.027144847,0.00017850615,0.009114476,0.020230392,0.000013299362,0.07976499,0.012591117,0.40701365],"study_design_scores_gemma":[0.3723742,0.039307028,0.40258247,0.0030492318,0.004815091,0.0011941646,0.019550644,0.037351236,0.0016969839,0.029851722,0.085782036,0.0024451786],"about_ca_topic_score_codex":0.0018424608,"about_ca_topic_score_gemma":0.002160431,"teacher_disagreement_score":0.4045685,"about_ca_system_score_codex":0.00054898555,"about_ca_system_score_gemma":0.0009709355,"threshold_uncertainty_score":0.93438405},"labels":[],"label_agreement":null},{"id":"W4417299894","doi":"10.1080/13696998.2025.2599670","title":"Impact of pembrolizumab on health outcomes and productivity in earlier-stage cancers within the US Medicare population","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Canada; Merck","keywords":"Pembrolizumab; Productivity; Population; Investment (military); Work productivity; Exploratory analysis","score_opus":0.016483279543900966,"score_gpt":0.34714052042635307,"score_spread":0.33065724088245213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417299894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9633151,0.0008437,0.000010479563,0.03515609,0.00039712738,0.00017328702,0.000007818471,0.0000022185075,0.000094153256],"genre_scores_gemma":[0.9966645,0.0014960844,0.000029261257,0.001661622,0.000087607375,0.0000015007648,0.0000019185118,0.0000058021064,0.000051676834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987772,0.00008124028,0.0006740937,0.000104345294,0.00024399484,0.00011912714],"domain_scores_gemma":[0.99904984,0.00014409161,0.00050203333,0.00014559909,0.00003530405,0.00012311009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018465624,0.0000908099,0.00047501057,0.00013272109,0.000032424286,0.00000858215,0.00011292083,0.00008955702,0.000053222597],"category_scores_gemma":[0.00046387914,0.000051567276,0.00013555257,0.000105807405,0.00013403334,0.000058840982,0.000019524257,0.00040333995,1.2121299e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004521062,0.00016410086,0.8978665,0.00015413844,0.00046754666,0.000011877974,0.0007190118,0.0005699722,0.000020278418,0.00032877116,0.0010417461,0.094135016],"study_design_scores_gemma":[0.0045188027,0.00072453136,0.9925435,0.00042958473,0.000022421495,0.000044051416,0.00021639175,0.0006895771,0.00002514015,0.00012250942,0.0006217664,0.000041728792],"about_ca_topic_score_codex":0.0034823988,"about_ca_topic_score_gemma":0.0018827755,"teacher_disagreement_score":0.094677016,"about_ca_system_score_codex":0.0008388226,"about_ca_system_score_gemma":0.0020183395,"threshold_uncertainty_score":0.52643687},"labels":[],"label_agreement":null},{"id":"W4417432359","doi":"10.1080/13696998.2025.2600217","title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Antibody therapy; Immunotherapy; Salvage therapy; Cell therapy; Safety profile","score_opus":0.12464273081717334,"score_gpt":0.41862964772985595,"score_spread":0.29398691691268264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417432359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047787325,0.9913105,0.0003353497,0.0002738021,0.00019218659,0.0074601523,0.00023064927,0.000007813033,0.0001418069],"genre_scores_gemma":[0.000009722615,0.9958249,0.00034651312,0.0005322463,0.00013406937,0.00047905577,0.000085478976,0.00008389057,0.0025041657],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99271446,0.0018937646,0.0036828073,0.0005123682,0.00076641585,0.00043020316],"domain_scores_gemma":[0.9878282,0.006544362,0.0037019248,0.0008422884,0.0004929572,0.00059024635],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0147611005,0.0006225117,0.018531851,0.0009625957,0.000060706847,0.0000363834,0.0008039645,0.00072236196,0.0028751655],"category_scores_gemma":[0.00215938,0.00035605903,0.006480167,0.00082224683,0.00014529367,0.000093352275,0.00012379418,0.00082912896,0.000007899725],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052293384,0.001245834,9.3925087e-7,0.84676564,0.12146892,0.000028725637,0.00002429471,2.3171498e-7,0.0000024299763,0.000008619028,0.00073830684,0.029193157],"study_design_scores_gemma":[0.006390558,0.0010415169,5.739735e-7,0.07257721,0.49285993,0.00017289708,0.000027402039,0.000021339574,0.000017613718,0.000006101327,0.42661116,0.0002737211],"about_ca_topic_score_codex":0.000007701538,"about_ca_topic_score_gemma":0.000003496884,"teacher_disagreement_score":0.7741884,"about_ca_system_score_codex":0.00052496046,"about_ca_system_score_gemma":0.004335918,"threshold_uncertainty_score":0.99988914},"labels":[],"label_agreement":null},{"id":"W7117357242","doi":"10.1080/13696998.2025.2604971","title":"A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"AstraZeneca United States","keywords":"Ibrutinib; Tolerability; Drug; Health care; Lymphoma; Resource use","score_opus":0.02686499075694019,"score_gpt":0.3300574816797413,"score_spread":0.3031924909228011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117357242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955438,0.00094572763,0.000016645397,0.0010424326,0.00020486649,0.0018189562,0.000010451882,0.00004003508,0.00037710462],"genre_scores_gemma":[0.99662596,0.00060777745,0.0007263326,0.0013348464,0.00025273339,0.00003514266,0.000023319053,0.000087130655,0.0003067839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932063,0.000678387,0.0025099956,0.00090730324,0.0016545024,0.0010434922],"domain_scores_gemma":[0.99458885,0.0015393891,0.0011871078,0.0009819624,0.00053476606,0.0011679298],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005589876,0.0005649001,0.0020152694,0.0008890092,0.0002223489,0.00015248354,0.00065833866,0.00026585473,0.000067619345],"category_scores_gemma":[0.0013567222,0.00042304062,0.00016718559,0.0007783621,0.00057257194,0.00036070478,0.00040206962,0.0011107932,0.000005109071],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04076124,0.0023539658,0.80810803,0.003483319,0.0016287179,0.0015147504,0.011077648,0.008652201,0.0000022432498,0.00017766145,0.0017892546,0.12045096],"study_design_scores_gemma":[0.34593067,0.017826792,0.5603142,0.007219402,0.0006006701,0.00060334534,0.005939297,0.057751734,0.000035703877,0.00003686194,0.0029480339,0.00079332746],"about_ca_topic_score_codex":0.0072048516,"about_ca_topic_score_gemma":0.009082013,"teacher_disagreement_score":0.3051694,"about_ca_system_score_codex":0.27872804,"about_ca_system_score_gemma":0.22269225,"threshold_uncertainty_score":0.99982214},"labels":[],"label_agreement":null}]}